JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Author, | Klitzman Robert L. | ear_ | 2020 | Record | Number 1 | 33103966_MADI |
|---------|---|-------|----------|----------|----------|-------------------|
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | \times | | | |
| 2. | Does the source of opinion have standing in the of expertise? | field | | \times | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | | | \times | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion express | ed? | | \times | | |
| 5. | Is there reference to the extant literature? | | | \times | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | | \times | | |
| Overall | appraisal; Include 🗆 Exclude Seek f | urthe | r info | | | |
| Comme | nts (Including reason for exclusion) | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| authorHoon Baang I., Smith C., Mirabelli C., et al | Year 2020 | Record | d Number_ | 2_330893 |
|--|------------------|--------|-----------|-------------------|
| | Yes | . No | Unclear | Not applicable |
| Were patient's demographic characteristics clearly described? | • | | | |
| 2. Was the patient's history clearly described and pre as a timeline? | esented E | | | |
| 3. Was the current clinical condition of the patient or presentation clearly described? | | | | |
| Were diagnostic tests or assessment methods and results clearly described? | the | | | |
| 5. Was the intervention(s) or treatment procedure(s) described? | clearly | | | |
| 5. Was the post-intervention clinical condition clearly described? | | | | |
| 7. Were adverse events (harms) or unanticipated eve identified and described? | ents | | | |
| 8. Does the case report provide takeaway lessons? | | | | |
| Overall appraisal: Include | k further info | | | |
| Comments (Including reason for exclusion) | | | | |

| eview | er Daniel de la Rosa | Date | | | | |
|-------|--|---------------|-----|-------|----------|-------------------|
| uthor | Thomas Sonnweber et al | Year_2 | 020 | Recor | d Number | 3_33087116 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited same population? | from the | | | | |
| 2. | Were the exposures measured similarly to a people to both exposed and unexposed gro | 31(0) 1785.33 | D | | | |
| 3. | Was the exposure measured in a valid and way? | reliable | • | | | |
| 4. | Were confounding factors identified? | | | | 1 | |
| 5. | Were strategies to deal with confounding fa stated? | actors | | | Z | |
| 6. | Were the groups/participants free of the ou at the start of the study (or at the moment exposure)? | | 6 | | | |
| 7. | Were the outcomes measured in a valid and way? | d reliable | | | | |
| 8. | Was the follow up time reported and suffice be long enough for outcomes to occur? | ent to | | | 1 | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and e | | | | 1 | |
| 10. | Were strategies to address incomplete folloutilized? | w up | | | * | |
| 11. | Was appropriate statistical analysis used? | | | | | |

Comments (Including reason for exclusion)

30% Insuficiencia de hierro, 13% deficiencia de hierro absoluta, 17% deficiencia de hierro funcional, anemia 9.2%. Se encontró una asociación positiva significativa entre anemia y enfermedad crítica por COVID-19, y anemia y citocinas proinfiamatorias (IL-6, TNF-aplha e IL-10). El 38% de los pacientes presentaba hiperferritinemia (48% de los hombres y 23% de las mujeres). Los niveles de ferritina fueron mayores en pacientes con enfermedad severa (p=0.001) y la hiperferritinemia se asoció con un mayor CT-Score (p=0.001). No se encontró una asociación entre hiperferritinemia y edad, género, comorbilidades.

© JBI, 2020. All rights reserved. JBI grants use of these

© JBI, 2020. All rights reserved. JBI grants use of these tools for research purposes only. All other enquiries should be sent to jbisynthesis@adelaide.edu.au.

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| uthor Buselli R., Corsi M., Necciari G., et al. Year 2 | 020 | Record | Number_4 | 4_3307814 |
|---|-------|--------|----------|-------------------|
| | Yes | No | Unclear | Not applicable |
| Were patient's demographic characteristics clearly described? | | | | |
| Was the patient's history clearly described and presented as a timeline? | | | | |
| Was the current clinical condition of the patient on presentation clearly described? | | | | |
| Were diagnostic tests or assessment methods and the results clearly described? | | | | |
| Was the intervention(s) or treatment procedure(s) clearly described? | | | | |
| Was the post-intervention clinical condition clearly described? | | | | |
| Were adverse events (harms) or unanticipated events identified and described? | | | | |
| . Does the case report provide takeaway lessons? | | | | |
| overall appraisal: Include | nfo 🗌 | | | |
| omments (Including reason for exclusion) | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | er Marco Antonio Delaye Martínez Date | 14/ | 11/20 | | |
|----------|---|------------|--------|-------------|-------------------|
| Author_ | Ricardo J. José, Manuel A. et. al. Year | 2020 | Record | l Number 5 | _33054432_MA |
| | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | | | |
| 2. | Does the source of opinion have standing in the field of expertise? | • | | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expressed? | • | | | |
| 5. | Is there reference to the extant literature? | • | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | • | | |
| Overalla | appraisal; Include 🔲 Exclude 🗎 Seek furthe | er info | ĺ | | |
| Commer | nts (Including reason for exclusion) | | | | |
| s | lo aporta información concreta para los objeti istemática. Aún existen limitaciones en detern sociadas a COVID-19 representan un hallazgo | ninarsi la | presei | ncia de bro | onquiectasias |

| uthor | Bhattacharya B., Kumar R., Prakash V., Year | 2020 | Recor | d Number | 6_3305318 |
|-------|--|------|-------|----------|-------------------|
| | et al. | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | D | | | |
| 4. | Were confounding factors identified? | | | | |
| 5. | Were strategies to deal with confounding factors stated? | | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | | | |
| 11. | Was appropriate statistical analysis used? | | | | |

Comments (Including reason for exclusion)

Existen errores metodológicos en la presentación e interpretación de datos, lo que lo hace un artículo poco confiable. No reporta información relevante relacionada a longcovid.

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| uthor | Wijeratne T., Crewther S. | /ear_2020 | _ Record | Number 7 | 33070003 |
|--------|---|--------------|----------|----------|-------------------|
| | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | • | | | |
| 2. | Does the source of opinion have standing in the of expertise? | field | | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | D | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion express | sed? | | | |
| 5. | Is there reference to the extant literature? | | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | • | | |
| verall | appraisal; Include 🔲 Exclude 🖳 Seek | further info | l | | |
| omme | nts (Including reason for exclusion) | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR QUALITATIVE RESEARCH

| Reviewer | Marco Antonio Delaye Martínez | Date 23 | /11/20 | | |
|----------------|---|----------------|--------|-----------|----------------------|
| Author K | ingstone T., Taylor A., O'Donell C., et al. | Year_2020 | Reco | ord Numbe | r <u>8_3305122</u> 3 |
| | | Ye | es No | Unclear | Not applicable |
| | ere congruity between the stated philosoph sective and the research methodology? | hical E | | | |
| | ere congruity between the research methodo the research question or objectives? | logy | | | |
| | ere congruity between the research methodo the methods used to collect data? | logy [| | | |
| | ere congruity between the research methodo the representation and analysis of data? | logy [| | | |
| | ere congruity between the research methodo the interpretation of results? | logy | | | |
| | ere a statement locating the researcher cultu eoretically? | rally [| | | |
| | e influence of the researcher on the research, versa, addressed? | and e | | | |
| . Are repre | participants, and their voices, adequates | ately [| | | |
| for r | e research ethical according to current criteria ecent studies, and is there evidence of eth oval by an appropriate body? | - 100 h | | | |
| | ne conclusions drawn in the research report the analysis, or interpretation, of the data? | flow | | | |
| overall app | oraisal: Include 🔲 Exclude 🔟 Seek | further info | , 🗆 | | |
| omments | (Including reason for exclusion) | | | | |
| | rta estimadores en relación a la persiste o, aporta información útil para incluir en | | | | ntes, sin |

| er | DDMR | _Date | 29 11 20 | | _ |
|---------|---|--|---|--|--|
| Konst | tantinidisa et alYear_2020_ Recor | d Number | _ 9_33049 | 753 | |
| | | Ye | s No | Unclear | Not applicable |
| | | the [| | | |
| | - (TO C.) - (TO CO.) - (TO C.) | 20 | | | |
| | | ble [| | | |
| Were | e confounding factors identified? | | | | |
| | - (1. 선생님의 발생 1. 전 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. | rs [| | | |
| at the | e start of the study (or at the moment of | me | | | |
| | | iable [| | | |
| | 그들은 아이지 않아 보면 다른데 바다가 되었다면 하면 하면 하는데 하는데 하는데 되어 되어 있다면 하는데 하는데 하다. | to [| | | |
| | | ored? | | | |
| | | p E | | | |
| Was | appropriate statistical analysis used? | | <u> </u> | | |
| apprais | sal: Include 🔲 Exclude 🔲 Seek | further info | . 🗆 | | |
| nts (In | cluding reason for exclusion) | | | | |
| | | | | | |
| | Were same Were state Were state Were way? Was be lo Was rease way? Was apprain | Were the two groups similar and recruited from same population? Were the exposures measured similarly to assig people to both exposed and unexposed groups? Was the exposure measured in a valid and relial way? Were confounding factors identified? Were strategies to deal with confounding factor stated? Were the groups/participants free of the outcor at the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliway? Was the follow up time reported and sufficient be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and explosured? Were strategies to address incomplete follow up utilized? | Were the exposures measured similarly to assign people to both exposed and unexposed groups? Was the exposure measured in a valid and reliable way? Were strategies to deal with confounding factors stated? Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliable way? Were the outcomes measured in a valid and reliable way? Were the outcomes measured in a valid and reliable way? Was the follow up time reported and sufficient to be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and explored? Were strategies to address incomplete follow up utilized? Was appropriate statistical analysis used? Exclude Seek further info | Were the exposures measured similarly to assign people to both exposed and unexposed groups? Was the exposure measured in a valid and reliable way? Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliable way? Were the follow up time reported and sufficient to be long enough for outcomes to occur? Was appropriate statistical analysis used? Were strategies to address incomplete follow up utilized? Were strategies to address incomplete follow up appraisal: Include Exclude Seek further info | Were the exposures measured similarly to assign people to both exposed and unexposed groups? Was the exposure measured in a valid and reliable way? Were the groups/perticipants free of the outcome at the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliable way? Were the outcomes measured in a valid and reliable way? Were the groups/perticipants free of the outcome at the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliable way? Was the follow up time reported and sufficient to be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and explored? Were strategies to address incomplete follow up utilized? Was appropriate statistical analysis used? |

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| | ewer Daniel de la Rosa | Date | 14-11- | -20 | |
|-------|--|-----------------|--------|----------|-------------------|
| Autho | or Franziska Weichmanna and Peter Rohdewaldb | Year 2020 | Record | d Number | 10_33045354 |
| | | Yes | . No | Unclear | Not applicable |
| i. I | Is the review question clearly and explicitly state | ed? | | | |
| | Were the inclusion criteria appropriate for the re question? | eview | | | |
| 3. | Was the search strategy appropriate? | | | | 1 |
| | Were the sources and resources used to search studies adequate? | for | | | ď |
| 5. | Were the criteria for appraising studies appropri | iate? | | | |
| | Was critical appraisal conducted by two or more reviewers independently? | · 🗆 | | | ₫ |
| | Were there methods to minimize errors in data extraction? | | | | |
| 3. | Were the methods used to combine studies app | ropriate? | | | 7 |
| 9. | Was the likelihood of publication bias assessed? | | | | |
| | Were recommendations for policy and/or practi supported by the reported data? | ce 🗹 | | | |
| | Were the specific directives for new research appropriate? | _ | | | |
| Overa | all appraisal: Include 🔲 Exclude 📈 Se | ek further info |] | | |
| Comn | ments (Including reason for exclusion) | | | | |

JBI Critical Appraisal Checklist for Case Series

| Reviewer Marco Antonio Delaye Martínez | Date 29/1 | 1/20 | | |
|---|----------------|--------|--------------|------------------------|
| Author_Wootton S., King M., Alison J., et al. | Year_2020 | Re | cord Numb | er <u>11_33042</u> 547 |
| | Yes | No | Unclear | Not applicable |
| • Were there clear criteria for inclusion in the case series? | | • | | |
| Was the condition measured in a standard, reliable way for all participants included in the case series? | | | | |
| Were valid methods used for identification of the condition for all participants included in the case series? | 9 | | | |
| Did the case series have consecutive inclusion of participants? | | | | |
| Did the case series have complete inclusion of participants? | | | | |
| Was there clear reporting of the demographics of the participants in the study? | D | | | |
| Was there clear reporting of clinical information of the participants? | e 🔟 | | | |
| - Were the outcomes or follow up results of cases clearly reported? | | | | |
| Was there clear reporting of the presenting site(s)/clinic(s) demographic information? | | | | |
| Was statistical analysis appropriate? | | | | |
| Overall appraisal: Include Exclude Seel | k further info | | | |
| Comments (Including reason for exclusion) | | | | |
| Se excluye por ser serie de casos. Sin embargo | , contiene ir | nforma | ación útil p | ara la discusión. |

| Review | er Marco Antonio Delaye Martínez Dat | e_ 29/1 | 1/20 | | |
|-----------|--|-----------|---------|----------|-------------------|
| Author | Afshar Y., Gaw S., Flaherman V., et al Year | 2020 | _ Recor | d Number | 12_33027186 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | | | | 5 |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | | | |
| 4. | Were confounding factors identified? | | | | |
| 5. | Were strategies to deal with confounding factors stated? | | | D | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | | | |
| 11. | Was appropriate statistical analysis used? | | | | |
|)verall : | appraisal: Include | er info 🗆 |] | | |
| omme | nts (Including reason for exclusion) | | | | |
| No co | mments | | | | |

| Author | Ramasamy K., Saniasiaya J., Abdul N. Year | 2020 | Recor | d Number | 13_33025798 |
|--------|--|------|-------|----------|-------------------|
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | | | | • |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | | | |
| 4. | Were confounding factors identified? | | | | |
| 5. | Were strategies to deal with confounding factors stated? | | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | | | |
| 11. | Was appropriate statistical analysis used? | | | | |

Comments (Including reason for exclusion)

El estudio se centra en determinar la prevalencia y el grado de severidad de anemia y agencia como síntomas que conforman el cuadro agudo de COVID-19. No aporta información útil para COVID prolongado; el tiempo de seguimiento es muy corto.

| Review | er Marco Antonio Delaye Martínez | Date | 29/1 | 1/20 | | |
|---------|--|------------|--------|-------|----------|-------------------|
| Author | Carvalho-Schneider C., Laurent E., | Year_2 | 020 | Recor | d Number | 14_33031948 |
| | Lemaignen A., et al. | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited fro same population? | om the | | | | |
| 2. | Were the exposures measured similarly to ass people to both exposed and unexposed group | 15.00 | | | | |
| 3. | Was the exposure measured in a valid and rel way? | liable | | | | |
| 4. | Were confounding factors identified? | | | | | |
| 5. | Were strategies to deal with confounding fact stated? | tors | | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | | | |
| 7. | Were the outcomes measured in a valid and r way? | reliable | | | | |
| 8. | Was the follow up time reported and sufficier be long enough for outcomes to occur? | ntto | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and exp | | | | | |
| 10. | Were strategies to address incomplete follow utilized? | rup | | | | |
| 11. | Was appropriate statistical analysis used? | | | | | |
|)verall | appraisal: Include 🕒 Exclude 🗌 See | ek further | info 🗆 |] | | |
| omme | nts (Including reason for exclusion) | | | | | |
| lo cor | mments. | | | | | |

| uthor S. Belli et al. | | ar 2020 | Recor | Record Number 15_3276411 | | |
|-----------------------|--|----------|-------|--------------------------|-------------------|--|
| | | Yes | No | Unclear | Not applicable | |
| 1. | Were the two groups similar and recruited from to same population? | he 🗆 | | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | | | | |
| 4. | Were confounding factors identified? | | | | | |
| 5. | Were strategies to deal with confounding factors stated? | | | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | <u> </u> | | | | |
| 7. | Were the outcomes measured in a valid and reliab way? | ole 🗑 | | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | • | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explore | ed? | | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | D | | | |
| 11. | Was appropriate statistical analysis used? | | | | | |

Comments (Including reason for exclusion)

No reporta la persistencia de síntomas asociados a COVID, según la definición de Long-COVID. Sin embargo, evalúa de forma de integral la disfunción física y capacidad para realizar las ADLs. Es útil para discusión.

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Paniel de la Rosa | _Date_ | 14/1 | 1/20 | | - |
|--|---|--|--|---|--|
| Jérôme René Lechien et al | Year_2 | 020 | Record | l Number_ | 16_33000300 |
| | | Yes | No | Unclear | Not applicable |
| Is the source of the opinion clearly identified? | | 1 | | | |
| Does the source of opinion have standing in th of expertise? | e field | d | | | |
| Are the interests of the relevant population the central focus of the opinion? | e | 0 | | | |
| 보고 있다면서 가게 보고 있다면 하다 그리는 경우를 가지 않는데 그렇게 되었다면 하는데 되었다면 하는데 하는데 그렇게 되었다면 하는데 그렇게 하는데 | | 0 | | | |
| Is there reference to the extant literature? | | 10 | | | |
| Is any incongruence with the literature/source logically defended? | S | | | F | |
| appraisal: Include 🔲 Exclude 🕒 Seel | cfurther | info 🔲 | | | |
| nts (Including reason for exclusion) | | | | | |
| | | | | | |
| | Jérôme René Lechien et al Is the source of the opinion clearly identified? Does the source of opinion have standing in the of expertise? Are the interests of the relevant population the central focus of the opinion? Is the stated position the result of an analytical process, and is there logic in the opinion express there reference to the extant literature? Is any incongruence with the literature/source logically defended? Exclude Seeing | Jérôme René Lechien et al Year 2 Is the source of the opinion clearly identified? Does the source of opinion have standing in the field of expertise? Are the interests of the relevant population the central focus of the opinion? Is the stated position the result of an analytical process, and is there logic in the opinion expressed? Is there reference to the extant literature? Is any incongruence with the literature/sources logically defended? Exclude Seek further | Jérôme René Lechien et al Year 2020 Yes Is the source of the opinion clearly identified? Does the source of opinion have standing in the field of expertise? Are the interests of the relevant population the central focus of the opinion? Is the stated position the result of an analytical process, and is there logic in the opinion expressed? Is there reference to the extant literature? Is any incongruence with the literature/sources logically defended? Exclude Seek further info | Jérôme René Lechien et al Year 2020 Record Yes No Is the source of the opinion clearly identified? Does the source of opinion have standing in the field of expertise? Are the interests of the relevant population the central focus of the opinion? Is the stated position the result of an analytical process, and is there logic in the opinion expressed? Is there reference to the extant literature? Is any incongruence with the literature/sources logically defended? Include Exclude Seek further info | Jérôme René Lechien et al Year 2020 Record Number_ Yes No Unclear Is the source of the opinion clearly identified? Does the source of opinion have standing in the field of expertise? Are the interests of the relevant population the central focus of the opinion? Is the stated position the result of an analytical process, and is there logic in the opinion expressed? Is there reference to the extant literature? Is any incongruence with the literature/sources logically defended? Exclude Seek further info |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | Daniel de la Rosa | Date | 20/1 | 1/20 | | |
|----------|--|--------|-----------|--------|-----------|-------------------|
| Author_ | Espen Lindholm | Year_ | 2020 | Record | l Number_ | 17_33070586_DDI |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | 1 | | | |
| 2. | Does the source of opinion have standing in the of expertise? | field | do | | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | | | | P | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expres | sed? | | • | | |
| 5. | Is there reference to the extant literature? | | 1 | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | | | | |
| Overalla | appraisal; Include 🔲 Exclude 😡 Seek | furthe | er info 🔲 | | | |
| Commer | nts (Including reason for exclusion) | | | | | |
| | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| eviewe | er Daniel de la Rosa Martinez | - | Date | 29/1 | 1/20 | | |
|--------|--|--------|-------------|----------|--------|---------|-------------------|
| uthor_ | Kamal et al | Year | 2020 | Record 1 | Number | 18_329 | 91035 |
| | | | | Yes | No | Unclear | Not applicable |
| | Were the criteria for inclusion in the sa defined? | mple | clearly | | | | |
| | Were the study subjects and the settin detail? | g des | cribed in | | | | |
| | Was the exposure measured in a valid a way? | and re | eliable | | | | |
| | Were objective, standard criteria used measurement of the condition? | for | | | | | |
| 5. | Were confounding factors identified? | | | | | | |
| | Were strategies to deal with confoundi stated? | ing fa | ctors | | | | |
| | Were the outcomes measured in a valid way? | d and | reliable | | | | |
| 8. | Was appropriate statistical analysis use | id? | | | | | |
| | eppraisal: Include Exclude Ents (Including reason for exclusion) | ☐ s | eek further | info 🗌 | | | |
| | |] s | eek further | info 🔲 | | | |

EXPLANATION OF ANALYTICAL CROSS SECTIONAL STUDIES CRITICAL APPRAISAL

How to cite: Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, 2020. Available from https://synthesismanual.jbi.global

Analytical cross sectional studies Critical Appraisal Tool

Answers: Yes, No, Unclear or Not/Applicable

Were the criteria for inclusion in the sample clearly defined?

The authors should provide clear inclusion and exclusion criteria that they developed prior to recruitment of the study participants. The inclusion/exclusion criteria should be specified (e.g., risk, stage of disease progression) with sufficient detail and all the necessary information critical to the study.

2. Were the study subjects and the setting described in detail?

The study sample should be described in sufficient detail so that other researchers can determine if it is comparable to the population of interest to them. The authors should provide a clear description of the population from which the study participants were selected or recruited, including demographics, location, and time period.

3. Was the exposure measured in a valid and reliable way?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

Reliability refers to the processes included in an epidemiological study to check repeatability of measurements of the exposures. These usually include intra-observer reliability and inter-observer reliability.

4. Were objective, standard criteria used for measurement of the condition?

It is useful to determine if patients were included in the study based on either a specified diagnosis or definition. This is more likely to decrease the risk of bias. Characteristics are another useful approach to matching groups, and studies that did not use specified diagnostic methods or definitions should provide evidence on matching by key characteristics.

5. Were confounding factors identified?

Confounding has occurred where the estimated intervention exposure effect is biased by the presence of some difference between the comparison groups (apart from the exposure investigated/of interest). Typical confounders include baseline characteristics, prognostic factors, or concomitant exposures (e.g. smoking). A confounder is a difference between the comparison groups and it influences the direction of the study results. A high quality study at the level of cohort design will identify the potential confounders and measure them (where possible). This is difficult for studies where behavioral, attitudinal or lifestyle factors may impact on the results.

6. Were strategies to deal with confounding factors stated?

Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or stratifying sampling of participants, effects of confounding factors can be adjusted for. When dealing with adjustment in data analysis, assess the statistics used in the study. Most will be some form of multivariate regression analysis to account for the confounding factors measured.

7. Were the outcomes measured in a valid and reliable way?

Read the methods section of the paper. If for e.g. lung cancer is assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If lung cancer is assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

Having established the objectivity of the outcome measurement (e.g. lung cancer) instrument, it's important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? (e.g. radiographers). If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised?

8. Was appropriate statistical analysis used?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.

For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| iewer | Daniel de la Rosa Date | | 21-11- | 20 | |
|---------------|--|--|---|--|---|
| hor | Dmitri Bougakov et al Year | 2020 | Record | Number | 19_32990925_DDM |
| | | Yes | No | Unclear | Not applicable |
| Is the rev | ew question clearly and explicitly stated? | 1 | | | |
| | | | | | |
| Was the s | earch strategy appropriate? | | | | ď |
| | | | | | |
| Were the | criteria for appraising studies appropriate? | | | | 7 |
| | | | | | ₫ |
| | | | | | |
| Were the | methods used to combine studies appropriate | , _□ | | | |
| Was the li | kelihood of publication bias assessed? | | | | |
| | [일본(BERTHER) HONOR H | | | | |
| | | 1 | | | |
| rall appraisa | l: Include | r info | | | |
| ments (Incl | uding reason for exclusion) | | | | |
| | | | | | |
| | Were the question? Was the s Were the studies ad Were the Was critic reviewers Were the extraction Were the was the li Were recommendate appropria | Is the review question clearly and explicitly stated? Were the inclusion criteria appropriate for the review question? Was the search strategy appropriate? Were the sources and resources used to search for studies adequate? Were the criteria for appraising studies appropriate? Was critical appraisal conducted by two or more reviewers independently? Were there methods to minimize errors in data extraction? Were the methods used to combine studies appropriate? Was the likelihood of publication bias assessed? Were recommendations for policy and/or practice supported by the reported data? Were the specific directives for new research appropriate? | Dmitri Bougakov et al Year 2020 Yes Is the review question clearly and explicitly stated? Were the inclusion criteria appropriate for the review question? Was the search strategy appropriate? Were the sources and resources used to search for studies adequate? Were the criteria for appraising studies appropriate? Was critical appraisal conducted by two or more reviewers independently? Were there methods to minimize errors in data extraction? Were the methods used to combine studies appropriate? Was the likelihood of publication bias assessed? Were recommendations for policy and/or practice supported by the reported data? Were the specific directives for new research appropriate? Tall appraisal: Include | No Some the review question clearly and explicitly stated? Yes No | No Unclear Is the review question clearly and explicitly stated? Were the inclusion criteria appropriate for the review question? Was the search strategy appropriate? Were the sources and resources used to search for studies adequate? Were the criteria for appraising studies appropriate? Was critical appraisal conducted by two or more reviewers independently? Were there methods to minimize errors in data extraction? Were the methods used to combine studies appropriate? Was the likelihood of publication bias assessed? Were the recommendations for policy and/or practice supported by the reported data? Were the specific directives for new research appropriate? Include |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Reviewe | Daniel de la Rosa | Date_ | 20 |)-11-20 | | | |
|---------|--|---------|--------|---------|---------|-------------------|-----|
| Author_ | Karimi-Galougahi et al | аг | 2020 | Record | Number_ | 20_330147 | 751 |
| | | | Yes | No | Unclear | Not applicable | |
| 1. | Were the criteria for inclusion in the sample clea defined? | arly | 1 | | | | |
| 2. | Were the study subjects and the setting describe detail? | ed in | | | | | |
| 3. | Was the exposure measured in a valid and reliab way? | ole | Z | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | N | | | | |
| 5. | Were confounding factors identified? | | | | | | |
| 6. | Were strategies to deal with confounding factor stated? | s | | | 1 | | |
| 7. | Were the outcomes measured in a valid and relia way? | able | Z | | | | |
| 8. | Was appropriate statistical analysis used? | | N | | | | |
| | opraisal: Include | rther i | info 🗌 | | | | |
| Follow | up time less than 21 days | | | | | | |
| | | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Reviewer | | Daniel de la Rosa Date | | 21-11- | 20 | |
|----------|---------------------|--|---------|--------|----------|-------------------|
| Aut | hor | Scott Rooney, et al Year | 2020 | Record | l Number | 21_32737507 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the rev | iew question clearly and explicitly stated? | 1 | | | |
| 2. | Were the question? | inclusion criteria appropriate for the review | | | | Z |
| 3. | Was the s | search strategy appropriate? | | | | Z |
| 4. | Were the | sources and resources used to search for dequate? | | | | Ø |
| 5. | Were the | criteria for appraising studies appropriate? | | | | K |
| 6. | | cal appraisal conducted by two or more independently? | | | | Ø |
| 7. | Were the extraction | re methods to minimize errors in data n? | | | | Ø |
| 8. | Were the | methods used to combine studies appropriate | ? | | | Ø |
| 9. | Was the I | ikelihood of publication bias assessed? | | | | V |
| 10. | | ommendations for policy and/or practice d by the reported data? | Z | | | |
| 11. | Were the appropria | specific directives for new research ite? | Ø | | | |
| Ove | rall appraisa | al: Include 🔲 Exclude 🖊 Seek furthe | er info | Į. | | |
| Con | ments (Incl | uding reason for exclusion) | | | | |
| | | | | | | |
| | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Reviewe | Daniel de la Rosa Date | 2 | 2-11-20 | | |
|---------|--|--------|----------|---------|-------------------|
| Author_ | Antonio Rosales-Castillo+, Year_ | 2020 | Record ! | Number_ | 22_33077167 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | | | | |
| 2. | Were the study subjects and the setting described in detail? | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | Z | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | 1 | | | |
| 5. | Were confounding factors identified? | | 1 | | |
| 6. | Were strategies to deal with confounding factors stated? | | 1 | | |
| 7. | Were the outcomes measured in a valid and reliable way? | Z | | | |
| 8. | Was appropriate statistical analysis used? | N | | | |
| | opraisal: Include | info 🗌 | | | |
| | "El tiempo de seguimiento no se especifica par ademas el metodo diagnostico no fue PO | | | enes, | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Autho | Novak P. | Year 200 | 20 | Pacard | Number 5 | 23_3298456 |
|----------|---|-------------|-----|--------|----------|-------------------|
| -tutil | | real | | Necoru | Number_ | 0_0270400 |
| | | | Yes | No | Unclear | Not applicable |
| | Vere patient's demographic characteristics clearly escribed? | | | | | |
| | as the patient's history clearly described and press a timeline? | ented | D | | | |
| | as the current clinical condition of the patient on resentation clearly described? | | • | | | |
| | ere diagnostic tests or assessment methods and the sults clearly described? | he | | | | |
| | /as the intervention(s) or treatment procedure(s) of escribed? | clearly | | | | |
| | as the post-intervention clinical condition clearly escribed? | | | | | |
| | Vere adverse events (harms) or unanticipated even lentified and described? | nts | | | | |
| 8. D | oes the case report provide takeaway lessons? | | | | | |
| Overa | ll appraisal: Include 🔲 Exclude 🖨 Seek | further inf | . 🗆 | | | |
| Comm | nents (Including reason for exclusion) | | | | | |
| Po co | nents (Including reason for exclusion) or los antecedentes médicos del paciente es rresponde a una exacerbacion de la enferme ndrome post-COVID. | | | | | |

JBI Critical Appraisal Checklist for Case Series

| Reviewer Marco Antonio Delaye Martínez | _Date_ 3 | 1/12/2 | 0 | |
|---|--------------|------------------|-----------|------------------------|
| Author Brogna B., Bignardi E., Brogna C., et al. | Year 20 | 0 20 _ Re | cord Numb | er <u>24_3299</u> 8840 |
| | Yes | No | Unclear | Not applicable |
| Were there clear criteria for inclusion in the case series? | | | | |
| Was the condition measured in a standard, reliable way for all participants included in the case series? | | | | |
| Were valid methods used for identification of the condition for all participants included in the case series? | 2 | | | |
| Did the case series have consecutive inclusion of participants? | | | | |
| Did the case series have complete inclusion of participants? | • | | | |
| Was there clear reporting of the demographics of the participants in the study? | | | | |
| Was there clear reporting of clinical information of the participants? | e 🕞 | | | |
| Were the outcomes or follow up results of cases clearly reported? | | | | |
| Was there clear reporting of the presenting site(s)/clinic(s) demographic information? | | | | |
| Was statistical analysis appropriate? | | | | |
| Overall appraisal: Include | k further in | fo 🗌 | | |
| Comments (Including reason for exclusion) | | | | |

El estudio no tiene por objetivo reportar la presencia de síntomas persistentes en los pacientes, más bien resalta el papel de la TAC de tórax para el diagnóstico de COVID-19 en pacientes con sintomatología sugestiva de la enfermedad y pruebas RT-PCR negativas .

| Review | er Marco Antonio Delaye Martínez Da | te_31/12 | /20 | | |
|---------|--|----------|--------|-----------|-------------------|
| Author | Landi F., Carfi A., Benvenuto F., et al. Yea | r2020 | _ Reco | rd Number | 25_33041095 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from th same population? | e 📵 | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | | | |
| 4. | Were confounding factors identified? | | | | |
| 5. | Were strategies to deal with confounding factors stated? | | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | | |
| 7. | Were the outcomes measured in a valid and reliab way? | e 🖭 | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored | d? • | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | | | |
| 11. | Was appropriate statistical analysis used? | | | | |
| Overall | appraisal: Include 🖬 Exclude 🔲 Seek furt | her info |] | | |
| Comme | nts (Including reason for exclusion) | | | | |
| No co | mments. | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Re | viewer Marco Antonio Delaye Martínez Date 3 | 31/12/2 | 20 | | - |
|----|---|---------|--------|----------|----------------------|
| Au | thor Carroll E., Neumann H., Aguero Year 2 Rosenfield M., et al. | 2020 | Record | Number_2 | 2 <u>6_3294</u> 4946 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were patient's demographic characteristics clearly described? | | | | |
| 2. | Was the patient's history clearly described and presented as a timeline? | | | | |
| 3. | Was the current clinical condition of the patient on presentation clearly described? | • | | | |
| 4. | Were diagnostic tests or assessment methods and the results clearly described? | | | | |
| 5. | Was the intervention(s) or treatment procedure(s) clearly described? | | | | |
| 6. | Was the post-intervention clinical condition clearly described? | | | | |
| 7. | Were adverse events (harms) or unanticipated events identified and described? | | | | |
| 8. | Does the case report provide takeaway lessons? | | | | |
| Ov | erall appraisal: Include 🔲 Exclude 🕒 Seek further | info 🔲 | | | |
| Co | mments (Including reason for exclusion) | | | | |
| | Caso poco específico para long-COVID | | | | |
| | | | | | |

JBI Critical Appraisal Checklist for Case Series

| Reviewer Marco Antonio Delaye Martínez | _Date | 31/12/20 | 0 | |
|--|-------------|----------|------------|-------------------------|
| Author Masset C., Ville S., Halary F., et al. | Year 2 | 020_Re | cord Numb | er_ <u>27_3293</u> 9955 |
| | Yes | No | Unclear | Not applicable |
| • Were there clear criteria for inclusion in the case series? | | 8 | | |
| Was the condition measured in a standard, reliable way for all participants included in the case series? | | | | |
| • Were valid methods used for identification of the condition for all participants included in the case series? | • | | | |
| Did the case series have consecutive inclusion of participants? | | | | |
| Did the case series have complete inclusion of participants? | | | | |
| Was there clear reporting of the demographics of the participants in the study? | | • | | |
| Was there clear reporting of clinical information of the participants? | e D | | | |
| Were the outcomes or follow up results of cases clearly reported? | | | | |
| Was there clear reporting of the presenting site(s)/clinic(s) demographic information? | | | | |
| Was statistical analysis appropriate? | | | | |
| Overall appraisal: Include | k further i | nfo 🗌 | | |
| Comments (Including reason for exclusion) | | | | |
| Los síntomas reportados no cumplen con el crit persistentes. | terio de t | tempora | lidad para | sintomas |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Review | er Marco Antonio Delaye Martínez Da | ite_31/12/ | 20 | | |
|---------|---|-------------|--------|-----------|-------------------|
| Author, | W. Vaes A., Machado F., Meys R., et al. Yea | r_ 2020 | Record | Number_ | 28_32932582 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | ' □ | | | |
| 2. | Were the study subjects and the setting described detail? | in 🕩 | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | |
| 5. | Were confounding factors identified? | | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | | |
| | Were the outcomes measured in a valid and reliable way? | le 🕦 | | | |
| 8. | Was appropriate statistical analysis used? | • | | | |
| | appraisal: Include | her info 🗌 | | | |
| del 17 | porción de pacientes con diagnóstico confir %; el resto fue diagnosticado por síntomas o o. Sin embargo por la información que aporta | no tenía di | agnóst | ico al mo | mento del |

| Author | Pizzini A., Aichner M., Sahanic S., et al. Year | 2020 | Recor | d Number | 29_3293283 |
|--------|--|------|-------|----------|-------------------|
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | | | |
| 4. | Were confounding factors identified? | • | | | |
| 5. | Were strategies to deal with confounding factors stated? | | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | • | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | | | |
| 11. | Was appropriate statistical analysis used? | | | | |

Comments (Including reason for exclusion)

No se reportan síntomas persistentes por COVID-19, sin embargo se descarta la asociación de deficiencia de vitamina D y el desarrollo de sí tomas persistentes. El artículo es útil para discusión.

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Lawrence B. Afrina et al. Year | 2020 | | | |
|--|--|--|---|--|
| | | Record | Number | 30_32920235_DDN |
| | Yes | No | Unclear | Not applicable |
| iew question clearly and explicitly stated? | | | | |
| inclusion criteria appropriate for the review | | | | |
| earch strategy appropriate? | | | | |
| sources and resources used to search for dequate? | | | | K |
| criteria for appraising studies appropriate? | | | | |
| al appraisal conducted by two or more independently? | | | | Ø |
| re methods to minimize errors in data n? | | | | Ø |
| methods used to combine studies appropriate? | | | | K |
| ikelihood of publication bias assessed? | | | | P |
| ommendations for policy and/or practice d by the reported data? | K | | | |
| specific directives for new research te? | P | | | |
| | info 🗌 | | | |
| | inclusion criteria appropriate for the review earch strategy appropriate? sources and resources used to search for dequate? criteria for appraising studies appropriate? cal appraisal conducted by two or more independently? re methods to minimize errors in data n? methods used to combine studies appropriate? ikelihood of publication bias assessed? ommendations for policy and/or practice d by the reported data? specific directives for new research ite? | inclusion criteria appropriate for the review cearch strategy appropriate? sources and resources used to search for dequate? criteria for appraising studies appropriate? cal appraisal conducted by two or more independently? re methods to minimize errors in data n? methods used to combine studies appropriate? ikelihood of publication bias assessed? ommendations for policy and/or practice by the reported data? specific directives for new research ate? ikelihood of publication bias assessed? | inclusion criteria appropriate for the review cearch strategy appropriate? control dequate? criteria for appraising studies appropriate? cal appraisal conducted by two or more independently? re methods to minimize errors in data n? methods used to combine studies appropriate? cikelihood of publication bias assessed? commendations for policy and/or practice d by the reported data? specific directives for new research specific directives for new research | iew question clearly and explicitly stated? inclusion criteria appropriate for the review cearch strategy appropriate? counters and resources used to search for dequate? criteria for appraising studies appropriate? cal appraisal conducted by two or more independently? re methods to minimize errors in data n? methods used to combine studies appropriate? chikelihood of publication bias assessed? commendations for policy and/or practice diby the reported data? specific directives for new research tite? specific directives for new research tite? Seek further info |

| Review | er Marco Antonio Delaye Martinez Date | 04/0 | 1/21 | | |
|---------|--|-----------|-------|----------|-------------------|
| Author | Chen J., Xu X., Hu J., et al. Year | 2020 | Recor | d Number | 31_32909961 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | |
| 3, | Was the exposure measured in a valid and reliable way? | | | | |
| 4. | Were confounding factors identified? | | | | |
| 5. | Were strategies to deal with confounding factors stated? | | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | | | |
| 11. | Was appropriate statistical analysis used? | | | | |
|)verall | appraisal: Include 🔲 Exclude 🛢 Seek furthe | er info 🗀 |] | | |
| omme | nts (Including reason for exclusion) | | | | |
| No | se reporta la persistencia de síntomas por CO | VID-19. | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Reviewe | Daniel de la Rosa | Date_ | 2. | 3-11-20 | | |
|---------|--|--------|--------|----------|---------|-------------------|
| Author_ | Helen O'Brien | ear | 2020 | Record I | Number_ | 32_32894436 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample cleadefined? | arly | | V | | |
| 2. | Were the study subjects and the setting describ detail? | ed in | | | | |
| 3. | Was the exposure measured in a valid and relial way? | ble | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | | 1 |
| 5. | Were confounding factors identified? | | | | | 1 |
| 6. | Were strategies to deal with confounding factor stated? | s: | | | | 1 |
| 7. | Were the outcomes measured in a valid and reli way? | iable | | | | V |
| 8. | Was appropriate statistical analysis used? | | | | | 1 |
| 100 | opraisal: Include Exclude Seek fu | urther | info 🗌 | | | |
| | "El tiempo de seguimiento no se especifica ademas el metodo diagnostico no fu | | | | enes, | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| uthor | Davido B., Seang S., Barizien N., et al. Year 20 | 20 | Record | Number_ | 33_3289871 |
|--------|--|-------|--------|---------|-------------------|
| | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | • | | | |
| 2. | Does the source of opinion have standing in the field of expertise? | | | | |
| 3, | Are the interests of the relevant population the central focus of the opinion? | | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expressed? | | | | |
| 5. | Is there reference to the extant literature? | • | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | | | |
| verall | appraisal; Include 🔲 Exclude 🖸 Seek further i | nfo 🗆 | | | |
| omme | nts (Including reason for exclusion) | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Re | viewer Marco Antonio Delaye Martínez Date | 31/12/ | 20 | | |
|----|---|----------|--------|-----------|----------------------|
| Au | thor_Wang M., Li T., Qiao F., et al. Year_ | 2020 | Record | l Number_ | 3 <u>4_3289</u> 8993 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were patient's demographic characteristics clearly described? | | | | |
| 2. | Was the patient's history clearly described and presented as a timeline? | | | | |
| 3. | Was the current clinical condition of the patient on presentation clearly described? | | | | |
| 4. | Were diagnostic tests or assessment methods and the results clearly described? | | | | |
| 5. | Was the intervention(s) or treatment procedure(s) clearled described? |) | | | |
| 6. | Was the post-intervention clinical condition clearly described? | | | | |
| 7. | Were adverse events (harms) or unanticipated events identified and described? | | | | |
| 8. | Does the case report provide takeaway lessons? | | | | |
| Ov | erall appraisal: Include Exclude Seek further | er info | | | |
| Co | mments (Including reason for exclusion) | | | | |
| | do que es un reporte de caso, el artículo se excluy nbargo aporta información relevante que puede se | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | ver_Marco Antonio Delaye Martínez | ate_04/01/ | /21 | | |
|---------|--|-------------------------------------|--|---------------------------------------|--|
| Author | Miglis M., Goodman B., Chémali K., et al. Ye | ar <u>2020</u> | Record | l Number 35 | 5 <u>3289</u> 1765 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | | | |
| 2. | Does the source of opinion have standing in the fi of expertise? | eld 👅 | | | |
| 3, | Are the interests of the relevant population the central focus of the opinion? | • | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expresse | d? 🕞 | | | |
| 5. | Is there reference to the extant literature? | • | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | | | |
| Overall | appraisal; Include 🔲 Exclude 🖭 Seek fu | rther info | | | |
| Comme | ents (Including reason for exclusion) | | | | |
| | ículo carece de información relevante para i de con el criterio de inclusión en cuanto al ti | I WOMEN A SOUTH OF THE RESIDENCE OF | The State of the s | Charles Company to the action and the | 5 To 10 To 1 |

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| iewer | Daniel de la Rosa Date | | 24-12- | 20 | |
|---------------|---|---|--|---|---|
| hor | Mathew G Wilson, et al Year | 2020 | Record Number | | 21_32737507 |
| | | Yes | No | Unclear | Not applicable |
| Is the rev | iew question clearly and explicitly stated? | 1 | | | |
| | | | | | \square |
| Was the s | search strategy appropriate? | | | | V |
| | | | | | Ø |
| Were the | criteria for appraising studies appropriate? | | | | d |
| | | | | | Ø |
| | | | | | Ø |
| Were the | methods used to combine studies appropriate | ? | | | Ø |
| Was the I | ikelihood of publication bias assessed? | | | | Ø |
| | 실실: (1.) 사용 (1.) (1.) 전입 (1.) (1.) (1.) (1.) (1.) (1.) (1.) (1.) (1.) (1.) (1.) (1.) (1.) (1.) | Ø | | | |
| | | Ø | | | |
| rall appraisa | al: Include \square Exclude $ ot\!$ | er info | | | |
| ments (Incl | luding reason for exclusion) | | | | |
| | | | | | |
| | Were the studies as Were the studies as Were the were the extraction were the was the I Were recomported were the appropriate | Is the review question clearly and explicitly stated? Were the inclusion criteria appropriate for the review question? Was the search strategy appropriate? Were the sources and resources used to search for studies adequate? Were the criteria for appraising studies appropriate? Was critical appraisal conducted by two or more reviewers independently? Were there methods to minimize errors in data extraction? Were the methods used to combine studies appropriate Was the likelihood of publication bias assessed? Were recommendations for policy and/or practice supported by the reported data? Were the specific directives for new research appropriate? | Mathew G Wilson, et al Year Yes Is the review question clearly and explicitly stated? Were the inclusion criteria appropriate for the review question? Was the search strategy appropriate? Were the sources and resources used to search for studies adequate? Were the criteria for appraising studies appropriate? Was critical appraisal conducted by two or more reviewers independently? Were there methods to minimize errors in data extraction? Were the methods used to combine studies appropriate? Was the likelihood of publication bias assessed? Were recommendations for policy and/or practice supported by the reported data? Were the specific directives for new research appropriate? rall appraisal: Include | Mathew G Wilson, et al Year Yes No Is the review question clearly and explicitly stated? Were the inclusion criteria appropriate for the review question? Was the search strategy appropriate? Were the sources and resources used to search for studies adequate? Were the criteria for appraising studies appropriate? Was critical appraisal conducted by two or more reviewers independently? Were there methods to minimize errors in data extraction? Were the methods used to combine studies appropriate? Was the likelihood of publication bias assessed? Were recommendations for policy and/or practice supported by the reported data? Were the specific directives for new research appropriate? Tall appraisal: Include | No Unclear Is the review question clearly and explicitly stated? Were the inclusion criteria appropriate for the review question? Was the search strategy appropriate? Were the sources and resources used to search for studies adequate? Were the criteria for appraising studies appropriate? Was critical appraisal conducted by two or more reviewers independently? Were there methods to minimize errors in data extraction? Were the methods used to combine studies appropriate? Was the likelihood of publication bias assessed? Were the recommendations for policy and/or practice supported by the reported data? Were the specific directives for new research appropriate? Include |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Review | er_Marco Antonio Delaye Martinez | Date | 04/0 | 1/21 | | |
|--------|--|-----------|-----------|--------|-----------|-------------------|
| Author | Krisztian S., Palmer J., Chen D., et al. | _Year | 2020 | Recor | d Number | 37_33091285 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited fro same population? | m the | | | | |
| 2. | Were the exposures measured similarly to ass people to both exposed and unexposed group | C-86. | | | | |
| 3, | Was the exposure measured in a valid and reli way? | iable | | | | |
| 4. | Were confounding factors identified? | | | | | |
| 5. | Were strategies to deal with confounding fact stated? | ors | | | • | |
| 6. | Were the groups/participants free of the outcoment at the start of the study (or at the moment of exposure)? | ome | • | | | |
| 7. | Were the outcomes measured in a valid and roway? | eliable | • | | | |
| 8. | Was the follow up time reported and sufficient be long enough for outcomes to occur? | tto | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and exp | olored? | | | | |
| 10. | Were strategies to address incomplete follow utilized? | up | | D | | |
| 11. | Was appropriate statistical analysis used? | | | | | |
| | appraisal: Include | k further | info 🗌 | | | |
| | | malaa - | on les | | d. + | n a ratide d |
| Adem | ntomas persistentes que reportan no cur ás, no sé reporta la proporción de cada s | intoma | . 2011103 | riterk | os de tem | poralidad. |

© JBI, 2020. All rights reserved. JBI grants use of these tools for research purposes only. All other enquiries should be sent to jbisynthesis@adelaide.edu.au.

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| review | er Marco Antonio Delaye Martínez Date | 04/01/ | /21 | | - |
|----------|--|--------|--------|---------|-------------------|
| Author | lancu G., Salomon A., Birlutiu V. Year | 2020 | Record | Number_ | 38_32871902 |
| | | Yes | No | Unclear | Not applicable |
| | re patient's demographic characteristics clearly cribed? | | | | |
| | s the patient's history clearly described and presented a timeline? | | | | |
| | s the current clinical condition of the patient on sentation clearly described? | | | | |
| | re diagnostic tests or assessment methods and the ults clearly described? | | | | |
| | s the intervention(s) or treatment procedure(s) clearly cribed? | | | | |
| | s the post-intervention clinical condition clearly cribed? | • | | | |
| | re adverse events (harms) or unanticipated events ntified and described? | | | | |
| B. Doe | es the case report provide takeaway lessons? | ₽ | | | |
| Overalla | appraisal: Include Exclude Seek further | info 🗌 | | | |
| | nts (Including reason for exclusion) | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | Marco Antonio Delaye Martínez | _Date | 04/01/ | 21 | | |
|----------|--|--------|----------|--------|-----------|-------------------|
| Author_ | Garg P., Arora U., Kumar A., et al. | Year_ | 2020 | Record | Number 39 | 32852801 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | • | | | |
| | Does the source of opinion have standing in the of expertise? | field | | | | |
| | Are the interests of the relevant population the central focus of the opinion? | 60 | | | | |
| | Is the stated position the result of an analytical process, and is there logic in the opinion expres | | | | | |
| 5. | Is there reference to the extant literature? | | • | | | |
| | Is any incongruence with the literature/sources logically defended? | | | | | |
| overalla | appraisal; Include | furthe | r info 🔲 | | | |
| ommer | nts (Including reason for exclusion) | | | | | |
| | ntomas persistentes que reportan corres mplados para la revisión en la misma bas zado. | | | | | |

JBI Critical Appraisal Checklist for Case Series

| Reviewer Marco Antonio Delaye Martínez | _Date04 | 1/01/2 | | |
|---|---------------|--------|------------|-------------------|
| Author Roth C., Berat N., Schnider P., et al. | Year 20 | 20_ Re | cord Numbe | er_40_32852173 |
| | Yes | No | Unclear | Not applicable |
| Were there clear criteria for inclusion in the case series? | | | | |
| Was the condition measured in a standard, reliable way for all participants included in the case series? | | | | |
| Were valid methods used for identification of the condition for all participants included in the case series? | • | | | |
| Did the case series have consecutive inclusion of participants? | | | | |
| Did the case series have complete inclusion of participants? | ◙ | | | |
| Was there clear reporting of the demographics of the participants in the study? | | • | | |
| Was there clear reporting of clinical information of the participants? | e 💌 | | | |
| Were the outcomes or follow up results of cases clearly reported? | | | | |
| Was there clear reporting of the presenting site(s)/clinic(s) demographic information? | | | | |
| Was statistical analysis appropriate? | | | | |
| Overall appraisal: Include | k further inf | . 🗆 | | |
| Comments (Including reason for exclusion) | | | | |

Por las caracteristicasbdel cuadro clínico de los pacientes, el artículo ofrece información relevante para la discusión. Sin embargo, se excluye de I revisión sistemática por el diseño del estudio.

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| iewer | Daniel de la Rosa Date | | 21-12 | 20 | |
|------------|--|---|---|--|---|
| hor | Piero Portincasa, et al Year | 2020 | Record Number | | 41_32589264 |
| | | Yes | No | Unclear | Not applicable |
| Is the rev | iew question clearly and explicitly stated? | 1 | | | |
| | n de la constant product de la constant de la constant de la persona de la constant de la constant de la const O la constant de la c | | | | |
| Was the : | search strategy appropriate? | | | | |
| | | | | ď | |
| Were the | criteria for appraising studies appropriate? | | | | Z |
| | The first of the control of the cont | | | | Ø |
| | | | | | Ø |
| Were the | methods used to combine studies appropriate | ? | | | Ø |
| Was the I | likelihood of publication bias assessed? | | | | |
| | 보일없는 가 뭐지 않지 않는데 열어가 되었다면 하세요? [4] - 1 ch ch (4) (ch ch c | Z | | | |
| | | Ø | | | |
| | | r info | | | |
| ments (Inc | luding reason for exclusion) | | | | |
| | Were the studies as Were the studies as Were the extraction were the extraction were the was the were reconsupported were the appropriate appropriate appropriate were the approp | Is the review question clearly and explicitly stated? Were the inclusion criteria appropriate for the review question? Was the search strategy appropriate? Were the sources and resources used to search for studies adequate? Were the criteria for appraising studies appropriate? Was critical appraisal conducted by two or more reviewers independently? Were there methods to minimize errors in data extraction? Were the methods used to combine studies appropriate Was the likelihood of publication bias assessed? Were recommendations for policy and/or practice supported by the reported data? Were the specific directives for new research appropriate? | Piero Portincasa, et al Year Yes Is the review question clearly and explicitly stated? Were the inclusion criteria appropriate for the review question? Was the search strategy appropriate? Were the sources and resources used to search for studies adequate? Were the criteria for appraising studies appropriate? Was critical appraisal conducted by two or more reviewers independently? Were there methods to minimize errors in data extraction? Were the methods used to combine studies appropriate? Was the likelihood of publication bias assessed? Were recommendations for policy and/or practice supported by the reported data? Were the specific directives for new research appropriate? Fall appraisal: Include Exclude Seek further info | Piero Portincasa, et al Year Yes No Is the review question clearly and explicitly stated? Were the inclusion criteria appropriate for the review question? Was the search strategy appropriate? Were the sources and resources used to search for studies adequate? Were the criteria for appraising studies appropriate? Was critical appraisal conducted by two or more reviewers independently? Were there methods to minimize errors in data extraction? Were the methods used to combine studies appropriate? Was the likelihood of publication bias assessed? Were recommendations for policy and/or practice supported by the reported data? Were the specific directives for new research appropriate? Tall appraisal: Include | hor Piero Portincasa, et al Year 2020 Record Number Yes No Unclear Is the review question clearly and explicitly stated? Were the inclusion criteria appropriate for the review question? Was the search strategy appropriate? Were the sources and resources used to search for studies adequate? Were the criteria for appraising studies appropriate? Was critical appraisal conducted by two or more reviewers independently? Were there methods to minimize errors in data extraction? Were the methods used to combine studies appropriate? Was the likelihood of publication bias assessed? Were recommendations for policy and/or practice supported by the reported data? Were the specific directives for new research appropriate? Include Exclude Seek further info |

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Reviewer | | Daniel de la Rosa Da | te | 21-12- | 20 | |
|----------|---------------------|---|----------|---------------|---------|-------------------|
| Aut | hor | Chanu Rhee, et al. Year | 2020 | Record Number | | 42_33029620 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the rev | iew question clearly and explicitly stated? | Z | | | |
| 2. | Were the question? | inclusion criteria appropriate for the review | | | | \square |
| 3. | Was the s | earch strategy appropriate? | | | | Z |
| 4. | Were the studies ac | sources and resources used to search for dequate? | | | | Ø |
| 5. | Were the | criteria for appraising studies appropriate? | | | | K |
| 6. | | cal appraisal conducted by two or more independently? | | | | Ø |
| 7. | Were the extraction | re methods to minimize errors in data n? | | | | Ø |
| 8. | Were the | methods used to combine studies appropriat | e? 🔲 | | | Ø |
| 9. | Was the I | ikelihood of publication bias assessed? | | | | Ø |
| 10. | | ommendations for policy and/or practice d by the reported data? | Z | | | |
| 11. | Were the appropria | specific directives for new research ite? | Ø | | | |
| Ove | rall appraisa | al: Include 🔲 Exclude 🖊 Seek furth | ner info | | | |
| Con | nments (Incl | uding reason for exclusion) | | | | |
| | | | | | | |
| | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | er Marco Antonio Delaye Martínez | _Date | 05 | /01/21 | | |
|----------|--|--------|------------|---------|-------------|---------------------|
| Author_ | Sebio R. | Year_ | 2020 | Record | l Number_4 | 13 <u>3284</u> 4317 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | 9 | | | |
| 2. | Does the source of opinion have standing in the of expertise? | field | | | | |
| 3, | Are the interests of the relevant population the central focus of the opinion? | 60 | 5 | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expres | sed? | • | | | |
| 5. | Is there reference to the extant literature? | | • | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | | | | |
| Overalla | appraisal; Include 🔲 Exclude 🛍 Seek | furthe | er info | | | |
| ommei | nts (Including reason for exclusion) | | | | | |
| | culo no proporciona información útil más | allá c | le la ya c | onsulta | ida para lo | s propósitos |
| | resente revisión sistemática. | | ic id ya c | onounc | da para io | а рі орозіть |

| Review | er Marco Antonio Delaye Martínez Date | _05/01 | /21 | | |
|-----------|--|----------|----------------|---------|-------------------|
| Author | Garrigues E., Janvier P., Kherabi Y., et al., Year | 2020 | Record | Number_ | 44_32853602 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | | | | |
| 2. | Were the study subjects and the setting described in detail? | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | |
| 5. | Were confounding factors identified? | | • | | |
| 6. | Were strategies to deal with confounding factors stated? | | \blacksquare | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was appropriate statistical analysis used? | | | | |
| Overall : | appraisal: Include Exclude Seek further | r info 🗌 | | | |

Comments (Including reason for exclusion)

Las datos que aquí reportan pertenecen a un estudio transversal contenido dentro de una carta al editor. Por la información descrita, el artículo es útil para los propósitos de la revisión sistemática. Sin embargo, Su aceptación al estudio está a reserva de discusión con los otros revisores.

| Review | er Marco Antonio Delaye Martínez | Date | 05/01/ | 21 | | |
|---------|--|---------|--------|--------|---------|-------------------|
| Author, | Tomasoni D., Bai F., Castoldi R., et al. | Year | 2020 | Record | Number_ | 45_32841387 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample cle defined? | arly | | | | |
| 2. | Were the study subjects and the setting describ detail? | ed in | | | | |
| 3. | Was the exposure measured in a valid and relia way? | ble | • | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | | |
| 5. | Were confounding factors identified? | | | | | |
| 6. | Were strategies to deal with confounding factor stated? | rs | | | | |
| | Were the outcomes measured in a valid and rel way? | iable | | | | |
| 8. | Was appropriate statistical analysis used? | | • | | | |
| Overali | appraisal: Include 🗭 Exclude 🔲 Seek | further | info 🗌 | | | |
| Comme | nts (Including reason for exclusion) | | | | | |
| No co | mments. | | | | | |
| | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE CONTROL STUDIES

| h H. L. Ng, et al. | Year 20 | 20 Record I | Number_46_32 | 2999893 |
|---|---|--|---|--|
| | Yes | No | Unclear | Not applicable |
| ps comparable other than the sease in cases or the absence of rols? | ø | | | |
| d controls matched | | | | |
| e criteria used for identification ontrols? | | | | |
| measured in a standard, valid sy? | | | | |
| measured in the same way for rols? | 6 | | | |
| ding factors identified? | | | | |
| s to deal with confounding | 4 | | | |
| s assessed in a standard, valid by for cases and controls? | | | | |
| ure period of interest long neaningful? | | | | |
| te statistical analysis used? | | | | |
| ude 🗌 Exclude 🗹 Seel | k further info | | | |
| son for exclusion) | | | | |
| elevant information regarding | persistent : | symptoms | | |
| 1 1 1 1 | rols? ling factors identified? s to deal with confounding s assessed in a standard, valid y for cases and controls? ure period of interest long neaningful? te statistical analysis used? Ide | ling factors identified? Is to deal with confounding Is assessed in a standard, valid by for cases and controls? Interpretation of interest long the eningful? It is statistical analysis used? Indee | ling factors identified? Is to deal with confounding Is assessed in a standard, valid by for cases and controls? Interpretation of interest long heaningful? It is statistical analysis used? Interpretation of line in the line of line of line in the line of line | ling factors identified? Is to deal with confounding Is assessed in a standard, valid by for cases and controls? Interperiod of interest long beaningful? It is statistical analysis used? Interperiod of Exclude Interperiod of Exclude Interperiod of Seek further info Interperiod of Exclude Interperiod of Exclu |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | Daniel de la Rosa | _Date_ | 14/1 | 1/20 | | |
|---------|---|---------|------------|--------|---------|-------------------|
| Author | Arsun Bektas et al | Year_2 | 2020 | Record | Number_ | 47_32849908 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | 1 | | | |
| 2. | Does the source of opinion have standing in the of expertise? | field | do | | | |
| 3, | Are the interests of the relevant population the central focus of the opinion? | | 0 | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion express | sed? | (3) | | | |
| 5. | Is there reference to the extant literature? | | 100 | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | 8 | | | |
| Overall | appraisal; Include 🔲 Exclude 🛍 Seek | further | info 🔲 | | | |
| | nts (Including reason for exclusion) | | | | | |
| Re | eview | | | | | |
| - | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Review | er Daniel de la Rosa | Date | | 05-0 | 1-21 | |
|----------|---|--------|----------|-------|-----------|-------------------|
| Author | Sachie Ikegami et al. | ear_ | | Recor | d Number_ | 48_32840002 |
| | | | Yes | No | Unclear | Not applicable |
| 1, | Were the two groups similar and recruited from same population? | the | • | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | 3 | | | |
| 3. | Was the exposure measured in a valid and reliab way? | le | | | 6 | |
| 4. | Were confounding factors identified? | | 1 | | | |
| 5. | Were strategies to deal with confounding factors stated? | 5 | Ø | | | |
| 6. | Were the groups/participants free of the outcom at the start of the study (or at the moment of exposure)? | ne | | | 2 | |
| 7. | Were the outcomes measured in a valid and relia way? | able | 1 | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 0 | | 90 | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explor | red? | | | | |
| 10. | Were strategies to address incomplete follow up utilized? | 1 | | 6 | | |
| 11. | Was appropriate statistical analysis used? | 1 | @ | | | |
| Overalla | appraisal: Include Exclude Seek fi | urther | info [|] | | |
| Comme | nts (Including reason for exclusion) | | | | | |
| No co | mments. | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Re | viewer Marco Antonio Delaye Martínez Dat | e_05/01/ | /21 | | |
|-----|--|-----------|--------|---------|-------------------|
| Au | thor_Wang J., Hang X., Wei B., et al. Year | 2020 | Record | Number_ | 49_32846839 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were patient's demographic characteristics clearly described? | | | | |
| 2. | Was the patient's history clearly described and presente as a timeline? | d 👅 | | | |
| 3. | Was the current clinical condition of the patient on presentation clearly described? | | | | |
| 4. | Were diagnostic tests or assessment methods and the results clearly described? | | | | |
| 5. | Was the intervention(s) or treatment procedure(s) clear described? | y 🖥 | | | |
| 6. | Was the post-intervention clinical condition clearly described? | | | | |
| 7. | Were adverse events (harms) or unanticipated events identified and described? | | | | |
| 8. | Does the case report provide takeaway lessons? | | | | |
| Ow | erali appraisal: Include 🔲 Exclude 🕒 Seek furth | er info 🔲 | | | |
| Col | nments (Including reason for exclusion) | | | | |
| art | bido que no sé reporta la persistencia de síntoma ículo queda excluido de la revisión sistemática. As eño para su inclusión. | | | | |

| Reviewe | Daniel de la Rosa | ite | 10 |)-01-21 | | |
|---------|--|---------|------|---------|---------|-------------------|
| Author_ | Peng Xia et al Yea | r_ 2 | 2020 | Record | Number_ | 50_32826326 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | У | / | | | |
| 2. | Were the study subjects and the setting described detail? | lin | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | Z | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | 1 | |
| 5. | Were confounding factors identified? | | | | 1 | |
| 6. | Were strategies to deal with confounding factors stated? | | | | 1 | |
| 7. | Were the outcomes measured in a valid and reliab way? | ole | | | 1 | |
| 8. | Was appropriate statistical analysis used? | | N | | | |
| | ppraisal: Include | her inf | io 🗌 | | | |
| No info | rmation on long term manifestation of COVID- | 19 | | | | |
| 11 | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Review | er Daniel de la Rosa | Date | | 05-0 | 1-21 | |
|-----------|---|-----------|----------|---------|-----------|-------------------|
| Author | Maria A. Corcorran, et al. | _Year_ | 2020 | _ Recor | d Number_ | 51_32827597 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited fro same population? | om the | • | | | |
| 2. | Were the exposures measured similarly to ass people to both exposed and unexposed group | 15.00 | 3 | | | |
| 3. | Was the exposure measured in a valid and re way? | liable | | | | |
| 4. | Were confounding factors identified? | | | 1 | | |
| 5. | Were strategies to deal with confounding fact stated? | tors | | 9 | | |
| 6. | Were the groups/participants free of the oute at the start of the study (or at the moment of exposure)? | | Ø | | | |
| 7. | Were the outcomes measured in a valid and r way? | reliable | Z | | | |
| 8. | Was the follow up time reported and sufficient be long enough for outcomes to occur? | nt to | | 60 | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and ex | | | | • | |
| 10. | Were strategies to address incomplete follow utilized? | up | | 6 | | |
| 11. | Was appropriate statistical analysis used? | | @ | | | |
| Overall a | appraisal: Include 🔲 Exclude 磨 Sec | ek furthe | er info |] | | |
| Comme | nts (Including reason for exclusion) | | | | | |
| No co | mments. | | | | | |

CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

Critical Appraisal tools for use in JBI Systematic Reviews

INTRODUCTION

JBI is an JBI is an international research organisation based in the Faculty of Health and Medical Sciences at the University of Adelaide, South Australia. JBI develops and delivers unique evidence-based information, software, education and training designed to improve healthcare practice and health outcomes. With over 70 Collaborating Entities, servicing over 90 countries, JBI is a recognised global leader in evidence-based healthcare.

JBI Systematic Reviews

The core of evidence synthesis is the systematic review of literature of a particular intervention, condition or issue. The systematic review is essentially an analysis of the available literature (that is, evidence) and a judgment of the effectiveness or otherwise of a practice, involving a series of complex steps. JBI takes a particular view on what counts as evidence and the methods utilised to synthesise those different types of evidence. In line with this broader view of evidence, JBI has developed theories, methodologies and rigorous processes for the critical appraisal and synthesis of these diverse forms of evidence in order to aid in clinical decision-making in healthcare. There now exists JBI guidance for conducting reviews of effectiveness research, qualitative research, prevalence/incidence, etiology/risk, economic evaluations, text/opinion, diagnostic test accuracy, mixed-methods, umbrella reviews and scoping reviews. Further information regarding JBI systematic reviews can be found in the JBI Evidence Synthesis Manual.

JBI Critical Appraisal Tools

All systematic reviews incorporate a process of critique or appraisal of the research evidence. The purpose of this appraisal is to assess the methodological quality of a study and to determine the extent to which a study has addressed the possibility of bias in its design, conduct and analysis. All papers selected for inclusion in the systematic review (that is – those that meet the inclusion criteria described in the protocol) need to be subjected to rigorous appraisal by two critical appraisers. The results of this appraisal can then be used to inform synthesis and interpretation of the results of the study. JBI Critical appraisal tools have been developed by the JBI and collaborators and approved by the JBI Scientific Committee following extensive peer review. Although designed for use in systematic reviews, JBI critical appraisal tools can also be used when creating Critically Appraised Topics (CAT), in journal clubs and as an educational tool.

| Reviewer: Daniel de la Rosa Martinez | | | Date: 27 d | e abril 2020 |
|--|--------|-------|-------------|-------------------|
| Author: Year: 2020 | Record | Numbe | er: 52_328: | 39787_DDM |
| | Yes | No | Unclear | Not applicable |
| Were the criteria for inclusion in the sample clearly defined? | | | | |
| 2. Were the study subjects and the setting described in detail? | | | | |
| 3. Was the exposure measured in a valid and reliable way? | | | | |
| 4. Were objective, standard criteria used for measurement of the condition? | | | | |
| 5. Were confounding factors identified? | | | | |
| 6. Were strategies to deal with confounding factors stated? | | | | |
| 7. Were the outcomes measured in a valid and reliable way? | | | | |
| 8. Was appropriate statistical analysis used? | | | | |
| Overall appraisal: Include | nfo 🗌 | | | |
| Comments (Including reason for exclusion) | | | | |

_No se mencionan sintomas persistentes, se hace una exploración de la clínica pero sin el seguimiento suficiente para explorar secuelas o long covid

EXPLANATION OF ANALYTICAL CROSS SECTIONAL STUDIES CRITICAL APPRAISAL

How to cite: Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, 2020. Available from https://synthesismanual.jbi.global

Analytical cross sectional studies Critical Appraisal Tool

Answers: Yes, No, Unclear or Not/Applicable

Were the criteria for inclusion in the sample clearly defined?

The authors should provide clear inclusion and exclusion criteria that they developed prior to recruitment of the study participants. The inclusion/exclusion criteria should be specified (e.g., risk, stage of disease progression) with sufficient detail and all the necessary information critical to the study.

2. Were the study subjects and the setting described in detail?

The study sample should be described in sufficient detail so that other researchers can determine if it is comparable to the population of interest to them. The authors should provide a clear description of the population from which the study participants were selected or recruited, including demographics, location, and time period.

Was the exposure measured in a valid and reliable way?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

Reliability refers to the processes included in an epidemiological study to check repeatability of measurements of the exposures. These usually include intra-observer reliability and inter-observer reliability.

4. Were objective, standard criteria used for measurement of the condition?

It is useful to determine if patients were included in the study based on either a specified diagnosis or definition. This is more likely to decrease the risk of bias. Characteristics are another useful approach to matching groups, and studies that did not use specified diagnostic methods or definitions should provide evidence on matching by key characteristics

5. Were confounding factors identified?

Confounding has occurred where the estimated intervention exposure effect is biased by the presence of some difference between the comparison groups (apart from the exposure investigated/of interest). Typical confounders include baseline characteristics, prognostic factors, or concomitant exposures (e.g. smoking). A confounder is a difference between the comparison groups and it influences the direction of the study results. A high quality study at the level of cohort design will identify the potential confounders and measure them (where possible). This is difficult for studies where behavioral, attitudinal or lifestyle factors may impact on the results.

6. Were strategies to deal with confounding factors stated?

Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or stratifying sampling of participants, effects of confounding factors can be adjusted for. When dealing with adjustment in data analysis, assess the statistics used in the study. Most will be some form of multivariate regression analysis to account for the confounding factors measured.

7. Were the outcomes measured in a valid and reliable way?

Read the methods section of the paper. If for e.g. lung cancer is assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If lung cancer is assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

Having established the objectivity of the outcome measurement (e.g. lung cancer) instrument, it's important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? (e.g. radiographers). If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised?

8. Was appropriate statistical analysis used?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.

For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Reviewer | Daniel de la Rosa Martinez | _Date_ | 15-01 | 1-21 | | |
|-----------------------|---|---------|--------|--------|-----------|-------------------|
| Author | Tale et al | Year_ | 2020 | Record | Number_ | 53_32814978_DDI |
| | | | Yes | No | Unclear | Not applicable |
| . Were pa describe | tient's demographic characteristics clearly d? | | | | | |
| . Was the as a time | patient's history clearly described and pres line? | sented | 0 | | | |
| | current clinical condition of the patient on tion clearly described? | | 9 | | | |
| | gnostic tests or assessment methods and t early described? | the | | | | |
| . Was the describe | intervention(s) or treatment procedure(s) d? | clearly | | | | @ |
| . Was the describe | post-intervention clinical condition clearly d? | | | | | • |
| | verse events (harms) or unanticipated ever d and described? | nts | | | 30 | |
| . Does the | case report provide takeaway lessons? | | 0 | | | |
| Overall apprai | sal: Include 🗌 Exclude 📆 Seek | further | info 🗌 | | | |
| omments (In | cluding reason for exclusion) | | | | | |
| Case rep | port | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Rev | iewer | Daniel de la Rosa Date 21-11-20 | | | | |
|--------|---------------------|--|----------|--------|-----------|-------------------|
| Author | | J. R. Kelly et al Year | 2020 | Record | l Number_ | 54_32811575 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the revi | ew question clearly and explicitly stated? | | | | |
| 2. | Were the question? | inclusion criteria appropriate for the review | | | | Z |
| 3. | Was the s | earch strategy appropriate? | | | | Z |
| 4. | Were the studies ad | sources and resources used to search for lequate? | | | | Ø |
| 5. | Were the | criteria for appraising studies appropriate? | | | | d |
| 6. | | al appraisal conducted by two or more independently? | | | | Ø |
| 7. | Were the | re methods to minimize errors in data n? | | | | Ø |
| 8. | Were the | methods used to combine studies appropriat | e? | | | Ø |
| 9. | Was the li | kelihood of publication bias assessed? | | | | Ø |
| 10. | | ommendations for policy and/or practice I by the reported data? | | | Ø | |
| 11. | Were the appropria | specific directives for new research te? | Ø | | | |
| Ove | rall appraisa | l: Include Exclude Seek furth | ner info | | | |
| Com | ments (Incl | uding reason for exclusion) | | | | |
| - | Review - I | Excludes | | | | |

| Reviewe | Daniel de la Rosa | | 10 | 5-01-21 | | |
|---------|--|--------|----------|---------|---------|-------------------|
| Author_ | Christine Miaskowski et al | ear_ | 2020 | Record | Number_ | 55_32809060 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample cle defined? | arly | 1 | | | |
| 2. | Were the study subjects and the setting describ detail? | ed in | 2 | | | |
| 3. | Was the exposure measured in a valid and relia way? | ble | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | 1 | | | |
| 5. | Were confounding factors identified? | | | 1 | | |
| 6. | Were strategies to deal with confounding facto stated? | rs: | | 1 | | |
| 7. | Were the outcomes measured in a valid and rel way? | iable | Z | | | |
| 8. | Was appropriate statistical analysis used? | | N | | | |
| | opraisal: Include | urther | info 🗌 | | | |
| No inf | formation about PACS | | | | | |
| | | | | | | |

| Reviewe | Daniel de la Rosa | Date | | 20-01-2 | 1 | | |
|-----------|--|-----------|-------|----------|-----------|-------------------|------|
| Author_ | Ding Shi, et al | Year | 2020 | Record I | Number 56 | _32614392_ | _DDM |
| | | | Yes | No | Unclear | Not applicable | |
| 1. | Were the criteria for inclusion in the sample cledefined? | early | 1 | | | | |
| 2. | Were the study subjects and the setting descri detail? | bed in | 2 | | | | |
| 3. | Was the exposure measured in a valid and relia way? | able | | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | 1 | | | | |
| 5. | Were confounding factors identified? | | 1 | | | | |
| 6. | Were strategies to deal with confounding factorstated? | ors | K | | | | |
| 7. | Were the outcomes measured in a valid and re way? | liable | Z | | | | |
| 8. | Was appropriate statistical analysis used? | | N | | | | |
| Overall a | ppraisal: Include 🔲 Exclude 🖊 Seek | further i | nfo 🗌 | | | | |
| Commen | ts (Including reason for exclusion) | | | | | | |
| No info | rmation about long-term manifestations | | | | | | |

| Reviewe | Daniel de la Rosa | ite_ | 2 | 2-11-20 | | |
|---------|--|------|--------|---------|---------|-------------------|
| Author_ | Martijn A. Spruit et al Yea | r | 2020 | Record | Number_ | 58_32817258 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clear defined? | y | | | 2 | |
| 2. | Were the study subjects and the setting described detail? | l in | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | 2 | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | | |
| 5. | Were confounding factors identified? | | | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | | | 1 |
| 7. | Were the outcomes measured in a valid and relial way? | ole | | | | P |
| 8. | Was appropriate statistical analysis used? | | | | | N |
| Commen | opraisal: Include | her | info 🗌 | | | |
| Guide | liness based on expert opinion | | | | | |

JBI Critical Appraisal Checklist for Case Series

| Reviewer | Daniel de la Rosa Martinez | _Date04 | 4/01/2 | 1 | |
|--|--|---------------|--------|------------|-------------------|
| Author | Martin A. Vilela-Estradaa | Year 20 | 20_ Re | cord Numbe | er_59_32804922 |
| | | Yes | No | Unclear | Not applicable |
| • Were there series? | clear criteria for inclusion in the case | | Z | | |
| | ndition measured in a standard, reliable participants included in the case series? | 1 | | | |
| | methods used for identification of the or all participants included in the case | t | | | |
| Did the case participants | e series have consecutive inclusion of s? | | | | |
| Did the case participants | e series have complete inclusion of s? | 1 | | | |
| | clear reporting of the demographics of the s in the study? | 1 | | | |
| Was there of participants | clear reporting of clinical information of the \$? | | | | |
| - Were the o | utcomes or follow up results of cases orted? | | | | |
| | clear reporting of the presenting c(s) demographic information? | 1 | | | |
| • Was statisti | ical analysis appropriate? | | | | 1 |
| | aisal: Include | k further inf | 。 □ | | |
| Property of the Control of the Contr | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Reviewer_ | Daniel de la Rosa | Date_ | | 21-01 | -21 | |
|------------------------|---|------------|----------|--------|---------|-------------------|
| Author_Pe | dro Augusto Sampaio Rocha-Filho, | _Year_ | 2020 | Record | Number_ | 60_32790179 |
| | | | Yes | No | Unclear | Not applicable |
| Were p describe | atient's demographic characteristics clear ed? | У | d | | | |
| 2. Was the as a tim | e patient's history clearly described and pr eline? | esented | | | | |
| | e current clinical condition of the patient o ation clearly described? | n | | | | |
| | lagnostic tests or assessment methods and clearly described? | d the | 1 | | | |
| 5. Was the describe | e intervention(s) or treatment procedure(s ed? | ;) clearly | | | | |
| 6. Was the describe | e post-intervention clinical condition clear ed? | ly | | | | |
| | dverse events (harms) or unanticipated ev ed and described? | ents | * | | | |
| 8. Does th | e case report provide takeaway lessons? | | 1 | | | |
| Overall appr | aisal: Include 🔲 Exclude 🗹 Sec | ≥k further | info 🗌 | | | |
| Comments (I | ncluding reason for exclusion) | | | | | |
| Case | eport | | | | | |
| | | | | | | |

| Reviewe | Daniel de la Rosa | ate_ | 20 | 5-01-21 | | |
|---------|---|--------|-------|---------|---------|-------------------|
| Author_ | Salma Batool-Anwar, Yea | ar | 2020 | Record | Number_ | 61_32780011 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clear defined? | ly | Z | | | |
| 2. | Were the study subjects and the setting described detail? | d in | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | e | Z | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | N | | | |
| 5. | Were confounding factors identified? | | | 1 | | |
| 6. | Were strategies to deal with confounding factors stated? | | | 1 | | |
| 7. | Were the outcomes measured in a valid and relial way? | ble | N | | | |
| 8. | Was appropriate statistical analysis used? | | N | | | |
| | ppraisal: Include Exclude Seek funt ts (Including reason for exclusion) | ther i | nfo 🗌 | | | |
| | No information about PACS | | | | | |
| 2 | | | | | | |

| Review | er Daniel de la Rosa Martine: | | Dat | e | 29/11 | /20 | | |
|-----------|--|---------|----------|------------|----------|-----|----------|-------------------|
| Author_ | Ye | ar2 | 020 | Record | l Number | 62 | 32644129 | E |
| | | | | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in th defined? | e sam | iple cle | arly | | | | |
| 2. | Were the study subjects and the se detail? | tting | describ | ed in | | | | |
| 3. | Was the exposure measured in a va way? | alid an | nd relia | ble | | | | |
| 4. | Were objective, standard criteria u measurement of the condition? | sed fo | or | | | | | |
| 5. | Were confounding factors identifie | d? | | | | | | |
| 6. | Were strategies to deal with confor stated? | undin | g facto | rs | | | | |
| 7. | Were the outcomes measured in a way? | valid : | and rel | iable | | | | |
| 8. | Was appropriate statistical analysis | used | ? | | | | | |
| Overall a | appraisal: Include Exclude | | Seek | further in | nfo 🗌 | | | |
| Commer | nts (Including reason for exclusion) | | | | | | | |
| | | | | | | | | |
| 2 | | | | | | | | |

EXPLANATION OF ANALYTICAL CROSS SECTIONAL STUDIES CRITICAL APPRAISAL

How to cite: Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, 2020. Available from https://synthesismanual.jbi.global

Analytical cross sectional studies Critical Appraisal Tool

Answers: Yes, No, Unclear or Not/Applicable

Were the criteria for inclusion in the sample clearly defined?

The authors should provide clear inclusion and exclusion criteria that they developed prior to recruitment of the study participants. The inclusion/exclusion criteria should be specified (e.g., risk, stage of disease progression) with sufficient detail and all the necessary information critical to the study.

2. Were the study subjects and the setting described in detail?

The study sample should be described in sufficient detail so that other researchers can determine if it is comparable to the population of interest to them. The authors should provide a clear description of the population from which the study participants were selected or recruited, including demographics, location, and time period.

3. Was the exposure measured in a valid and reliable way?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

Reliability refers to the processes included in an epidemiological study to check repeatability of measurements of the exposures. These usually include intra-observer reliability and inter-observer reliability.

4. Were objective, standard criteria used for measurement of the condition?

It is useful to determine if patients were included in the study based on either a specified diagnosis or definition. This is more likely to decrease the risk of bias. Characteristics are another useful approach to matching groups, and studies that did not use specified diagnostic methods or definitions should provide evidence on matching by key characteristics.

5. Were confounding factors identified?

Confounding has occurred where the estimated intervention exposure effect is biased by the presence of some difference between the comparison groups (apart from the exposure investigated/of interest). Typical confounders include baseline characteristics, prognostic factors, or concomitant exposures (e.g. smoking). A confounder is a difference between the comparison groups and it influences the direction of the study results. A high quality study at the level of cohort design will identify the potential confounders and measure them (where possible). This is difficult for studies where behavioral, attitudinal or lifestyle factors may impact on the results.

6. Were strategies to deal with confounding factors stated?

Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or stratifying sampling of participants, effects of confounding factors can be adjusted for. When dealing with adjustment in data analysis, assess the statistics used in the study. Most will be some form of multivariate regression analysis to account for the confounding factors measured.

7. Were the outcomes measured in a valid and reliable way?

Read the methods section of the paper. If for e.g. lung cancer is assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If lung cancer is assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

Having established the objectivity of the outcome measurement (e.g. lung cancer) instrument, it's important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? (e.g. radiographers). If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised?

8. Was appropriate statistical analysis used?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.

For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Review | er Daniel de la Rosa | Date | | 30-01 | -21 | |
|-----------|--|-----------|----------|-------|----------|-------------------|
| Author_ | Vallari Shah, et al | Year_ | 2020 | Recor | d Number | 63_32526039 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited fro same population? | m the | 0 | | | |
| 2. | Were the exposures measured similarly to assi people to both exposed and unexposed group: | | Q | | | |
| 3, | Was the exposure measured in a valid and reli way? | able | * | | | |
| 4. | Were confounding factors identified? | | | | • | |
| 5. | Were strategies to deal with confounding factorstated? | ors | | | 0 | |
| 6. | Were the groups/participants free of the outco at the start of the study (or at the moment of exposure)? | ome | | | 8 | |
| 7. | Were the outcomes measured in a valid and re way? | eliable | 0 | | | |
| 8. | Was the follow up time reported and sufficient be long enough for outcomes to occur? | tto | P | | | |
| | Was follow up complete, and if not, were the reasons to loss to follow up described and exp | lored? | | | | Ō |
| 10. | Were strategies to address incomplete follow utilized? | up | | | | @ |
| 11. | Was appropriate statistical analysis used? | | | | | |
| Overall a | appraisal: Include 🔲 Exclude 🏮 See | k further | info 🗌 | | | |
| | nts (Including reason for exclusion) Iformation about PACS | | | | | |
| INO IN | normation about PACS | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Re | viewer_ | Daniel de la Rosa | Date | | 31-01 | 1-21 | |
|--------|---------|---|-------------|--------|------------------|---------|-------------------|
| Author | | Sam K. Touisserkani et al | Year | 2020 | Record Number_ | | 64_3280254 |
| | | | | Yes | No | Unclear | Not applicable |
| 1. | Were p | atient's demographic characteristics clea ed? | rly | | | | |
| 2. | Was the | e patient's history clearly described and peline? | presented | | | | |
| 3. | | e current clinical condition of the patient ation clearly described? | on | Z | | | |
| 4. | | iagnostic tests or assessment methods a clearly described? | nd the | d | | | |
| 5. | Was the | e intervention(s) or treatment procedure ed? | (s) clearly | Z | | | |
| 6. | Was the | e post-intervention clinical condition clea ed? | rly | | | | |
| 7. | | dverse events (harms) or unanticipated e ed and described? | events | | | | Z |
| 8. | Does th | e case report provide takeaway lessons? | | | | | |
| | | alsal: Include | eek further | info 🗌 | 2 2 2 2 | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Review | Daniel de la Rosa Martinez Date | | | 31-0 | 1-21 | |
|---------|--|---------|-------|-------|-----------|-------------------|
| Author | Carlo Gaspardone, et al. Ye | ar | 2020 | Recor | d Number_ | 65_32770687 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from to same population? | he | 1 | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | 1 | | | |
| 3. | Was the exposure measured in a valid and reliable way? | 8 | | | | |
| 4. | Were confounding factors identified? | | | Ø | | |
| 5. | Were strategies to deal with confounding factors stated? | | | 1 | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | | | Z |
| 7. | Were the outcomes measured in a valid and relial way? | ole | / | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | | 6 | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explore | ed? | | | 1 | |
| 10. | Were strategies to address incomplete follow up utilized? | | | 1 | | |
| 11. | Was appropriate statistical analysis used? | | | | | |
| Overall | appraisal: Include 🗆 Exclude 🕈 Seek fu | rther i | nfo 🗌 | | | |
| Comme | nts (Including reason for exclusion) | | | | | |
| No co | mments. | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Rev | iewer | wer Daniel de la Rosa | | 31 | -01-20 | | |
|-----|--|---|----------------|----------------|--------|---------|---|
| Aut | hor | orXuemin Guo et al | | Record Number_ | | | 66_3284965 |
| | | | | Yes | No | Unclear | Not applicable |
| 1. | Were pati described | ent's demographic characteristics c ? | learly | 1 | | | |
| 2. | Was the p as a timeli | atient's history clearly described an ne? | nd presented | | | | |
| 3. | | urrent clinical condition of the patie on clearly described? | ent on | Z | | | |
| 4. | The state of the s | nostic tests or assessment method arly described? | s and the | 1 | | | |
| 5. | Was the ir described | ntervention(s) or treatment proced ? | ure(s) clearly | 1 | | | |
| 6. | Was the p described | ost-intervention clinical condition o | learly | ø | | | |
| 7. | | erse events (harms) or unanticipate and described? | d events | # | | | |
| 8. | Does the | case report provide takeaway lesso | ns? | | | | |
| Ove | rall apprais | al: Include 🗌 Exclude 🗹 | Seek further i | nfo 🔲 | | | |
| Con | nments (Incl | uding reason for exclusion) | | | | | |
| | Case rep | port | | | | | ======================================= |

JBI CRITICAL APPRAISAL CHECKLIST FOR QUASI-EXPERIMENTAL STUDIES

| Review | er Isaac David Juárez Cruz | Date | | 1 | 4/11/2020 | |
|---------|--|--------|----------------|--------|-----------|-------------------|
| Author | Supeng Wang, Yang Pan, Quanyi Wang, Huangyu Miao, Ashley N. Brown, Libin Rong | ear_ | 2020 | Record | Number 6 | 37_32771304_IDJ0 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is it clear in the study what is the 'cause' and who the 'effect' (i.e. there is no confusion about which variable comes first)? | | | | | |
| 2. | Were the participants included in any compariso similar? | ns | | | | |
| 3. | Were the participants included in any compariso receiving similar treatment/care, other than the exposure or intervention of interest? | | | | | |
| 4. | Was there a control group? | | | | | |
| 5. | Were there multiple measurements of the outco both pre and post the intervention/exposure? | me | 1 | | | |
| 6. | Was follow up complete and if not, were different between groups in terms of their follow up adequately described and analyzed? | nces | | | | |
| 7. | Were the outcomes of participants included in a comparisons measured in the same way? | ny | | | | |
| 8. | Were outcomes measured in a reliable way? | | | | | |
| 9. | Was appropriate statistical analysis used? | | | | | |
| Overall | appraisal: Include 🔲 Exclude 🗐 Seek f | urther | info \square | | | |
| Comme | nts (Including reason for exclusion) | | | | | |
| interé | xcluye este Artículo, no por su cálidad, sin es para la revisión. No hace mención a da emento. | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Reviewe | Daniel de la Rosa Date | 3 | 1-01-21 | | |
|---------|---|--------|---------|---------|-------------------|
| Author_ | Vaira LA, et al Year_ | 2020 | Record | Number_ | 68_32762737 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | 1 | | | |
| 2. | Were the study subjects and the setting described in detail? | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | Z | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | 1 | | | |
| 5. | Were confounding factors identified? | | / | | |
| 6. | Were strategies to deal with confounding factors stated? | | 1 | | |
| 7. | Were the outcomes measured in a valid and reliable way? | Z | | | |
| 8. | Was appropriate statistical analysis used? | N | | | |
| Commen | opraisal: Include | info 🗌 | | | |
| | | | | | |
| | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Reviewer | Daniel de la Rosa | Date_ | 3. | 1-01-21 | | |
|----------|---|--------|--------|----------|---------|-------------------|
| Author | Cristina Corsini Campiolia, et al. | ear_ | 2020 | Record I | Number_ | 69_32777762 |
| | | | Yes | No | Unclear | Not applicable |
| | Were the criteria for inclusion in the sample cle defined? | arly | | | | |
| | Were the study subjects and the setting describ detail? | ed in | | | | |
| | Was the exposure measured in a valid and relial way? | ble | Z | | | |
| | Were objective, standard criteria used for measurement of the condition? | | 1 | | | |
| 5. | Were confounding factors identified? | | | 1 | | |
| | Were strategies to deal with confounding factor stated? | rs | | 1 | | |
| | Were the outcomes measured in a valid and rel way? | iable | N | | | |
| 8. | Was appropriate statistical analysis used? | | N | | | |
| | praisal: Include | urther | info 🗌 | | | |
| | s (Including reason for exclusion) ow up time less than 21 days | | | | | |
| 3107111 | | | | | | |
| 7 | | | | | | |

| Review | er Isaac David Juárez Cruz | Date | | 14/11/20 | | | |
|--------|--|---------|--------|----------|----------|-------------------|--|
| Author | | Year | 2020 | Recor | d Number | 70_32757419_IDJC | |
| | Pon et-Megemont L, Paris P, Tronchere A, Salazar JP, Pereira B, Dallel R, Aumeran C, Beytout J, Jacome C, Laurichesse H, Lessens O, Mrozeck N, Vidal M, Moisés X | C | Yes | No | Unclear | Not applicable | |
| 1. | Were the two groups similar and recruited from same population? | the | | | | | |
| 2. | Were the exposures measured similarly to assig people to both exposed and unexposed groups | | | | | | |
| 3, | Was the exposure measured in a valid and relial way? | ble | | | | | |
| 4. | Were confounding factors identified? | | | | | | |
| 5. | Were strategies to deal with confounding factor stated? | rs | | 4 | | | |
| 6. | Were the groups/participants free of the outcor at the start of the study (or at the moment of exposure)? | ne | | | | | |
| 7. | Were the outcomes measured in a valid and reli way? | iable | | | | | |
| 8. | Was the follow up time reported and sufficient be long enough for outcomes to occur? | to | | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explo | ored? | 1 | | | | |
| 10. | Were strategies to address incomplete follow up utilized? | p | | | | | |
| 11. | Was appropriate statistical analysis used? | | | | | | |
| | appraisal: Include | further | info 🗆 | l | | | |

Se incluye. Aporta información sobre la persistencia de síntomas neurologicos, su relación con cefalea y la prevalencia de dolores de cabeza durante fase aguda y post infección.

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Reviewe | | Isaac David Juárez Cruz | | | Date | | 15 | V11/20 | | | |
|---------|--------|-------------------------|-----------------------|-----------|-------------------------------|----------------------|-------------|----------|--------|---------|-------------------|
| Auth | or | | | | tetta, I. Pino io Amendoli | o, C. Mariner ia. | o. Year_ | 2020 | Record | Number_ | 71_32840156_IDJC |
| | | | | | | | | Yes | No | Unclear | Not applicable |
| 1. | Is the | e review | question | clearly | and expl | icitly state | ed? | 1 | | | |
| | | e the inc | lusion cri | teria ap | propriate | for the n | eview | ď | | | |
| 3. | Was | the sear | ch strate | gy appr | opriate? | | | | | | |
| | | e the so ies adeq | | resour | ces used | to search | for | | | | |
| 5. | Wer | e the cri | teria for a | ppraisi | ng studie | s appropr | iate? | | | | |
| | | | appraisal depender | | ted by tw | o or more | • | | | | |
| | | e there raction? | nethods 1 | to minir | nize erro | rs in data | | | П | | |
| 8. | Wen | e the me | thods us | ed to co | ombine st | udies app | ropriate | ' 🗹 | | | |
| 9. | Was | the likel | ihood of | publica | tion bias | assessed? | ÿ | | | | |
| | | | mendation the repo | | - 22 | /or practi | ce | | | | |
| | | e the spo opriate? | | ctives f | or new re | search | , | | | | |
| Over | all ap | praisal: | Include | | Exclude | ☐ Se | ek furthe | r info 🔲 | | | |
| Comr | nent | (Includi | ng reason | for excl. | ision) | | | | | | |

Se excluye, si bien es una buena revisión, no hace mención de síntomas persistentes o algún dato de utilidad para nuestra revisión, por el hecho de que es una revisión muy temprana, lo hay muchos datos disponibles.

CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

Critical Appraisal tools for use in JBI Systematic Reviews

INTRODUCTION

JBI is an JBI is an international research organisation based in the Faculty of Health and Medical Sciences at the University of Adelaide, South Australia. JBI develops and delivers unique evidence-based information, software, education and training designed to improve healthcare practice and health outcomes. With over 70 Collaborating Entities, servicing over 90 countries, JBI is a recognised global leader in evidence-based healthcare.

JBI Systematic Reviews

The core of evidence synthesis is the systematic review of literature of a particular intervention, condition or issue. The systematic review is essentially an analysis of the available literature (that is, evidence) and a judgment of the effectiveness or otherwise of a practice, involving a series of complex steps. JBI takes a particular view on what counts as evidence and the methods utilised to synthesise those different types of evidence. In line with this broader view of evidence, JBI has developed theories, methodologies and rigorous processes for the critical appraisal and synthesis of these diverse forms of evidence in order to aid in clinical decision-making in healthcare. There now exists JBI guidance for conducting reviews of effectiveness research, qualitative research, prevalence/incidence, etiology/risk, economic evaluations, text/opinion, diagnostic test accuracy, mixed-methods, umbrella reviews and scoping reviews. Further information regarding JBI systematic reviews can be found in the JBI Evidence Synthesis Manual.

JBI Critical Appraisal Tools

All systematic reviews incorporate a process of critique or appraisal of the research evidence. The purpose of this appraisal is to assess the methodological quality of a study and to determine the extent to which a study has addressed the possibility of bias in its design, conduct and analysis. All papers selected for inclusion in the systematic review (that is – those that meet the inclusion criteria described in the protocol) need to be subjected to rigorous appraisal by two critical appraisers. The results of this appraisal can then be used to inform synthesis and interpretation of the results of the study. JBI Critical appraisal tools have been developed by the JBI and collaborators and approved by the JBI Scientific Committee following extensive peer review. Although designed for use in systematic reviews, JBI critical appraisal tools can also be used when creating Critically Appraised Topics (CAT), in journal clubs and as an educational tool.

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Review | er: Daniel de la Rosa Martinez. | | Date: I | unes 26 de | Abril 2021 |
|-----------|--|----------|---------|------------|-------------------|
| Author: | Anika Singanayagam, et al Year: 2020 | Record 1 | Number | : 72_3279 | 4447_DDM |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | | | | |
| 2. | Were the study subjects and the setting described in detail? | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | |
| 5. | Were confounding factors identified? | | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was appropriate statistical analysis used? | | | | |
| Overall : | appraisal; Include | nfo 🗆 | | | |
| Comme | nts (Including reason for exclusion) | | | | |

No aporta datos en relacion a sintomas persistentes, hace referencia a niveles de CT y su asociacion a desenlaces clínicos

EXPLANATION OF ANALYTICAL CROSS SECTIONAL STUDIES CRITICAL APPRAISAL

How to cite: Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, 2020. Available from https://synthesismanual.jbi.global

Analytical cross sectional studies Critical Appraisal Tool

Answers: Yes, No, Unclear or Not/Applicable

Were the criteria for inclusion in the sample clearly defined?

The authors should provide clear inclusion and exclusion criteria that they developed prior to recruitment of the study participants. The inclusion/exclusion criteria should be specified (e.g., risk, stage of disease progression) with sufficient detail and all the necessary information critical to the study.

2. Were the study subjects and the setting described in detail?

The study sample should be described in sufficient detail so that other researchers can determine if it is comparable to the population of interest to them. The authors should provide a clear description of the population from which the study participants were selected or recruited, including demographics, location, and time period.

3. Was the exposure measured in a valid and reliable way?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

Reliability refers to the processes included in an epidemiological study to check repeatability of measurements of the exposures. These usually include intra-observer reliability and inter-observer reliability.

4. Were objective, standard criteria used for measurement of the condition?

It is useful to determine if patients were included in the study based on either a specified diagnosis or definition. This is more likely to decrease the risk of bias. Characteristics are another useful approach to matching groups, and studies that did not use specified diagnostic methods or definitions should provide evidence on matching by key characteristics

5. Were confounding factors identified?

Confounding has occurred where the estimated intervention exposure effect is biased by the presence of some difference between the comparison groups (apart from the exposure investigated/of interest). Typical confounders include baseline characteristics, prognostic factors, or concomitant exposures (e.g. smoking). A confounder is a difference between the comparison groups and it influences the direction of the study results. A high quality study at the level of cohort design will identify the potential confounders and measure them (where possible). This is difficult for studies where behavioral, attitudinal or lifestyle factors may impact on the results.

6. Were strategies to deal with confounding factors stated?

Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or stratifying sampling of participants, effects of confounding factors can be adjusted for. When dealing with adjustment in data analysis, assess the statistics used in the study. Most will be some form of multivariate regression analysis to account for the confounding factors measured.

7. Were the outcomes measured in a valid and reliable way?

Read the methods section of the paper. If for e.g. lung cancer is assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If lung cancer is assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

Having established the objectivity of the outcome measurement (e.g. lung cancer) instrument, it's important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? (e.g. radiographers). If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised?

8. Was appropriate statistical analysis used?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.

For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE CONTROL STUDIES

| Reviewe | r_ Isaac David Juárez Cruz | _Date | 18/11/ | 20 | |
|-----------|---|---------------|-------------|--------------|-----------------|
| Author_ | Vaira L, Hopkins C, Petrocelli M, Lechien J R, Chiesa-EstombaC M, Salzano G, Cucurullo M, Salzano F A, Saussez S, Boscolo-Rizzo P, Biglioli FDe Riu G. | Year 20 | 20 Record N | umber_73_327 | 82030_IDJ |
| | | Yes | No | Unclear | Not applicat |
| 1. | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | 4 | | | |
| 2. | Were cases and controls matched appropriately? | | | | |
| | Were the same criteria used for identification of cases and controls? | | | | |
| 4. | Was exposure measured in a standard, valid and reliable way? | | | | |
| 5. | Was exposure measured in the same way for cases and controls? | | | | |
| 6. | Were confounding factors identified? | | | | |
| 7. | Were strategies to deal with confounding factors stated? | | | | |
| 8. | Were outcomes assessed in a standard, valid and reliable way for cases and controls? | | | | |
| 9. | Was the exposure period of interest long enough to be meaningful? | | | | |
| 10. | Was appropriate statistical analysis used? | | | | |
| Overall a | | cfurther info | . 🗆 | | |
| Commer | ts (Including reason for exclusion) | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Review | er Daniel Eduardo Sandoval Colin Da | te 03/04 | 1/2021 | | |
|-----------|--|-------------|--------------|-----------|-------------------|
| Author_ | Alexander Wieck Fjaeldstad Year | 2020 | _ Record | l Number | 74_32741438_DESC |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | | X | | |
| 2. | Were the study subjects and the setting described in detail? | n 🗆 | | X | |
| 3. | Was the exposure measured in a valid and reliable way? | | \mathbf{x} | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | X | | |
| 5. | Were confounding factors identified? | | X | | |
| 6. | Were strategies to deal with confounding factors stated? | | X | | |
| 7. | Were the outcomes measured in a valid and reliable way? | e 🗆 | X | | |
| 8. | Was appropriate statistical analysis used? | | | \square | |
| Overall a | appraisal: Include 🔲 Exclude 🕱 Seek furti | herinfo [|] | | |
| Commer | nts (Including reason for exclusion) | | | | |
| No in | cluye sujetos con prueba (PCR o antígenos) pos | sitiva para | a SARS- | CoV2. | |
| | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Author | Manuela Pennisi, Giuseppe Lanza, Luca Falzone et al. Year | 2020 | Record | Number 75 | _32751841_DESC |
|--------------|--|-----------|--------|-----------|-------------------|
| | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | | | |
| 2. | Does the source of opinion have standing in the field of expertise? | | | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expressed? | | | | |
| 5. | Is there reference to the extant literature? | | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | | | |
| Overall : | appraisal: Include 🔲 Exclude 🗵 Seek furthe | rinfo 🗆 | 1 | | |
| Comme | nts (Including reason for exclusion) | | | | |
| No se Rev | realiza cuestionario porque no cumple con los criterios | de inclus | sión. | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Author, | Mark W. Tenforde, Sara S. Kim, Christopher J. Lindsell, et al. Year 20 | 20 | Record | Number_7 | 6_32730238_DES |
|---------|---|--------|-----------|---------------|-------------------|
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | X | | | |
| 2. | Were the study subjects and the setting described in detail? | X | | | |
| 3. | Was the exposure measured in a valid and reliable way? | X | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | X | | | |
| 5. | Were confounding factors identified? | | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | X | | | |
| 8. | Was appropriate statistical analysis used? | X | | | |
| | appraisal: Include | info X | | | |
| | nts (Including reason for exclusion) ir más información sobre las frecuencias de los síntomas no m | | las an al | and the state | |



doi: 10.1093/qimed/hcra255 Advance Access Publication Date: 19 August 2000 Clinical picture

CLINICAL PICTURE

Post-COVID-19 pneumonia pulmonary fibrosis

Case

A 48-year-old male patient with no prior co-morbidities presented to the emergency department with complaints of dry cough, fever and throat pain for the preceding Sdays followed by shortness of breath for the past 2 days. He had no significant travel or contact history. His vitals were stable except for mild hypoxemia on room air (SpO2 of 92%). On laboratory investigation he had lymphopenia, elevated Lactate dehydrogenase (LDH), raised C-reactive protein and elevated D-dimer levels. Initial chest radiograph revealed peripheral multiple inhomogeneous opacities in bilateral lung fields. His reverse transcriptasepolymerase chain reaction nasal and orophanyngeal swab for COVID-19 came out be positive and he was managed conservatively with supplemental oxygen, low molecular weight heparin, dexamethasone and antipyretics. He was symptomatically improved but continued to have hypoxemia even after 3 weeks of treatment, so a high resolution computed tomography of the chest was performed and it showed architectural distortion. interlobar septal thickening and traction bronchiectasis features (shown in Figure 1A and B) suggestive of fibratic lung disease. He was discharged on home oxygen therapy and planned to enroll him in antifibrotic therapy trail during the subsequent follow-up.

Discussion

Clinical manifestations of Corona virus disease-2019 (COVID-19) have ranged from asymptomatic/mild symptoms to severe illness and mortality.1 Most of the mild and moderate cases are recovered completely but a small proportion of severe cases with acute respiratory distress syndrome continued to remain hypoxemic despite adequate treatment. Chest imaging of this subset of patients revealed fibrotic changes in the form of traction bronchiectasis, architectural distortion and septal thickening similar to the changes seen in other fibrotic lung diseases.2 The pathogenesis of post-infective pulmonary fibrosis includes dysregulated release of matrix metalloproteinases during the inflammatory phase of adult respiratory distress syndrome (ARDS) causing epithelial and endothelial injury with unchecked fibroproliferation. There is also a vascular dysfunction which is a key component of the switch from ARDS to fibrosis, with vascular endothelial growth factor and cytokines such as interleukin-6 and tumor necrosis factor alpha being implicated.3 Although the role of presently available antifibrotic drugs (pirfenidone and nintedanib) for fibrotic lung diseases beyond idiopathic pulmonary fibrosis have been evaluated by some authors4 their role in post-COVID-19 pneumonia pulmonary fibrosis need further research in the present pandemic.

Photographs and text from: S. Tale . Department of Pulmonary Medicine, All India Institute of Medical Sciences, Rishikesh 249203, India; S. Chosh, Post Graduate Institute of Medical Education and Research, Chandigath 160012, India; S.P. Meitei, All India Institute of Medical Sciences, Rishikesh 249203, India;






Figure 1. (A and B) Traction bronchiectasis, architectural disportion and interiobse septal thickening suggestive of pulmonary filmosis.

© The Author(s) 2020. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved.
For permissions, please email: journals permissions@oup.com.

M. Kolli, Gandhi Medical College, Secunderabad 500025, India; A.K. Garbhapu, Dr. RMI. Medical College, Delhi 110001, India; S. Pudi, All India Institute of Medical Sciences, Rishikesh, India. email: drtale sudheer@gmail.com

Conflict of interest: None declared.

References

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He ZX, et al. Clinical characteristics of comnavirus disease 2019 in China. N Engl J Med 2020: 382:1708-20.

- 2 Kalchiem DO, Galvin JR, Burke AP, Atamas SP, Todd NW. Interstitial lung disease and pulmonary fibrosis: a practical approach for general medicine physicians with focus on the medical history. J Clin Med 2018; 7:476.
- 3. Collins BF, Raghu G. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmorary fibrosis. Eur Respir Rev 2019; 28:190022.
- 4. Burnham EL, Janssen WJ, Riches DW, Moss M, Downey GP. The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Fespir J 2014; 43:276-85

| Review | er Isaac David Juárez Cruz | Date | | 24/11/20 | | | | |
|---------|---|--|--------|----------|----------|-------------------|--|--|
| Author | Tingting Guo, Xiaoming Liu, Cihao Xu, Jiazheng Wang, Lian Yang, Heshui Shi, | Year_ | 2020 | Recor | d Number | 77_32922173_IDJC | | |
| | Meng Dai. | | Yes | No | Unclear | Not applicable | | |
| 1. | Were the two groups similar and recruite same population? | ed from the | | | | | | |
| 2. | Were the exposures measured similarly to people to both exposed and unexposed p | DUDGE 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | | | | | | |
| 3. | Was the exposure measured in a valid an way? | nd reliable | | | | | | |
| 4. | Were confounding factors identified? | | | | | | | |
| 5. | Were strategies to deal with confounding stated? | g factors | | | | | | |
| 6. | Were the groups/participants free of the at the start of the study (or at the mome exposure)? | | | | | | | |
| 7. | Were the outcomes measured in a valid way? | and reliable | | | | | | |
| 8. | Was the follow up time reported and suf be long enough for outcomes to occur? | ficient to | | | | | | |
| 9, | Was follow up complete, and if not, were reasons to loss to follow up described an | | | | | | | |
| 10 | Were strategies to address incomplete for utilized? | ollow up | | | | | | |
| 11. | Was appropriate statistical analysis used | ? | | | | | | |
| Overall | appraisal: Include \square Exclude \square | Seek further | info 🗾 | , | | | | |
| Comme | nts (Including reason for exclusion) | | | | | | | |
| | No estoy seguro de la inclusión o e maneja únicamente datos de CT a | | | | | | | |
| 8 | despues de inicio de los sintomas, | DOUGHT STATE OF THE STATE OF TH | | | | - 9 | | |
| | sintomas persistentes | 00 | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR QUALITATIVE RESEARCH

| Revi | ewer_ | Isaac David Juárez Cruz | Date | | | | |
|------|---------------|--|--------|--------|------|-----------|--------------------|
| Auth | nor | Pratas Diogo, Silva Jorge | /ear_ | 2020 | Reco | ord Numbe | r_78_32730589_IDJ0 |
| | | | | Yes | No | Unclear | Not applicable |
| 1. | | e congruity between the stated philosoph ctive and the research methodology? | nical | | | | |
| 2. | | e congruity between the research methodo e research question or objectives? | logy | | | | |
| 3. | | e congruity between the research methodo e methods used to collect data? | logy | | | | |
| 4. | | e congruity between the research methodo e representation and analysis of data? | logy | | | | |
| 5. | | e congruity between the research methodo e interpretation of results? | logy | | | | |
| 6. | | e a statement locating the researcher cultur pretically? | rally | | | | |
| 7, | | nfluence of the researcher on the research, ersa, addressed? | and | | | | |
| 8. | Are presented | participants, and their voices, adequa ented? | itely | | | | |
| 9. | for red | esearch ethical according to current criteria ent studies, and is there evidence of eth al by an appropriate body? | - 70 | | | | |
| 10. | | conclusions drawn in the research report to be analysis, or interpretation, of the data? | flow | | | | |
| | all appra | ANGER - ANGER ANGER STEEL EN GEREN EN AMERIKAN DE FERNEN EN | furthe | r info |] | | |
| Com | ments () | ncluding reason for exclusion) | | | | | |

Se excluye, debido a que no propociona información que empate xon lo que buscamos

Se centra en el reconocimiento de secuencias de ADN, de proteinas y como esto puede auxiliar en

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Review | er Daniel Eduardo Sandoval Colin Da | te 31/03 | 3/2021 | | |
|--------|--|----------|--------|----------|-------------------|
| Author | Stephen J Halpin, Claire McIvor, Gemma Whyatt et al. Year | 2020 | Record | Number_7 | 9_32729939_DESC |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | X | | | |
| 2. | Were the study subjects and the setting described in detail? | n x | | | |
| 3. | Was the exposure measured in a valid and reliable way? | X | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | X | | | |
| 5. | Were confounding factors identified? | X | | | |
| 6. | Were strategies to deal with confounding factors stated? | | X | | |
| 7. | Were the outcomes measured in a valid and reliable way? | × | | | |
| 8. | Was appropriate statistical analysis used? | | x | | |
| | appraisal: Include X Exclude | her info | 1 | | |
| | | | | | |

JBI Critical Appraisal Checklist for Case Series

| Reviewer Daniel Eduardo Sandoval Colin | Date | 31/03/2021 | | | |
|---|-------------------------|------------|-----------|---------------------|--|
| Author_ E Guedj, M Million, P Dudouet et al. | _ _{Year} _ 202 | 0 Re | cord Numb | er 80_32728799_DESC | |
| | Yes | No | Unclear | Not applicable | |
| Were there clear criteria for inclusion in the case series? | | | | | |
| • Was the condition measured in a standard, reliable way for all participants included in the case series? | | | | | |
| Were valid methods used for identification of the condition for all participants included in the case series? | | | | | |
| • Did the case series have consecutive inclusion of participants? | | | | | |
| • Did the case series have complete inclusion of participants? | | | | | |
| Was there clear reporting of the demographics of the participants in the study? | . 🗆 | | | | |
| Was there clear reporting of clinical information of the participants? | ne 🔲 | | | | |
| Were the outcomes or follow up results of cases clearly reported? | | | | | |
| Was there clear reporting of the presenting site(s)/clinic(s) demographic information? | | | | | |
| Was statistical analysis appropriate? | | | | | |
| Overall appraisal: Include | k further in | fo 🗌 | | | |
| Comments (Including reason for exclusion) | | | | | |
| No se realiza cuestionario porque no cumple con los crite | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Review | er_Carlos Alberto Fermin Martinez | Date | | 02/04 | V2021 | | |
|----------|---|-----------|---------|--------|---------|-------------------|----------|
| Author | Barón-Sánchez, et al. | _Year_ | 2020 | Record | Number_ | 81_32900 | 532_CAFM |
| | | | Yes | No | Unclear | Not applicable | |
| 1. | Were the criteria for inclusion in the sample of defined? | learly | N | | | | |
| 2. | Were the study subjects and the setting descr detail? | ribed in | N | | | | |
| 3. | Was the exposure measured in a valid and rel way? | lable | | | N | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | N | | | | |
| 5. | Were confounding factors identified? | | | 1 | | | |
| 6. | Were strategies to deal with confounding fact stated? | tors | | A | | | |
| 7. | Were the outcomes measured in a valid and r way? | eliable | N | | | | |
| 8. | Was appropriate statistical analysis used? | | 1 | | | | |
| | appraisal: Include Exclude Sec | ek furthe | rinfo 🗆 | | | | |
| los resi | información sobre la duración de los sínton ultados de pacientes con "PCR positiva" per a o telefonica. | | | | | | |

| Review | erlsaac David Juárez Cruz | Date | | 28/11/2020 | | | | |
|---------|--|---|----------|------------|----------|-------------------|--|--|
| Author | * | Year_ | 2020 | Recor | d Number | 82_32725271_IDJC | | |
| | | | Yes | No | Unclear | Not applicable | | |
| 1. | Were the two groups similar and recruited to same population? | rom the | | | | | | |
| 2. | Were the exposures measured similarly to a people to both exposed and unexposed gro | 1 Car. 1 | | | | | | |
| 3. | Was the exposure measured in a valid and r way? | eliable | | | | | | |
| 4. | Were confounding factors identified? | | | | 1 | | | |
| 5. | Were strategies to deal with confounding fa stated? | ctors | | | 6 | | | |
| 6. | Were the groups/participants free of the ou at the start of the study (or at the moment exposure)? | | | | | | | |
| 7. | Were the outcomes measured in a valid and way? | l reliable | | | | | | |
| 8. | Was the follow up time reported and suffici be long enough for outcomes to occur? | ent to | | | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and e | | | | | | | |
| 10. | Were strategies to address incomplete follo utilized? | w up | | | | | | |
| 11. | Was appropriate statistical analysis used? | | | | | | | |
| Overall | appraisal: Include 🛘 Exclude 🔲 S | eek furthe | r info |] | | | | |
| Comme | nts (Including reason for exclusion) | | | | | | | |
| | Estudio de HCW, mencionado que las OTD | | | | | | | |
| | este personal, de igual forma desglosa en o medicas es más común encontrar estos des | | alidades | 7 | | 2 | | |

© JBI, 2020. All rights reserved. JBI grants use of these tools for research purposes only. All other enquiries should be sent to jbisynthesis@adelaide.edu.au.



Ithzel Maria Villarreal, Marta Morato, Mar Martínez-RuizCoello, Andrés Navarro, Raimon Garcia-Chillerón, Álvaro Ruiz, Isabella Vacallanos de Almeida, Luis Mazón, Guillermo Plaza

| Review | er Carlos Alberto Fermin Martínez | Date | | 02/04 | 4/2021 | |
|----------|--|-----------|-----------|----------|-----------|-------------------|
| Author | Xu K, et al. | Year | 2020 | Recor | d Number | 83_32271376_CAFM |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited fro same population? | m the | 1 | | | |
| 2. | Were the exposures measured similarly to ass people | ign | | | | |
| 3. | to both exposed and unexposed groups? | | | | | |
| 4. | Was the exposure measured in a valid and rel way? | iable | 1 | | | |
| 5. | Were confounding factors identified? | | 1 | | | |
| 6. | Were strategies to deal with confounding fact stated? | lors | 1 | | | |
| 7. | Were the groups/participants free of the outcoment of the start of the study (or at the moment of exposure)? | | | | | |
| | Were the outcomes measured in a valid and r way? | eliable | | | | |
| 9. | Was the follow up time reported and sufficier be long enough for outcomes to occur? | nt to | / | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and exp | | 1 | | | |
| 11. | Were strategies to address incomplete follow utilizad? | up | | | | |
| 12. | Was appropriate statistical analysis used? | | 1 | | | |
| Overall: | appraisal: Include 🔲 Exclude 🎾 Sec | sk furthe | erinfo [|] | | |
| Commer | nts (Including reason for exclusion) | | | | | |
| Au | nque el artículo tiene una metodología robu: | sta y de | etallada, | la infor | mación qu | e provee |

© JBI, ZCZD, All rights reserved. JBI grants use of these tools for research purposes only. All other enquiries should be sent to jbisynthesis@adelaide.edu.au.

no entra en el alcance de nuestro estudio.

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Rev | viewer Daniel de la Rosa Date 01-02-21 | | | | | | |
|-----|--|--|---------|--------|---------------|---------|-------------------|
| Aut | hor | Maria Gavriatopoulou et al | Year | 2020 | Record Number | | 84_32720223 |
| | | Revi | ew | Yes | No | Unclear | Not applicable |
| 1. | Is the rev | iew question clearly and explicitly stated | 7 | | | | |
| 2. | Were the | inclusion criteria appropriate for the rev | iew | | | | |
| 3. | Was the | search strategy appropriate? | | | | | |
| 4. | | sources and resources used to search fo dequate? | r | | | | P |
| 5. | Were the | criteria for appraising studies appropriat | te? | | | | Ø |
| 6. | | cal appraisal conducted by two or more s independently? | | | | | Ø |
| 7. | Were the extraction | ere methods to minimize errors in data n? | | | | | Ø |
| 8. | Were the | methods used to combine studies appro | priate? | | | | P |
| 9. | Was the l | likelihood of publication bias assessed? | | | | | Ø |
| 10. | | ommendations for policy and/or practice d by the reported data? | | Ø | | | |
| 11. | Were the | specific directives for new research ate? | | Ø | | | |
| | | al: Include Exclude Seel | further | info 🗌 | | | |
| con | ments (nec | luding reason for exclusion) | | | | | |
| 7 | | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | erIsaac David Juárez Cruz | _Date | | 29/11 | 1/20 | |
|----------|--|---------|--------|--------|---------|-------------------|
| Author | Antonelli M, Donelli D. | Year_ | 2020 | Record | Number_ | 85_32710297_IDJ0 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | | | | |
| 2. | Does the source of opinion have standing in the of expertise? | e field | | | | |
| 3, | Are the interests of the relevant population the central focus of the opinion? | | | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expres | | | | | |
| 5. | Is there reference to the extant literature? | | | P | | |
| 6. | Is any incongruence with the literature/sources logically defended? | 5 | | | | |
| Overalla | appraisal; Include 🔲 Exclude 🖾 Seek | furthe | r info | | | |
| Comme | nts (Including reason for exclusion) | | | | | |
| | lo, solo menciona que es recomendable utilizar l rmente para fibrosis pulmonar entre otras. No ha | | | | | icas ya utlizadas |

| Review | er Isaac David Juárez Cruz | Date | | 29/11/20 | | | | |
|--------|---|--------------------------------|----------------------------------|----------------------------------|---------------------------------------|---|--|--|
| Author | * | Year_ | 2020 | _ Recor | d Number | 86_32929402_IDJC | | |
| | | | Yes | No | Unclear | Not applicable | | |
| 1. | Were the two groups similar and recruited fro same population? | m the | | | | | | |
| 2. | Were the exposures measured similarly to ass people to both exposed and unexposed group | | | | | | | |
| 3, | Was the exposure measured in a valid and reli way? | able | 1 | | | | | |
| 4. | Were confounding factors identified? | | | | | | | |
| 5. | Were strategies to deal with confounding factorstated? | ors | | | 6 | | | |
| 6. | Were the groups/participants free of the outcoment of the study (or at the moment of exposure)? | ome | | | | | | |
| 7. | Were the outcomes measured in a valid and re way? | eliable | 4 | | | | | |
| 8. | Was the follow up time reported and sufficien be long enough for outcomes to occur? | t to | | | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and exp | lored? | | | | | | |
| 10. | Were strategies to address incomplete follow utilized? | up | | | | | | |
| 11. | Was appropriate statistical analysis used? | | 6 | | | | | |
| | nts (Including reason for exclusion) recomendable sin embargo | e el seg no habl | uimiento a más de | de paci e ello. Se | entes que e menciona | nenciona que es han sido dados de alta an las medidas que | | |
| | unicamente h nts (Including reason for exclusion) recomendable sin embargo | e el seg no habl omar lo | uimiento a más do s pacien | de paci e ello. Se tes que | entes que e menciona han sido d | han sido dados an las medidas ads de alta par | | |

*

Lu Xia, Jun Chen, Thomas Friedemann, Zongguo Yang, Yun Ling, Xuhui Liu, Shuihua Lu, Tao Li, Zhigang Song, Wei Huang, Yunfei Lu, Sven Schröder, and Hongzhou Lu

| Review | er Isaac David Juárez Cruz | Date | | 29/11/20 | |
|--------|--|-----------|---------|-----------------|-------------------|
| Author | Davido B, Seang S, Tubiana R, Truchis P. | _Year_ | 2020 | _ Record Number | 87_32712242_IDJ0 |
| | | | Yes | No Unclear | Not applicable |
| 1. | Were the two groups similar and recruited fro same population? | om the | | | |
| 2. | Were the exposures measured similarly to ass people to both exposed and unexposed group | 158.55 | | | |
| 3, | Was the exposure measured in a valid and rel way? | liable | | | |
| 4. | Were confounding factors identified? | | | | |
| 5. | Were strategies to deal with confounding fact stated? | tors | | | 5 |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | 1 | | |
| 7. | Were the outcomes measured in a valid and r way? | reliable | | | |
| 8. | Was the follow up time reported and sufficier be long enough for outcomes to occur? | nt to | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and exp | | | | |
| 10. | Were strategies to address incomplete follow utilized? | up | | - d, | |
| 11. | Was appropriate statistical analysis used? | | | | |
| | appraisal: Include Exclude See | ek furthe | rinfo [| | |

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Reviewer_ | | Isaac | Date | 10/12/20 | | | | | |
|-----------|---------------|--|--|----------------|---------|----------------|---------|-------------------|--|
| Aut | hor | Weiss A, Jelling | sø, Morten S. | Year_ | 2020 | Record Number_ | | 88_32711256_IDJC | |
| | | | | | Yes | No | Unclear | Not applicable | |
| 1. | Is the | review question | clearly and explicitly | stated? | | | | | |
| 2. | Were quest | | eria appropriate for | the review | | | | | |
| 3. | Wast | he search strateg | y appropriate? | | | | | | |
| 4. | | the sources and essades | resources used to se | arch for | | | | | |
| 5. | Were | the criteria for a | praising studies app | ropriate? | | | | | |
| 6. | | critical appraisal c wers independent | onducted by two or ly? | more | | | | | |
| 7. | | there methods to | minimize errors in | data | | | | | |
| 8. | Were | the methods use | d to combine studie: | appropriate? | | | | | |
| 9. | Wast | he likelihood of p | ublication bias asses | sed? | | | | | |
| 10. | | recommendation orted by the repo | ns for policy and/or p ted data? | oractice | | | | | |
| 11. | | the specific directoriste? | tives for new resear | ch | | | | | |
| Ove | rall app | raisal: Include | ☐ Exclude ☐ | Seek further | info 🔲 | | | | |
| Com | ments | (Including reason fo | or exclusion) | | | | | | |
| _ | | | No aporta informa fase post aguda de analisis muy detall | e la enfermeda | d, hace | un | | | |
| - | | | acuda | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | Isaac David Juárez Cruz | | | 30/11/20 | | | | | |
|----------|--|---------|--------|----------|---------|-------------------|--|--|--|
| Author_ | David H & Rosalina G | Year_ | 2020 | Record | Number_ | 89_32700223_IDJC | | | |
| | | | Yes | No | Unclear | Not applicable | | | |
| 1. | Is the source of the opinion clearly identified? | | | | | | | | |
| 2. | Does the source of opinion have standing in the of expertise? | e field | | | | 1 | | | |
| 3, | Are the interests of the relevant population the central focus of the opinion? | 9 | | | | | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expres | | | | | | | | |
| 5. | Is there reference to the extant literature? | | | | | | | | |
| 6. | Is any incongruence with the literature/source: logically defended? | \$ | | | | | | | |
| Overalla | appraisal; Include 🌠 Exclude 🔲 Seek | further | info 🗆 | | | | | | |
| Commer | nts (Including reason for exclusion) | | | | | | | | |
| | | | | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Reviewer | Isaac David Juárez Cruz | Date_ | | 30/11/ | 20 | |
|-------------------|--|-----------|--------|--------|----------|-------------------|
| Author | Soon Tjin Lim, Benjamin Janaway, Harry Costello, Anand Trip and Gary Price | _Year | 2020 | Record | Number_§ | 90_3269735_IDJ0 |
| | | | Yes | No | Unclear | Not applicable |
| | patient's demographic characteristics clearly ibed? | / | 6 | | | |
| | he patient's history clearly described and pre imeline? | esented | | | | |
| | he current clinical condition of the patient or ntation clearly described? | n | | | | |
| | diagnostic tests or assessment methods and s clearly described? | l the | | | | |
| | he intervention(s) or treatment procedure(s) |) clearly | | | | |
| 6. Was t descr | he post-intervention clinical condition clearly ibed? | V | | | | |
| | adverse events (harms) or unanticipated eve fied and described? | ents | | | | |
| 8. Does | the case report provide takeaway lessons? | | | | | |
| Overall ap | praisal: Include 🗆 Exclude 🖺 See | k further | info 🗌 | | | |
| Comments | (Including reason for exclusion) | | | | | |
| | | | | | | - |

| Review | ALEJANDRO MÁRQUEZ SALINAS Date | | | 31/0 | 3/2021 | Liverie |
|--------|---|---------|------|-------|-----------|-------------------|
| Author | Querini-Rovere P, et al. | Year | 2020 | Recor | d Number_ | 91_32701913_AMS |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited fro same population? | m the | | | | |
| 2. | Were the exposures measured similarly to asspeople | ign. | | | | |
| 3. | to both exposed and unexposed groups? | | | | | |
| 4. | Was the exposure measured in a valid and rel way? | iable | | | \square | |
| 5. | Were confounding factors identified? | | Ø | | | |
| 6. | Were strategies to deal with confounding factorized? | tors | | | | |
| 7. | Were the groups/participants free of the outout at the start of the study (or at the moment of exposure)? | | | | | |
| 8. | Were the outcomes measured in a valid and may? | eliable | | | | |
| 9. | Was the follow up time reported and sufficient be long enough for outcomes to occur? | nt to | abla | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and exp | | | | | |
| 11. | Were strategies to address incomplete follow utilized? | up | | | \square | |
| | Was appropriate statistical analysis used? | | П | П | V | П |

Comments (Including reason for exclusion)

Esta artículo solamente describe brevemente a la cohorte que fue seguida sin presentar resultados relevantes para nuestro análisis, por lo que se excluye del estudio. Podría valer la pena revisar si se ha publicado información adicional utilizando esta cohorte de pacientes.

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | Daniel de la Rosa | _Date | - 1 | 02-02-2 | 1 | |
|----------|--|--------|----------|---------|---------|-------------------|
| Author_ | Mary Daval et al | Year_ | 2020 | Record | Number_ | 92_32690074 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | | | | • |
| 2. | Does the source of opinion have standing in the of expertise? | field | | | | a |
| 3. | Are the interests of the relevant population the central focus of the opinion? | | | | | G |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expres | sed? | 0 | | | |
| 5. | Is there reference to the extant literature? | | | | | 60 |
| 6. | Is any incongruence with the literature/sources logically defended? | | | | | |
| Overalla | appraisal: Include 🔲 Exclude 🚺 Seek | furthe | r info 🔲 | | | |
| Commer | nts (Including reason for exclusion) | | | | | |
| | | | | | | |

| Review | ALEJANDRO MÁRQUEZ SALINAS Date | | 31/03/2021 | | | | |
|--------|--|-----------|------------|-----------|-------------------|--|--|
| Author | Chiesa-Estomba CM, et al Yea | 2020 | Recor | d Number | 93_32677329_AMS | | |
| | | Yes | No | Unclear | Not applicable | | |
| 1. | Were the two groups similar and recruited from the same population? | • 🗆 | | | | | |
| 2. | Were the exposures measured similarly to assign people | | | \square | | | |
| 3. | to both exposed and unexposed groups? | | | | | | |
| 4. | Was the exposure measured in a valid and reliable way? | \square | | | | | |
| 5. | Were confounding factors identified? | | \square | | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | | | | |
| 7. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | Ø | | | | | |
| 8. | Were the outcomes measured in a valid and reliable way? | | | | | | |
| 9. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | abla | | | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored | n 🗆 | \square | | | | |
| 11. | Were strategies to address incomplete follow up utilizad? | | \square | | | | |
| 12. | Was appropriate statistical analysis used? | | | | | | |

Comments (Including reason for exclusion)

En la metodología del estudio se dice que se induyeron pecientes con PCR o con serología positiva, pero no se muestra información desagregada al respecto. Además, no todos los pacientes tuvieron el mismo tiempo de seguimiento (rango de seguimiento de 30 a 71 días), lo cual complica la evaluación de persistencia de sintomas. Por último, la descripción y presentación del análisis estadístico es confusa.

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Reviews | ALEJANDRO MÁRQUEZ SALINAS | | | 31/ | C. LINE | |
|---------|--|----------|-----------|-------|----------|-------------------|
| Author_ | Zhao Y, et al. | _Year_ | 2020 | Recor | d Number | 94_32838236_AMS |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited fro same population? | om the | abla | | | |
| 2. | Were the exposures measured similarly to as people | sign | abla | | | |
| 3. | to both exposed and unexposed groups? | | | | | |
| | Was the exposure measured in a valid and re way? | liable | \square | | | |
| 5. | Were confounding factors identified? | | abla | | | |
| 6. | Were strategies to deal with confounding fac stated? | tors | abla | | | |
| 7. | Were the groups/participants free of the out at the start of the study (or at the moment of exposure)? | | abla | | | |
| | Were the outcomes measured in a valid and way? | reliable | abla | | | |
| 9. | Was the follow up time reported and sufficie be long enough for outcomes to occur? | nt to | | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and ex | | Ø | | | |
| 11. | Were strategies to address incomplete follow utilizad? | /up | abla | | | |
| 12. | Was appropriate statistical analysis used? | | V | | | |

Comments (Including reason for exclusion)

Aunque no se analizan los factores de riesgo determinantes de persistencia de síntomas, sí se reporta la prevalencia de algunos síntomas persistentes. Además, se analizan los factores asociados con persistencia en la afección tomográfica y de la función pulmonar.

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | @r_Alejandro Sictia Andrade | Date 30/04/2021 | | | |
|-----------|--|-----------------|--------|---------|-------------------|
| Author | Megan M. Hosey, Dale M Needham | ear_2020 | Record | Number_ | 5 32669623 ASA |
| | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | ď | | | |
| 2. | Does the source of opinion have standing in the f of expertise? | ield 🚹 | | | |
| 3, | Are the interests of the relevant population the central focus of the opinion? | d | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expresse | ed? 🗹 | | | |
| 5. | Is there reference to the extant literature? | L | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | Z | | | |
|)verall a | appraisal; Include 🔲 Exclude 💆 Seek fu | urther info | Ê | | |
| | nts (Including reason for exclusion) | | | | |
| A pesar o | se que es un buen articulo, se excluye por tipo de estudio (No se incluye | en opiniones) | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE CONTROL STUDIES

| TewerAlejandro.Sicilia Andrade | Date30/0 | | | |
|---|----------------|----------|----------------|-------------------|
| hor Zhao Fu. Ningning Tang et al. | _Year_2020 | Record f | Number 95_3266 | 5633_ASA |
| | Yes | No | Unclear | Not applicable |
| Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | Ø | | | |
| Were cases and controls matched appropriately? | × | | | |
| 3. Were the same criteria used for identification of cases and controls? | Ø | | | |
| 4. Was exposure measured in a standard, valid and reliable way? | K | | | |
| 5. Was exposure measured in the same way for cases and controls? | Ø | | | |
| 6. Were confounding factors identified? | | P | | |
| 7. Were strategies to deal with confounding factors stated? | | | | |
| 8. Were outcomes assessed in a standard, valid and reliable way for cases and controls? | D | | | |
| Was the exposure period of interest long enough to be meaningful? | | | | |
| 10. Was appropriate statistical analysis used? | | | | |
| rall appraisal: Include 🔲 Exclude 📈 See | k further info | | | |
| nments (including reason for exclusion) | | | | |
| It does not report the follow-up time | | | | |
| factors stated? 8. Were outcomes assessed in a standard, valid and reliable way for cases and controls? 9. Was the exposure period of interest long enough to be meaningful? 10. Was appropriate statistical analysis used? rall appraisal: Include | k further info | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| uthor | Pellaud Charlotte, Grandmaison Gaël , et al. Year | 2020 | Recor | d Number | 97_32662869_AS |
|----------|--|--------|-------|----------|-------------------|
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | d | | | |
| 2. | Were the exposures measured similarly to assign people | N | | | |
| 3. | to both exposed and unexposed groups? | / | | | |
| 4. | Was the exposure measured in a valid and reliable way? | K | | | |
| 5. | Were confounding factors identified? | A | | | |
| 6. | Were strategies to deal with confounding factors stated? | V | | | |
| 7. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | P | | | |
| 8. | Were the outcomes measured in a valid and reliable way? | | | | |
| 9. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | |
| 11. | Were strategies to address incomplete follow up utilized? | Z | | | |
| 12. | Was appropriate statistical analysis used? | | Ø | | |
| /erall a | appraisal: Include 🕇 Exclude 🗆 Seek furthe | r info | | | |
| mme | nts (Including reason for exclusion) | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE CONTROL STUDIES

| Review | erIsaac David Juârez Cruz | _Date | 17/1: | 2/20 | _ |
|---------|---|----------------|-------------|-------------|-------------------|
| Author_ | * | Year 2020 | _ Record Nu | mber_98_326 | 62745_IDJC |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | | | | |
| 2. | Were cases and controls matched appropriately? | | | | |
| 3. | Were the same criteria used for identification of cases and controls? | | | | |
| 4, | Was exposure measured in a standard, valid and reliable way? | | | | |
| 5. | Was exposure measured in the same way for cases and controls? | | | | |
| 6. | Were confounding factors identified? | | | | |
| 7. | Were strategies to deal with confounding factors stated? | | | | |
| 8. | Were outcomes assessed in a standard, valid and reliable way for cases and controls? | G. | | | |
| 9. | Was the exposure period of interest long enough to be meaningful? | | | | |
| 10. | Was appropriate statistical analysis used? | | | | |
| | appraisal: Include | k further info | | | |
| | | | | | |
| | | | | | |



Luca D'Ascanio, Manlio Pandolfini, Cristina Cingolani, Gino Latini, Paolo Gradoni, Maria Capalbo, Gabriele Frausini, Massimo Maranzano, Michael J. Brenner, and Arianna Di Stadio.

JBI Critical Appraisal Checklist for Case Series

| Reviewer Alejandro Sicilia Andrade | _ Date | 30/04/20 | 21 | |
|---|----------------|----------|------------|----------------------------|
| Author_ Abdoulaye Keita, Hamza Abdou, Ibrahima Diallo, Alseny Camara | Year_2020 | Re | cord Numbe | 27 <u>99_32952820_</u> ASA |
| | Yes | No | Unclear | Not applicable |
| • Were there clear criteria for inclusion in the case series? | 6 | | | |
| Was the condition measured in a standard, reliable way for all participants included in the case series? | Ø | | | |
| Were valid methods used for identification of the condition for all participants included in the case series? | × | | | |
| Did the case series have consecutive inclusion of participants? | | 4 | | |
| Did the case series have complete inclusion of participants? | Þ | | | |
| Was there clear reporting of the demographics of the participants in the study? | 7 | | | |
| Was there clear reporting of clinical information of the participants? | e 🗗 | | | |
| Were the outcomes or follow up results of cases clearly reported? | F | | | |
| Was there clear reporting of the presenting site(s)/clinic(s) demographic information? | 4 | | | |
| Was statistical analysis appropriate? | | | | |
| Overall appraisal: Include | k further info | 。 □ | | |
| Comments (Including reason for exclusion) | | | | |
| Good evidence, but case series studies are not to be included according to | o our protocol | | | |

JBI Critical Appraisal Checklist for Case Series

| Reviewer_ | Alejandro Sicilia Andrade | _ Date | 30/04/202 | 1 | |
|--------------------------|---|----------------|-----------|-----------|--------------------|
| | Lan Lin, Shanshan-Luo, Renje Qin, Mengling Yang, Xiacbel Wang, et al. | Year_2020 | Rec | ord Numbe | r_100_32659373_ASA |
| | | Yes | No | Unclear | Not applicable |
| • Were the series? | re clear criteria for inclusion in the case | P | | | |
| | condition measured in a standard, reliable II participants included in the case series? | 7 | | | |
| | d methods used for identification of the for all participants included in the case | 4 | | | |
| • Did the c participa | ase series have consecutive inclusion of nts? | | V | | |
| Did the c participa | ase series have complete inclusion of hts? | 7 | | | |
| | e clear reporting of the demographics of the nts in the study? | P | | | |
| • Was ther participa | e clear reporting of clinical information of th nts? | e 🗆 | | Ø | |
| - Were the clearly re | outcomes or follow up results of cases ported? | A | | | |
| | e clear reporting of the presenting nic(s) demographic information? | P | | | |
| • Was stati | stical analysis appropriate? | D. | | | |
| Overall ap | praisal: Include 🔲 Exclude 🎜 See | k further info | . 🗆 | | |
| Comments | (Including reason for exclusion) | | | | |
| Quality of | he study is good, but case series are not to be included in our s | tudy | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Rev | /iewer_ Alejandro Schie Andrade | Date_ 3004/21 | | | |
|-----|--|---------------|--------|-----------|-------------------|
| Aut | thor_Alberto Aloffi, Barbara Bruni, Tulio Birachi, Andrea Monfisci, et al\ | ear_2020 | Record | l Number_ | 101_32664116_ASA |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were patient's demographic characteristics clearly described? | K | | | |
| 2. | Was the patient's history clearly described and press as a timeline? | ented | | | |
| 3. | Was the current clinical condition of the patient on presentation clearly described? | F | | | |
| 1- | Were diagnostic tests or assessment methods and the results clearly described? | ne 🎵 | | | |
| 5. | Was the intervention(s) or treatment procedure(s) or described? | learly 📈 | | | |
| j. | Was the post-intervention clinical condition clearly described? | ഥ | | | |
| 7. | Were adverse events (harms) or unanticipated even identified and described? | ts 🔲 | | | ഥ |
| 8. | Does the case report provide takeaway lessons? | F | | | |
| DVE | erall appraisal: Include 🔲 Exclude 🖊 Seek f | urther info | Ē | | |
| Con | nments (including reason for exclusion) | | | | |
| | Our study does not include case reports | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Reviewe | Enrique Cañedo Guerra | 29/03/2 Date | 021 | | |
|-----------|--|-----------------|--------|---------|-------------------|
| Author_ | Mouna Asly, Asmaa Hazim | ear 2020 | Record | Number | 102_32952812_ECG |
| | | Yes | No | Unclear | Not applicable |
| 1. | s the source of the opinion clearly identified? | | | | \square |
| | Does the source of opinion have standing in the of expertise? | field | | | d |
| | Are the interests of the relevant population the central focus of the opinion? | Ø | | | |
| | s the stated position the result of an analytical process, and is there logic in the opinion express | sed? | | | |
| 5. | s there reference to the extant literature? | | | | d |
| | s any incongruence with the literature/sources logically defended? | | d | | |
| Overall a | ppraisal: Include | further info | | | |
| | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE CONTROL STUDIES

| Review | er Isaac David Juárez Cruz | Date | 17/ | 12/20 | _ |
|-----------|---|--------------|------------|---------------|-------------------|
| Author_ | Feng Pan, Chuansheng Zheng, TianheYe, Lingli Li, Dehan Liu, Lin Li, Richard L. Hesketh & LianYang | Year 2020 | 0 Record N | lumber 103_32 | 647307_IDJ |
| | 37.50×30×30×30×30×30×30×30×30×30×30×30×30×30 | Yes | No | Unclear | Not applicable |
| 1. | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | | | | |
| 2. | Were cases and controls matched appropriately? | | | | |
| 3. | Were the same criteria used for identification of cases and controls? | | | | |
| 4, | Was exposure measured in a standard, valid and reliable way? | | | | |
| 5. | Was exposure measured in the same way for cases and controls? | | | | |
| 6. | Were confounding factors identified? | | | | |
| 7. | Were strategies to deal with confounding factors stated? | | | | d |
| 8. | Were outcomes assessed in a standard, valid and reliable way for cases and controls? | 5 | | | |
| 9. | Was the exposure period of interest long enough to be meaningful? | 4 | | | |
| 10. | Was appropriate statistical analysis used? | | | | |
| Overall : | appraisal: Include 🔲 Exclude 🗹 Seel | further info | | | |
| Comme | nts (Including reason for exclusion) | | | | |
| - | | | | | |
| _ | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| | Enrique Cañedo Guerra | Date | 29/03/ | 2021 | 10017 | |
|------------|---|----------|--------|-------|----------|-------------------|
| Authokon | g-Zeng Li, Zhen-Hum Cao, Yu Chen, Miao-Tan Cai, y Yu Zhang, Hui Xu, Jis-Ying Zhang, Chun-Hua Ma, | Year 2 | 020 | Recor | d Number | 104 32644223 ECG |
| | g Liu, Li-Juan Gao, Zhong-Hui Duan, Dan-Lei Mcu, Lian- n Liang | | Yes | No | Unclear | Not applicable |
| | Vere the two groups similar and recruited from ame population? | n the | d | | | |
| | Vere the exposures measured similarly to assign eople | gn. | 0 | | | |
| 3. to | both exposed and unexposed groups? | | | | | |
| | Vas the exposure measured in a valid and relia | ble | R | | | |
| 5. V | Vere confounding factors identified? | | d | | | |
| | Vere strategies to deal with confounding facto tated? | rs | | | | |
| a | Vere the groups/participants free of the outco it the start of the study (or at the moment of xposure)? | me | | | | |
| | Vere the outcomes measured in a valid and rel vay? | liable | | | | |
| | Vas the follow up time reported and sufficient e long enough for outcomes to occur? | to | d | | | |
| | Vas follow up complete, and if not, were the easons to loss to follow up described and expl | pred? | | | | |
| | Vere strategies to address incomplete follow u tilizad? | p | ď, | | | |
| 12. V | las appropriate statistical analysis used? | | d | | | |
| Overall ap | praisal: Include 🔲 Exclude 🗹 Seek | further | info 🗌 | | | |
| Comments | (Including reason for exclusion) | | | | | |
| No hay s | eguirmiento dilnico, el objetivo del estudio es ver replio | ación vi | ual . | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | er_ Enrique C | añedo Guerra | Date | 27/03/2 | 021 | | |
|-----------|-----------------------------|---|--------------|---------|--------|---------|-------------------|
| Author | Tahir Jameel | , Mukhtiar Baig , Zohair J. Gazzaz | Year_ | 2020 | Record | Number | 105_32782867_EC |
| | | | | Yes | No | Unclear | Not applicable |
| 1. | Is the sour | ce of the opinion clearly identifi | ed? | | | | ø, |
| 2. | Does the so | ource of opinion have standing e? | in the field | | | | |
| 3, | | erests of the relevant populatio us of the opinion? | n the | B | | | |
| 4. | | ed position the result of an analy and is there logic in the opinion e | | d | | | |
| 5. | Is there ref | erence to the extant literature? | | | | | d |
| 6. | Is any inco logically de | ngruence with the literature/so fended? | urces | | d | | |
| Overall : | appraisal: | Include | Seek furthe | r info | | | |
| Comme | nts (Including | reason for exclusion) | | | | | |
| - | | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Reviewe | Isaac David Juárez Cruz | Date_ | 25/12/20 | | | | |
|------------|--|--------|----------|-----------------|---------|-------------------|--|
| Author_ | Bell C, Crabtree S, Hall E, Sabdage S. Ye | ear | 2020 | Record Number 1 | | 106_32837330_IDJ | |
| | | | Yes | No | Unclear | Not applicable | |
| 1. Is th | e review question clearly and explicitly stated? | | | | | | |
| | re the inclusion criteria appropriate for the review stion? | W | | | | ď | |
| 3. Was | the search strategy appropriate? | | | | | | |
| | e the sources and resources used to search for lies adequate? | | | | | | |
| 5. Wei | e the criteria for appraising studies appropriate? | ? | | | | | |
| | critical appraisal conducted by two or more ewers independently? | | | | | | |
| | e there methods to minimize errors in data action? | | | | | | |
| 8. Wei | e the methods used to combine studies appropr | iate? | | | | | |
| 9. Was | the likelihood of publication bias assessed? | | | | d | | |
| | re recommendations for policy and/or practice ported by the reported data? | | | | | | |
| 11. Wei | e the specific directives for new research ropriate? | | d | | | | |
| Overall ap | opraisal: Include Exclude Seek fu | ırther | info 🗌 | | | | |
| Comment | s (Including reason for exclusion) | | | | | | |

JBI Critical Appraisal Checklist for Case Series

| Reviewer | Isaac David Juárez Cruz | _Date | | 03/01/21 | |
|----------------------------------|--|-------------|-------|-----------|-------------------|
| Author | * | Year20 | 20 Re | cord Numb | er_107_32614442_ |
| | | Yes | No | Unclear | Not applicable |
| Were there cl series? | ear criteria for inclusion in the case | | | | |
| | ition measured in a standard, reliable rticipants included in the case series? | | | | |
| | ethods used for identification of the all participants included in the case | | | | |
| Did the case s participants? | eries have consecutive inclusion of | | | | |
| Did the case s participants? | eries have complete inclusion of | | | | |
| Was there cle participants in | ar reporting of the demographics of the the study? | | | | |
| Was there cle participants? | ar reporting of clinical information of the | ٠ 🗹 | | | |
| Were the out clearly report | comes or follow up results of cases ed? | | | | |
| | ar reporting of the presenting) demographic information? | | | | |
| Was statistica | analysis appropriate? | 6 | | | |
| Overall apprais | al: Include | further inf | . 🗆 | | |
| Comments (Inc | luding reason for exclusion) | | | | |



Paolo Boscolo-Rizzo, MD; Daniele Borsetto, MD; Cristoforo Fabbris, MD; Giacomo Spinato, MD; Daniele Frezza, MD; Anna Menegaldo, MD; Francesca Mularoni, MD; Piergiorgio Gaudioso, MD; Diego Cazzador, MD; Silvia Marciani, MD; Samuele Frasconi, MD; Maria Ferraro, MD; Cecilia Berro, MD; Chiara Varago, MD; Piero Nicolai, MD; Giancarlo Tirelli, MD; Maria Cristina Da Mosto, MD; Rupert Obholzer, MA, MBBS; Roberto Rigoli, MD; Jerry Polesel, ScD; Claire Hopkins, MBBS

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Rev | iewer_ | Enrique Cañedo Guerrax | Date_ | 30/03/20 | 21 | | |
|-----|---------------|---|------------|-------------|--------|--------------------|---|
| Aut | hor_L | rz Elena Ojeda Carmona, Mar.a Del Carmen rdoba Niella , Alvaro Lus Diaz Alvarado | Year_20 | 20 j | Record | Number_ Unclear | 108_32618463_ECG d Not applicable |
| 1. | Is the | review question clearly and explicitly stated? | | × | | | |
| 2. | Were quest | the inclusion criteria appropriate for the revi ion? | ew | X | | | |
| 3. | Wast | he search strategy appropriate? | | N | | | |
| 4. | | the sources and resources used to search for is adequate? | | X | | | |
| 5, | Were | the criteria for appraising studies appropriate | e? | | | K | |
| 6. | | ritical appraisal conducted by two or more vers independently? | | | | \boxtimes | |
| 7. | | there methods to minimize errors in data tion? | | | | × | |
| 8. | Were | the methods used to combine studies approp | oriate? | X | | | |
| 9. | Wast | he likelihood of publication bias assessed? | | | | Ø | |
| 10. | | recommendations for policy and/or practice rted by the reported data? | | \boxtimes | | | |
| 11. | | the specific directives for new research priate? | | ¥ | | | |
| Ove | rall app | raisal: Include 🗌 Exclude 💢 Seek | further in | nfo 🗌 | | | |
| Com | ments | (Including reason for exclusion) | | | | | |
| No | incluye | información precisa sobre síntomas de long COVID. | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Reviewer | Isaac David Juárez Cruz | Date_ | | | | |
|--|---|-------------|--------|--------|---------|-------------------|
| Author | * | Year | 2020 | Record | Number_ | 109_32706216_IDJ |
| | | | Yes | No | Unclear | Not applicable |
| Were patie described? | nt's demographic characteristics clea | rly | | | | |
| Was the pa as a timelin | tient's history clearly described and p e? | presented | | | | |
| | rrent clinical condition of the patient n clearly described? | on | | | | |
| STATE OF THE PARTY | ostic tests or assessment methods a rly described? | nd the | 5 | | | |
| 5. Was the int described? | ervention(s) or treatment procedure | (s) clearly | | | | |
| 6. Was the po described? | st-intervention clinical condition clea | rly | | | | |
| | rse events (harms) or unanticipated e nd described? | events | | | | |
| 8. Does the ca | se report provide takeaway lessons? | | | | | |
| Overali appraisal | : Include | eek further | info 🗌 | | | |
| Comments (inclu | ding reason for exclusion) | | | | | |
| S | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

Reviewer Mónica Itzel Martínez Gutiérrez Date 03/04/2021

Author Ferrin R, Riste L, Hann M, Walther Year 2020 Record Number 110 32758891 MIMG
A, Mukherjee A, Heald A.

| | | Yes | No | Unclear | Not applicable |
|-----------|--|------------|----------|--------------|-------------------|
| 1. | Is the source of the opinion clearly identified? | 1 | | | |
| 2. | Does the source of opinion have standing in the field of expertise? | 1 | | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | 1 | | | |
| 4, | Is the stated position the result of an analytical process, and is there logic in the opinion expressed? | 1 | | | |
| 5. | Is there reference to the extant literature? | 1 | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | 1 | | | |
| | | k further | info [|] | |
| Commen | its (Including reason for exclusion) | | | | |
| Es una ca | erta al editor, basado en un reporte de caso, que remarca | a la posib | ilidad d | e un sindron | ne post -viral |
| or COV | D-19 | | | | |

© .BI, 2020. All rights reserved. JBI grants use of these tools for research purposes only. All other enquiries should be sent to jbisynthesis@adolaide.edu.au.

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Rev | iewer | Isaac David Juárez Cruz | Date | | 05/ | 01/21 | |
|-----|-------------|--|-----------|--------|--------|---------|-------------------|
| Aut | | I D. Mitrani, Nitika Dabas, Jeffrey | _Year_ | 2020 | Record | Number_ | 111_32599178_IDJC |
| | J. G | oldberger | | Yes | No | Unclear | Not applicable |
| 1. | Is the re | view question clearly and explicitly state | d? | | | | |
| 2. | Were the | e inclusion criteria appropriate for the re n? | view | | | ď | |
| 3. | Was the | search strategy appropriate? | | | | | |
| 4. | | e sources and resources used to search f adequate? | or | | | d | / 🗆 |
| 5. | Were th | e criteria for appraising studies appropri | ate? | | | | |
| 6. | | ical appraisal conducted by two or more rs independently? | | | | | |
| 7. | Were the | ere methods to minimize errors in data on? | | | | ď | |
| 8. | Were th | e methods used to combine studies appr | opriate | , _ | | | |
| 9. | Was the | likelihood of publication bias assessed? | | | | | |
| 10. | | commendations for policy and/or practice ed by the reported data? | ce | | | | |
| 11. | Were th | e specific directives for new research late? | | ď | | | |
| Ove | rall apprai | sal: Include Exclude Set | ek furthe | r info | | | |
| Соп | nments (In | cluding reason for exclusion) | | | | | |
| - | | | | | | | |
| | | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Review | erIsaac David Juárez Cruz | Date | 0.00000 | | 09/01/202 | 1 |
|--------|--|----------|---------|-------|-----------|-------------------|
| Author | * | Year | 2020 | Recor | d Number | 112_32586839_ID |
| | | | Yes | No | Unclear | Not applicable |
| 1, | Were the two groups similar and recruited fro same population? | m the | | | | |
| 2. | Were the exposures measured similarly to assi people to both exposed and unexposed group | | | | | |
| 3. | Was the exposure measured in a valid and reli way? | able | | | | |
| 4. | Were confounding factors identified? | | | | 1 | |
| 5. | Were strategies to deal with confounding factorstated? | ors | | | | |
| 6. | Were the groups/participants free of the outco at the start of the study (or at the moment of exposure)? | ome | | | | |
| 7. | Were the outcomes measured in a valid and re way? | eliable | d | | | |
| 8. | Was the follow up time reported and sufficient be long enough for outcomes to occur? | tto | | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and exp | lored? | | | | |
| 10. | Were strategies to address incomplete follow utilized? | up | | | 4 | |
| 11. | Was appropriate statistical analysis used? | | 6 | | | |
| | appraisal: Include | k furthe | rinfo 🗆 |] | | |
| ommei | nts (Including reason for exclusion) | | | | | |



Daoyuan Si, Beibei Du, Lujia Ni, Bo Yang MD, Huan Sun, Nan Jiang, Guohui Liu, Stéphane Massé, Lina Jin, Jared Nanthakumar, Abhishek Bhaskaran, Ping Yang, Kumaraswamy Nanthakumar

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Rev | iewer | Isaac David Juárez Cruz | Date | | - (| 09/01/21 | |
|------|-------------------|--|-----------------|--------|----------|-------------|-------------------|
| Auti | nor | or * | | 020 | Record | Number_ | 113_32574165_IDJC |
| | | | | Yes | No | Unclear | Not applicable |
| 1. | Is the rev | view question clearly and explicitly st | tated? | | | | |
| 2. | Were the question | e inclusion criteria appropriate for th ? | e review | | | | |
| 3. | Was the | search strategy appropriate? | | | | | |
| 4. | | e sources and resources used to sear dequate? | ch for | | P | | |
| 5. | Were the | e criteria for appraising studies appro | opriate? | | | | |
| 6. | | cal appraisal conducted by two or m s independently? | ore | | | | |
| 7. | Were the | ere methods to minimize errors in da on? | ita | 6 | , 🗆 | | |
| 8. | Were the | e methods used to combine studies : | appropriate? | 6 | | | |
| 9. | Was the | likelihood of publication bias assesse | ed? | | | | |
| 10. | | commendations for policy and/or pro ed by the reported data? | actice | | | | |
| 11. | Were the | e specific directives for new research ate? | / | | | | |
| Over | all apprais | sal: Include 🗆 Exclude 🗖 | Seek further in | nfo 🗌 | | | |
| Com | ments (Inc | cluding reason for exclusion) | | | | | |
| | | a proporción de algun sintoma persis pero no habla mas al respecto. | tente, solo me | nciona | 1 vez qu | ue se ha de | etectado tos |

*

Michael C. Grant, Luke Geoghegan, Marc Arbyn, Zakaria Mohammed, Luke McGuinness, Emily L. Clarke, Ryckie G. Wade

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Review | er Isaac David Juárez Cruz | Date | | | 10/01/21 | |
|-----------|---|------------|---------|-------|----------|-------------------|
| Author_ | * | Year_ | 2020 | Recor | d Number | 114_32574840_IDJ0 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited fro same population? | om the | | | | |
| 2. | Were the exposures measured similarly to ass people to both exposed and unexposed group | 1000 | 6 | | | |
| 3. | Was the exposure measured in a valid and rel way? | iable | | | | |
| 4. | Were confounding factors identified? | | | | 6 | |
| 5. | Were strategies to deal with confounding fact stated? | tors | | | 6 | |
| 6, | Were the groups/participants free of the outout at the start of the study (or at the moment of exposure)? | | | | | 6 |
| 7. | Were the outcomes measured in a valid and r way? | eliable | 6 | | | |
| 8. | Was the follow up time reported and sufficier be long enough for outcomes to occur? | nt to | 4 | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and exp | | 1 | | | |
| 10. | Were strategies to address incomplete follow utilized? | up | ₫, | | | |
| 11. | Was appropriate statistical analysis used? | | | | | |
| Overall a | appraisal: Include Exclude See | ek further | info 🗆 | | | |
| Commer | nts (Including reason for exclusion) | | | | | |
| | Sin información de utilidad | para la r | evisión | | | |



De Chang, Peng Zhao, Dawei Zhang, Jing-Hui Dong, Zhe Xu, Guang Yang, Bo-Yu Li, Hong-Xia Liu, Bo-An Li, Cheng-Feng Qin, Xiao-Hua Peng, Fu-Sheng Wang, Li-Xin Xie, Zhu Chen, Charles S. Dela Cruz, Lokesh Sharma, and En-Qiang Qin

JBI Critical Appraisal Checklist for Case Series

| Reviewer | Isaac David Juárez Cruz | _Date | | 10/01/21 | <u> </u> |
|---|--|-----------------|--------|------------|---------------------|
| Author | * | Year <u>2</u> (| 020 Re | cord Numbe | r_ 115_32549526_ID. |
| | | Yes | No | Unclear | Not applicable |
| • Were there clea series? | ar criteria for inclusion in the case | | | | |
| | ion measured in a standard, reliable icipants included in the case series? | | | | |
| | hods used for identification of the participants included in the case | | | | |
| Did the case ser participants? | ries have consecutive inclusion of | | | | |
| Did the case ser participants? | ries have complete inclusion of | | | | |
| Was there clear participants in t | reporting of the demographics of the he study? | | | | |
| • Was there clear participants? | reporting of clinical information of th | e 🗹 | | | |
| - Were the outco clearly reported | mes or follow up results of cases i? | | | | |
| | reporting of the presenting demographic information? | 6 | | | |
| • Was statistical a | analysis appropriate? | | | | |
| Overall appraisal | : Include 🔲 Exclude 🗹 See | k further in | nfo 🗌 | | |
| Comments (Inclu | ding reason for exclusion) | | | | |



Se Yoon Park, Soon Gyu Yun, Jeong Won Shin, Bo Young Lee, Hyo-Ju Son, Seungjae Lee, Eunjung Lee, and Tae Hyong Kim

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Reviewer | Isaac David Juárez Cruz | Date | | 11 | 01/21 | |
|-------------------------|---|---------|--------|--------|---------|-------------------|
| | f Ali, Smitha Mathew, Joseph M. | /ear | 2020 | Record | Number_ | 116_32544670_ID |
| | | | Yes | No | Unclear | Not applicable |
| Were part described | tient's demographic characteristics clearly d? | | | | | |
| 2. Was the as a time | patient's history clearly described and prese line? | ented | | | | |
| | current clinical condition of the patient on tion clearly described? | | | P | | |
| | gnostic tests or assessment methods and the early described? | he | | P | | |
| 5. Was the described | intervention(s) or treatment procedure(s) o d? | learly | | | | |
| 5. Was the described | post-intervention clinical condition clearly d? | | | | | |
| | verse events (harms) or unanticipated even d and described? | ts | 6 | | | |
| 8. Does the | case report provide takeaway lessons? | | 6 | | | |
| Overali apprai | sal: Include 🗌 Exclude 🗖 Seek f | further | info 🗌 | | | |
| Comments (In | cluding reason for exclusion) | | | | | |
| | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Review | er Isaac David Juárez Cruz Date | | | |
|----------|--|--------|-----------------|-------------------|
| Author | William R. Aaron S, Joseph P. Year | 2020 | _ Record Number | 117_32533556_IDJC |
| | | Yes | No Unclear | Not applicable |
| 1, | Were the two groups similar and recruited from the same population? | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | 00 | |
| 3. | Was the exposure measured in a valid and reliable way? | | | |
| 4. | Were confounding factors identified? | | | |
| 5. | Were strategies to deal with confounding factors stated? | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | | |
| 11. | Was appropriate statistical analysis used? | 6 | | |
| Overalla | appraisal: Include | info 🗆 | 1 | |
| Comme | nts (Including reason for exclusion) | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Author_Tage-chen, Y. Bianco-Alonso, S. Antion-Huguet, B., Year 2020 Yes No Unclear Not applicable Yes No Unclear Not applicable 1. Were patient's demographic characteristics clearly described? 2. Was the patient's history clearly described and presented as a timeline? 3. Was the current clinical condition of the patient on presentation clearly described? 4. Were diagnostic tests or assessment methods and the results clearly described? 5. Was the intervention(s) or treatment procedure(s) clearly described? 6. Was the post-intervention clinical condition clearly described? 7. Were adverse events (harms) or unanticipated events identified and described? 8. Does the case report provide takeaway lessons? Overall appraisal: Include Exclude Seek further info Comments (including reason for exclusion) | Reviewer Fernández Chirino Luisa Da | te 08/04/ | 2021 | | |
|---|--|-----------|----------|-------------|-----------------|
| applicable 1. Were patient's demographic characteristics clearly described? 2. Was the patient's history clearly described and presented as a timeline? 3. Was the current clinical condition of the patient on presentation clearly described? 4. Were diagnostic tests or assessment methods and the results clearly described? 5. Was the intervention(s) or treatment procedure(s) clearly described? 6. Was the post-intervention clinical condition clearly described? 7. Were adverse events (harms) or unanticipated events identified and described? 8. Does the case report provide takeaway lessons? Overall appraisal: Include Exclude Seek further info | Tung-Chen, Y. Bianco-Alonso, S., Antón-Huguet, B., Author_Figueras-López, C., Ugueto-Rodrigo, C. Year | 2020 | Record | i Number_1 | 18_32680679_LF0 |
| described? 2. Was the patient's history clearly described and presented as a timeline? 3. Was the current clinical condition of the patient on presentation clearly described? 4. Were diagnostic tests or assessment methods and the results clearly described? 5. Was the intervention(s) or treatment procedure(s) clearly described? 6. Was the post-intervention clinical condition clearly described? 7. Were adverse events (harms) or unanticipated events identified and described? 8. Does the case report provide takeaway lessons? Overall appraisal: Include | | Yes | No | Unclear | |
| as a timeline? 3. Was the current clinical condition of the patient on presentation clearly described? 4. Were diagnostic tests or assessment methods and the results clearly described? 5. Was the intervention(s) or treatment procedure(s) clearly described? 6. Was the post-intervention clinical condition clearly described? 7. Were adverse events (harms) or unanticipated events identified and described? 8. Does the case report provide takeaway lessons? Overall appraisal: Include | | | | | |
| presentation clearly described? 4. Were diagnostic tests or assessment methods and the results clearly described? 5. Was the intervention(s) or treatment procedure(s) clearly described? 6. Was the post-intervention clinical condition clearly described? 7. Were adverse events (harms) or unanticipated events identified and described? 8. Does the case report provide takeaway lessons? Overall appraisal: Include | 2008년 B. 조사이 : 'CONTROL TO CONTROL OF CONTROL OF CONTROL OF THE CONTROL OF CONTROL OF CONTROL OF CONTROL OF CO | ed 🔀 | | | |
| results clearly described? 5. Was the intervention(s) or treatment procedure(s) clearly described? 6. Was the post-intervention clinical condition clearly described? 7. Were adverse events (harms) or unanticipated events identified and described? 8. Does the case report provide takeaway lessons? | 하기 하고 함께 나는 하다면 하늘이 되면 있어요. 하다 하다 하지 않는 하는 | | | | |
| described? 6. Was the post-intervention clinical condition clearly described? 7. Were adverse events (harms) or unanticipated events identified and described? 8. Does the case report provide takeaway lessons? | | × | | | |
| described? 7. Were adverse events (harms) or unanticipated events | | rly 🔯 | | | |
| 8. Does the case report provide takeaway lessons? | . ~~~ | × | e textin | ere | |
| Overall appraisal: Include | | | | | |
| | 8. Does the case report provide takeaway lessons? | | | \boxtimes | |
| | | her info | | | |
| Insufficient description | Insufficient description | | | | - |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | erIsaac David Juárez Cruz | Date | | | 15/01/21 | |
|--------|---|--------|----------|--------|-----------------|-------------------|
| Author | Gemelli against COVID-19 post accute carestudy group | Year_ | 2020 | Record | Number <u>1</u> | 19_32529595_IDJC |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | | | | |
| 2. | Does the source of opinion have standing in the of expertise? | field | | | | |
| 3, | Are the interests of the relevant population the central focus of the opinion? | | | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion express | sed? | | | | |
| 5. | Is there reference to the extant literature? | | | | | 6 |
| 6. | Is any incongruence with the literature/sources logically defended? | | | | | |
| | appraisal; Include | furthe | r info 🔲 | | | |
| - | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Review | er Fermández Chirino Luisa Da | ite 08/04 | 4/2021 | | |
|--------|--|-------------|--------|----------|-------------------|
| Author | Park, S., Lee, C., Park, D., Hee-Yeon, W., Cheong, H. S. Ahn, K., Kwon, M., Joo, E. Yea | 2020 | Recor | d Number | 120_32534042_LFC |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | e 🔀 | | | |
| 2. | Were the exposures measured similarly to assign people | × | | | |
| 3, | to both exposed and unexposed groups? | | | | |
| 4. | Was the exposure measured in a valid and reliable way? | \boxtimes | | | |
| 5. | Were confounding factors identified? | | | × | |
| 6. | Were strategies to deal with confounding factors stated? | | | × | |
| 7. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | × | | |
| 8. | Were the outcomes measured in a valid and reliable way? | e 🛛 | | | |
| 9. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | × | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored | 17 💢 | | | |
| 11. | Were strategies to address incomplete follow up utilized? | X | | | |
| 12. | Was appropriate statistical analysis used? | × | | | |

Comments (including reason for exclusion)

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Review | er_Fernández Chirino Luisa | Date 08/04/2021 | | | | | |
|----------|--|-----------------|--------|-------------|-------------------|--|--|
| Author | Yan, C., Prajapati, D., Ritter, M., DeConde, A. Year 20 | 020 | Record | Number_ | 121_32513065_LFC | | |
| | | Yes | No | Unclear | Not applicable | | |
| 1. | Were the criteria for inclusion in the sample clearly defined? | | × | | | | |
| 2. | Were the study subjects and the setting described in detail? | × | | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | X | | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | × | | | | | |
| 5. | Were confounding factors identified? | | | \boxtimes | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | \bowtie | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | X | | | | | |
| 8. | Was appropriate statistical analysis used? | × | | | | | |
| | appraisal: Include | info 🔲 | | | | | |
| 55 55 | 1. | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| 08/04/ | 2021 | | |
|--------------|--------|-------------|---|
| 020 | Record | l Number_1 | 22_32522523_LF |
| Yes | No | Unclear | Not applicable |
| | | | |
| K | | | |
| | | | |
| × | | | |
| × | | | |
| × | | | |
| × | | | |
| | | \boxtimes | |
| info OVID, | as the | patient re | emained positive. |
| | Yes 🖂 | Yes No | Yes No Unclear No Unclear No |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE CONTROL STUDIES

| Review | er Fermández Chirino Luísa | Date_ 08/04 | | | |
|---------|---|---------------|----------|--------------|-------------------|
| Author, | Chung, T. W., Sridhar, S., Zhang, A., J., Chan, K., et al. | Year 2020 | Record N | lumber_123_3 | 2548209_LF0 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | × | | | |
| 2. | Were cases and controls matched appropriately? | \boxtimes | | | |
| 3. | Were the same criteria used for identification of cases and controls? | × | | | |
| 4. | Was exposure measured in a standard, valid and reliable way? | × | | | |
| 5. | Was exposure measured in the same way for cases and controls? | × | | | |
| 6. | Were confounding factors identified? | | | X | |
| 7. | Were strategies to deal with confounding factors stated? | | | | |
| 8. | Were outcomes assessed in a standard, valid and reliable way for cases and controls? | × | | | |
| 9. | Was the exposure period of interest long enough to be meaningful? | × | | | |
| 10. | Was appropriate statistical analysis used? | | | | |
| | appraisal: Include | (further info | | | |
| | | | | | |
| | | | | | |

EXPLANATION OF CASE CONTROL STUDIES CRITICAL APPRAISAL

How to cite: Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). IBI Manual for Evidence Synthesis. IBI, 2020. Available from https://synthesismanual.jbi.global

Case Control Studies Critical Appraisal Tool

Answers: Yes, No, Unclear or Not/Applicable

1. Were the groups comparable other than presence of disease in cases or absence of disease in controls?

The control group should be representative of the source population that produced the cases. This is usually done by individual matching; wherein controls are selected for each case on the basis of similarity with respect to certain characteristics other than the exposure of interest. Frequency or group matching is an alternative method. Selection bias may result if the groups are not comparable.

2. Were cases and controls matched appropriately?

As in item 1, the study should include clear definitions of the source population. Sources from which cases and controls were recruited should be carefully looked at. For example, cancer registries may be used to recruit participants in a study examining risk factors for lung cancer, which typify population-based case control studies. Study participants may be selected from the target population, the source population, or from a pool of eligible participants (such as in hospital-based case control studies).

3. Were the same criteria used for identification of cases and controls?

It is useful to determine if patients were included in the study based on either a specified diagnosis or definition. This is more likely to decrease the risk of bias. Characteristics are another useful approach to matching groups, and studies that did not use specified diagnostic methods or definitions should provide evidence on matching by key characteristics. A case should be defined clearly. It is also important that controls must fulfil all the eligibility criteria defined for the cases except for those relating to diagnosis of the disease.

4. Was exposure measured in a standard, valid and reliable way?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

Case control studies may investigate many different 'exposures' that may or may not be associated with the condition. In these cases, reviewers should use the main exposure of interest for their review to answer this question when using this tool at the study level.

Reliability refers to the processes included in an epidemiological study to check repeatability of measurements of the exposures. These usually include intra-observer reliability and inter-observer reliability.

5. Was exposure measured in the same way for cases and controls?

As in item 4, the study should clearly describe the method of measurement of exposure. The exposure measures should be clearly defined and described in detail. Assessment of exposure or risk factors should have been carried out according to same procedures or protocols for both cases and controls.

6. Were confounding factors identified?

Confounding has occurred where the estimated intervention exposure effect is biased by the presence of some difference between the comparison groups (apart from the exposure investigated/of interest). Typical confounders include baseline characteristics, prognostic factors, or concomitant exposures (e.g., smoking). A confounder is a difference between the comparison groups and it influences the direction of the study results. A high quality study at the level of case control design will identify the potential confounders and measure them (where possible). This is difficult for studies where behavioral, attitudinal or lifestyle factors may impact on the results.

7. Were strategies to deal with confounding factors stated?

Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or stratifying sampling of participants, effects of confounding factors can be adjusted for. When dealing with adjustment in data analysis, assess the statistics used in the study. Most will be some form of multivariate regression analysis to account for the confounding factors measured. Look out for a description of statistical methods as regression methods such as logistic regression are usually employed to deal with confounding factors/ variables of interest.

8. Were outcomes assessed in a standard, valid and reliable way for cases and controls?

Read the methods section of the paper. If for e.g. lung cancer is assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If lung cancer is assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

Having established the objectivity of the outcome measurement (e.g. lung cancer) instrument, it's important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? (e.g. radiographers). If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised?

9. Was the exposure period of interest long enough to be meaningful?

It is particularly important in a case control study that the exposure time was sufficient enough to show an association between the exposure and the outcome. It may be that the exposure period may be too short or too long to influence the outcome.

10. Was appropriate statistical analysis used?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.

For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.

| Review | rIsaac David Juárez Cruz | | | 29/0 | 1/21 | |
|----------|--|-------|--------|--------|----------|-------------------|
| Author_ | | ar_ | 2020 | Record | Number 1 | 24_30505489_IDJ0 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | | | | |
| 2. | Does the source of opinion have standing in the fi of expertise? | eld | | | | 1 |
| 3. | Are the interests of the relevant population the central focus of the opinion? | | | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expresse | d? | | | | |
| 5. | Is there reference to the extant literature? | | | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | | | | |
| Overalla | appraisal: Include 🔲 Exclude 🗂 Seek fu | rther | info 🗆 | | | |
| Commer | nts (Including reason for exclusion) | | | | | |
| | | | | | | |



Sandro Iannaccone, Paola Castellazzi, Andrea Tettamanti, Elise Houdayer, Luigia Brugliera, Francesco de Blasio, Paolo Cimino, Marco Ripa, Carlo Meloni, Federica Alemanno, Paolo Scarpellini

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Reviewer | Juárez Cruz Isaac David | Date_ | | 29/01 | /21 | |
|-----------------------------|--|------------|--------|--------|---------|-------------------|
| Mondhe | Jessica Xu, Daniel Samaha, Suhas , David MassicotteAzarniouch, Gregory arcel Ruzicka | Year | 2020 | Record | Number_ | 125_32483909_II |
| | | | Yes | No | Unclear | Not applicable |
| Were patier described? | nt's demographic characteristics clea | rly | 5 | | | |
| Was the par as a timelin | tient's history clearly described and p e? | resented | d | | | |
| | rent clinical condition of the patient n clearly described? | on | | | | |
| | ostic tests or assessment methods are ly described? | nd the | d | | | |
| Was the int described? | ervention(s) or treatment procedure | s) clearly | | | | |
| Was the po described? | st-intervention clinical condition clea | rly | | | | |
| | se events (harms) or unanticipated e nd described? | vents | | | | |
| Does the ca | se report provide takeaway lessons? | | | | | |
| verall appraisal | Include | ek further | info 🗌 | | | |
| omments (inclu | fing reason for exclusion) | | | | | |

| Review | erIsaac David Juárez Cruz | | 16/01/21 | | | | | |
|---------|--|------------|----------|--------|----------|-----------------------|--|--|
| Author_ | * | Year | 2020 | Record | Number_1 | <u>26_3238</u> 1497_I | | |
| | | | Yes | No | Unclear | Not applicable | | |
| 1. | Were the criteria for inclusion in the sample defined? | clearly | 4 | | | | | |
| 2. | Were the study subjects and the setting desc detail? | ribed in | | 5 | | | | |
| 3. | Was the exposure measured in a valid and re way? | liable | | | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | | | | |
| 5. | Were confounding factors identified? | | | d | | | | |
| | Were strategies to deal with confounding fac stated? | tors | | | 6 | | | |
| | Were the outcomes measured in a valid and way? | reliable | | | | | | |
| 8. | Was appropriate statistical analysis used? | | | | | | | |
| | appraisal: Include | ek further | info 🔲 | | | | | |

| Review | erIsaac David Juárez Cruz | | 16/01/21 | | | | | |
|---------|--|------------|----------|--------|----------|-----------------------|--|--|
| Author_ | * | Year | 2020 | Record | Number_1 | <u>26_3238</u> 1497_I | | |
| | | | Yes | No | Unclear | Not applicable | | |
| 1. | Were the criteria for inclusion in the sample defined? | clearly | 4 | | | | | |
| 2. | Were the study subjects and the setting desc detail? | ribed in | | 5 | | | | |
| 3. | Was the exposure measured in a valid and re way? | liable | | | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | | | | |
| 5. | Were confounding factors identified? | | | d | | | | |
| | Were strategies to deal with confounding fac stated? | tors | | | 6 | | | |
| | Were the outcomes measured in a valid and way? | reliable | | | | | | |
| 8. | Was appropriate statistical analysis used? | | | | | | | |
| | appraisal: Include | ek further | info 🔲 | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Rev | iewer | Isaac David Juárez Cruz | | | | 30/01/21 | |
|-----|---------------------------|---|------------------------|--------|-----------------|----------|---------------------|
| Aut | hor* | | Year_ | 2020 | Record Number | | 127_3224475821_IDJC |
| | | | | Yes | No | Unclear | Not applicable |
| 1. | Is the revie | w question clearly and explicitly sta | ted? | 6 | | | |
| 2. | Were the in question? | nclusion criteria appropriate for the | review | | | | |
| 3. | Was the se | arch strategy appropriate? | | | | | |
| 4. | Were the s studies ade | ources and resources used to search equate? | n for | | | | |
| 5. | Were the c | riteria for appraising studies approp | riate? | | | | |
| 6. | | l appraisal conducted by two or moi ndependently? | re | | | | |
| 7. | Were there extraction? | methods to minimize errors in data | ì | | | | |
| 8. | Were the n | nethods used to combine studies ap | propriate ² | · 🗹 | <i>,</i> \Box | | |
| 9. | Was the lik | elihood of publication bias assessed | 17 | d | | | |
| 10. | | mmendations for policy and/or prac by the reported data? | tice | | 6 | | |
| 11. | Were the s appropriate | pecific directives for new research e? | | | | | |
| Ove | rall appraisal: | Include Exclude | seek furthe | r info | | | |
| Соп | ments (Includ | ding reason for exclusion) | | | | | |
| _ | | | | | | | |



Robert M Barker-Davies, Oliver O'Sullivan, Kahawalage Pumi Prathima Senaratne, Polly Baker, Mark Cranley, Shreshth Dharm-Datta, Henrietta Ellis, Duncan Goodall,4,7 Michael Gough, Sarah Lewis, Jonathan Norman, Theodora Papadopoulou,4,8 David Roscoe, Daniel Sherwood, Philippa Turner, Tammy Walker, Alan Mistlin, Rhodri Phillip, Alastair M Nicol, Alexander N Bennett, Sardar Bahadur

JBI CRITICAL APPRAISAL CHECKLIST FOR STUDIES REPORTING PREVALENCE DATA

| Reviewer_ | Isaac David Juárez Cruz Dat | e | | 30 | | |
|------------------------------------|---|---------|-----|-----------------|---------|-------------------|
| Hog | hor Saurabh Gombara, Marcello Chang, Catherine A. Ya Hogan, James Zehnder, Scott Boyda, Benjamin A. Pinsky, Nigam H. Shah | | 20_ | _ Record Number | | 128_32505778_ID |
| | | Y | es | No | Unclear | Not applicable |
| Was the popula | e sample frame appropriate to address the targe tion? | t [| | | | |
| 2. Were s | tudy participants sampled in an appropriate way | ? [| | | | |
| 3. Wasth | e sample size adequate? | [| - | | | |
| 4. Were t detail? | he study subjects and the setting described in | [| | | | |
| | e data analysis conducted with sufficient coverage dentified sample? | ge [| | | | |
| 6. Were v | valid methods used for the identification of the on? | [| 1 | | | |
| | e condition measured in a standard, reliable way participants? | | 1 | | | |
| 8. Wasth | ere appropriate statistical analysis? | [| 1 | | | |
| | e response rate adequate, and if not, was the low se rate managed appropriately? | [| | | | 4 |
| Overall appra | aisal: Include Exclude Seek furth | er info | | | | |
| Comments (I | including reason for exclusion) | | | | | |

| Review | er Isaac David Juárez Cruz | | | 30/01/21 | | | | | |
|---------|---|-----------|--------|----------|---------|-------------------|--|--|--|
| Author, | Felix Inchausti, Angus MacBeth, Ilanit Hasson-Ohayon, Giancarlo Dimaggio | _Year | 2020 | Record | Number_ | 129_32836375_IDJC | | | |
| | | | Yes | No | Unclear | Not applicable | | | |
| 1. | Is the source of the opinion clearly identified? | | | | | | | | |
| 2. | Does the source of opinion have standing in that of expertise? | ne field | | | | | | | |
| 3. | Are the interests of the relevant population th central focus of the opinion? | e | | | | | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expression. | | | | | | | | |
| 5. | Is there reference to the extant literature? | | | | | | | | |
| 6. | Is any incongruence with the literature/source logically defended? | es. | | | 4 | | | | |
| | appraisal; Include | k further | info 🗌 | | | | | | |
| e – | | | | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Reviewe | er Marco Antonio Delaye Martínez | Date | 24/ | 04/21 | | |
|-----------|--|--|--------|-------|-----------|-------------------|
| Author_ | Huang L., Zhao P., Tang D., et al. | Year_2 | 020 | Recor | rd Number | 130_32763118 |
| | | | Yes | No | Unclear | Not applicable |
| | Were the two groups similar and recruited for same population? | rom the | • | | | |
| | Were the exposures measured similarly to a people to both exposed and unexposed grou | C. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | V | | | |
| | Was the exposure measured in a valid and roway? | eliable | 1 | | | |
| 4. | Were confounding factors identified? | | V | | | |
| | Were strategies to deal with confounding fa stated? | ctors | Y | | | |
| | Were the groups/participants free of the our at the start of the study (or at the moment of exposure)? | | 1 | | | |
| | Were the outcomes measured in a valid and way? | reliable | | | | |
| | Was the follow up time reported and sufficient be long enough for outcomes to occur? | ent to | V | | | |
| | Was follow up complete, and if not, were th reasons to loss to follow up described and e | | ✓ | | | |
| | Were strategies to address incomplete follow utilized? | w up | 1 | | | |
| 11. | Was appropriate statistical analysis used? | | | | | |
| Overall a | appraisal: Include 🗹 Exclude 🔲 S | eek further | info 🗆 | l | | |
| Commer | nts (Including reason for exclusion) | | | | | |
| No co | omments. | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Review | er Isaac David Juárez Cruz Date | 2 | 30 | /01/21 | |
|-----------|--|-----------|------------|-----------|-------------------|
| Author_ | | 2020 | Reco | rd Number | 131_32366299_IDJ |
| | B. Nirmal Kumar | Yes | No | Unclear | Not applicable |
| | Were the two groups similar and recruited from the same population? | | | | |
| | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | 4 |
| | Was the exposure measured in a valid and reliable way? | | | | |
| 4. | Were confounding factors identified? | | 6 | | |
| | Were strategies to deal with confounding factors stated? | | | | |
| | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | 3 | | |
| | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | | |
| | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | |
| | Were strategies to address incomplete follow up utilized? | 6 | / □ | | |
| 11. | Was appropriate statistical analysis used? | Д | | | |
| Overall a | ppraisal: Include | er info 🗆 | | | |
| Commer | nts (Including reason for exclusion) | | | | |
| No | a todos los participantes se les realizo RT-PCR por l | o que los | datos o | arecen de | validez |

| Neview | er_Marco Antonio Delaye MartínezDate_ | 7/04/2 | 21 | | |
|-----------------|--|--------|--------|-----------------|-------------------|
| Author <u>.</u> | Yan C., Prajapati D., Either M., et al. Year 2 | 020 | Record | Number <u>1</u> | 32_32513065 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | | | | |
| 2. | Were the study subjects and the setting described in detail? | | 1 | | |
| 3. | Was the exposure measured in a valid and reliable way? | 1 | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | ď | | |
| 5, | Were confounding factors identified? | | • | | |
| 6. | Were strategies to deal with confounding factors stated? | | Z | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was appropriate statistical analysis used? | | ✓ | | |

El estudio no aporta información completa sobre las características demográficas y clínicas de los pacientes. No se puede establecer de forma concreta el tiempo de seguimiento. Cabe la posibilidad de que algunos pacientesnfueran entrevistados antes de los 21 días de seguimiento.

| uthor | Barón-Sánchez J., Santiago C., Goizueta Year 20 G., et al. | 020 | Record | Number <u>1</u> | 33_329005 |
|--------|--|--------------|----------|-----------------|-------------------|
| | o., et al. | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | | | | |
| 2. | Were the study subjects and the setting described in detail? | \checkmark | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | V | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | V | | | |
| 5. | Were confounding factors identified? | | ✓ | | |
| 6. | Were strategies to deal with confounding factors stated? | | V | | |
| | Were the outcomes measured in a valid and reliable way? | 1 | | | |
| 8. | Was appropriate statistical analysis used? | • | | | |
| verall | appraisal: Include | nfo 🗌 | | | |
| omme | nts (Including reason for exclusion) | | | | |

| Reviewe | Daniel de la Rosa | Date_ | 2 | 2-11-20 | | |
|---------|--|---------|--------|----------|---------|-------------------|
| Author_ | Louis Poncet-Megemont, et al | аг | 2020 | Record 1 | Number_ | 35_32757419 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clea defined? | irly | | | | |
| 2. | Were the study subjects and the setting describe detail? | ed in | | | | |
| 3. | Was the exposure measured in a valid and reliab way? | le | Z | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | 1 | | | |
| 5. | Were confounding factors identified? | | | 1 | | |
| 6. | Were strategies to deal with confounding factor stated? | 8 | | 1 | | |
| 7. | Were the outcomes measured in a valid and relia way? | able | Z | | | |
| 8. | Was appropriate statistical analysis used? | | N | | | |
| | praisal: Include 🔲 Exclude 🖊 Seek fu | rther | info 🗌 | | | |
| | s (Including reason for exclusion) diagnostic method was not PCR for all partic | inan | ts | | | |
| | and the state of t | -pessi) | 89031 | | | |
| | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Review | er Marco Antonio Delaye Martinez | 07/04/21 | | | | |
|---|---|------------|----------|----------|--------------|-------------------|
| Author Gong Y., Guan L., Jin Z.m et al. | | Year 2020 | | Recor | 136_32441786 | |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited fro same population? | om the | ď | | | |
| 2. | Were the exposures measured similarly to ass people to both exposed and unexposed group | 15.85.55 | 1 | | | |
| 3. | Was the exposure measured in a valid and rel way? | liable | 1 | | | |
| 4. | Were confounding factors identified? | | | 1 | | |
| 5. | Were strategies to deal with confounding fact stated? | tors | | V | | |
| 6. | Were the groups/participants free of the outout at the start of the study (or at the moment of exposure)? | | √ | | | |
| 7. | Were the outcomes measured in a valid and r way? | reliable | Y | | | |
| 8. | Was the follow up time reported and sufficier be long enough for outcomes to occur? | ntto | √ | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and exp | | 7 | | | |
| 10. | Were strategies to address incomplete follow utilized? | up | | | ✓ | |
| 11. | Was appropriate statistical analysis used? | | ₹ | | | |
| Overall | appraisal: Include \square Exclude \checkmark See | ek further | info 🗌 | | | |
| Comme | nts (Including reason for exclusion) | | | | | |
| | culo no cumple con los criterios básicos | | | | | |
| omme El artí | nts (Including reason for exclusion) | | | | | |

© JBI, 2020. All rights reserved. JBI grants use of these tools for research purposes only. All other enquiries should be sent to jbisynthesis@adelaide.edu.au.

| Review | Marco Antonio Delaye Martínez Date 7/04/21 | | | | | | | |
|---------|--|----------|----|------------------------|-------------------|--|--|--|
| Author_ | Akter F., Mannan A., Mehedi H., et al. Year 2 | ear_2020 | | Record Number 137_3311 | | | | |
| | | Yes | No | Unclear | Not applicable | | | |
| 1. | Were the criteria for inclusion in the sample clearly defined? | Ø | | | | | | |
| 2. | Were the study subjects and the setting described in detail? | V | | | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | Z | | | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | | | | |
| 5. | Were confounding factors identified? | | | V | | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | 1 | | | | |
| | Were the outcomes measured in a valid and reliable way? | V | | | | | | |
| 8. | Was appropriate statistical analysis used? | V | | | | | | |
| | appraisal: Include | info 🗌 | | | | | | |
| | | | | | | | | |

| uthor | Klitzman R. | ear_2020 | Record | d Number <u>1</u> | 38_33103966 |
|---------|---|-------------|------------|-------------------|-------------------|
| | | Ye | es No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | 9 | | | |
| 2. | Does the source of opinion have standing in the of expertise? | field 🛡 | <i>!</i> □ | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | 8 | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion express | ed? | | | |
| 5. | Is there reference to the extant literature? | 5 | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | v | | | |
| Overall | appraisal; Include 🗆 Exclude 🖬 Seek f | urther info | | | |
| omme | nts (Including reason for exclusion) | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR COHORT STUDIES

| Review | er Marco Antonio Delaye Martínez Date | 07/ | 04/21 | | |
|---------|--|----------|-------|----------|-------------------|
| | Caronna E., Ballvé A., Llauradó A., et al. Year 2 | 2020 | Recor | d Number | 139_33146036 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | ≰ | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | V | | | |
| 3. | Was the exposure measured in a valid and reliable way? | 1 | | | |
| 4. | Were confounding factors identified? | | V | | |
| 5. | Were strategies to deal with confounding factors stated? | | 1 | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | ✓ | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | V | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | 1 | | |
| 10. | Were strategies to address incomplete follow up utilized? | V | | | |
| 11. | Was appropriate statistical analysis used? | • | | | |
| Overall | appraisal: Include Z Exclude \(\square\) Seek furthe | r info 🗆 | l | | |
| Comme | nts (Including reason for exclusion) | | | | |
| No | comments. | | | | |

CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

Critical Appraisal tools for use in JBI Systematic Reviews

INTRODUCTION

JBI is an JBI is an international research organisation based in the Faculty of Health and Medical Sciences at the University of Adelaide, South Australia. JBI develops and delivers unique evidence-based information, software, education and training designed to improve healthcare practice and health outcomes. With over 70 Collaborating Entities, servicing over 90 countries, JBI is a recognised global leader in evidence-based healthcare.

JBI Systematic Reviews

The core of evidence synthesis is the systematic review of literature of a particular intervention, condition or issue. The systematic review is essentially an analysis of the available literature (that is, evidence) and a judgment of the effectiveness or otherwise of a practice, involving a series of complex steps. JBI takes a particular view on what counts as evidence and the methods utilised to synthesise those different types of evidence. In line with this broader view of evidence, JBI has developed theories, methodologies and rigorous processes for the critical appraisal and synthesis of these diverse forms of evidence in order to aid in clinical decision-making in healthcare. There now exists JBI guidance for conducting reviews of effectiveness research, qualitative research, prevalence/incidence, etiology/risk, economic evaluations, text/opinion, diagnostic test accuracy, mixed-methods, umbrella reviews and scoping reviews. Further information regarding JBI systematic reviews can be found in the JBI Evidence Synthesis Manual.

JBI Critical Appraisal Tools

All systematic reviews incorporate a process of critique or appraisal of the research evidence. The purpose of this appraisal is to assess the methodological quality of a study and to determine the extent to which a study has addressed the possibility of bias in its design, conduct and analysis. All papers selected for inclusion in the systematic review (that is – those that meet the inclusion criteria described in the protocol) need to be subjected to rigorous appraisal by two critical appraisers. The results of this appraisal can then be used to inform synthesis and interpretation of the results of the study. JBI Critical appraisal tools have been developed by the JBI and collaborators and approved by the JBI Scientific Committee following extensive peer review. Although designed for use in systematic reviews, JBI critical appraisal tools can also be used when creating Critically Appraised Topics (CAT), in journal clubs and as an educational tool.

| Review | er: Daniel de la Rosa Martinez. | | Date: | Martes 13 | de Abril 2021 |
|---------|--|--------|--------|-----------|-------------------|
| Author | : Rossana Bussan, et al. Year: 2020 | Record | Number | : 140_331 | 58808_DDM |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | | | | |
| 2. | Were the study subjects and the setting described in detail? | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | |
| 5. | Were confounding factors identified? | | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was appropriate statistical analysis used? | | | | |
| Overall | appraisal; Include | nfo 🗆 | | | |
| Comme | nts (including reason for exclusion) | | | | |

No aporta información relevante para los fines de la revisión

Explanation of analytical cross sectional studies critical appraisal

How to cite: Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, 2020. Available from https://synthesismanual.jbi.global

Analytical cross sectional studies Critical Appraisal Tool

Answers: Yes, No, Unclear or Not/Applicable

Were the criteria for inclusion in the sample clearly defined?

The authors should provide clear inclusion and exclusion criteria that they developed prior to recruitment of the study participants. The inclusion/exclusion criteria should be specified (e.g., risk, stage of disease progression) with sufficient detail and all the necessary information critical to the study.

2. Were the study subjects and the setting described in detail?

The study sample should be described in sufficient detail so that other researchers can determine if it is comparable to the population of interest to them. The authors should provide a clear description of the population from which the study participants were selected or recruited, including demographics, location, and time period.

Was the exposure measured in a valid and reliable way?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

Reliability refers to the processes included in an epidemiological study to check repeatability of measurements of the exposures. These usually include intra-observer reliability and inter-observer reliability.

4. Were objective, standard criteria used for measurement of the condition?

It is useful to determine if patients were included in the study based on either a specified diagnosis or definition. This is more likely to decrease the risk of bias. Characteristics are another useful approach to matching groups, and studies that did not use specified diagnostic methods or definitions should provide evidence on matching by key characteristics

5. Were confounding factors identified?

Confounding has occurred where the estimated intervention exposure effect is biased by the presence of some difference between the comparison groups (apart from the exposure investigated/of interest). Typical confounders include baseline characteristics, prognostic factors, or concomitant exposures (e.g. smoking). A confounder is a difference between the comparison groups and it influences the direction of the study results. A high quality study at the level of cohort design will identify the potential confounders and measure them (where possible). This is difficult for studies where behavioral, attitudinal or lifestyle factors may impact on the results.

6. Were strategies to deal with confounding factors stated?

Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or stratifying sampling of participants, effects of confounding factors can be adjusted for. When dealing with adjustment in data analysis, assess the statistics used in the study. Most will be some form of multivariate regression analysis to account for the confounding factors measured.

7. Were the outcomes measured in a valid and reliable way?

Read the methods section of the paper. If for e.g. lung cancer is assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If lung cancer is assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

Having established the objectivity of the outcome measurement (e.g. lung cancer) instrument, it's important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? (e.g. radiographers). If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised?

8. Was appropriate statistical analysis used?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.

For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.

| Review | er Marco Antonio Delaye Martinez | Date 07/04 | /20 | | |
|---------|--|-----------------|---------|----------|---------------------|
| Author | Falahi S., Kenarkoohi A. | Year 2020 | Record | Number 1 | <u>41_332</u> 00033 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | ✓ | | | |
| 2. | Does the source of opinion have standing in th of expertise? | e field | | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | • 1 | | | |
| 4. | Is the stated position the result of an analytica process, and is there logic in the opinion expre | VI-0.00000000 | | | |
| 5. | Is there reference to the extant literature? | ✓ | | | |
| 6. | Is any incongruence with the literature/source logically defended? | s 🗸 | | | |
| Overall | appraisal: Include 🔲 Exclude 🗹 Seel | cfurther info | | | |
| Comme | ents (Including reason for exclusion) | | | | |
| | tículo no aporta informacion util para los mática. | fines de la pre | sente r | evisión | |

CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

Critical Appraisal tools for use in JBI Systematic Reviews

INTRODUCTION

JBI is an JBI is an international research organisation based in the Faculty of Health and Medical Sciences at the University of Adelaide, South Australia. JBI develops and delivers unique evidence-based information, software, education and training designed to improve healthcare practice and health outcomes. With over 70 Collaborating Entities, servicing over 90 countries, JBI is a recognised global leader in evidence-based healthcare.

JBI Systematic Reviews

The core of evidence synthesis is the systematic review of literature of a particular intervention, condition or issue. The systematic review is essentially an analysis of the available literature (that is, evidence) and a judgment of the effectiveness or otherwise of a practice, involving a series of complex steps. JBI takes a particular view on what counts as evidence and the methods utilised to synthesise those different types of evidence. In line with this broader view of evidence, JBI has developed theories, methodologies and rigorous processes for the critical appraisal and synthesis of these diverse forms of evidence in order to aid in clinical decision-making in healthcare. There now exists JBI guidance for conducting reviews of effectiveness research, qualitative research, prevalence/incidence, etiology/risk, economic evaluations, text/opinion, diagnostic test accuracy, mixed-methods, umbrella reviews and scoping reviews. Further information regarding JBI systematic reviews can be found in the JBI Evidence Synthesis Manual.

JBI Critical Appraisal Tools

All systematic reviews incorporate a process of critique or appraisal of the research evidence. The purpose of this appraisal is to assess the methodological quality of a study and to determine the extent to which a study has addressed the possibility of bias in its design, conduct and analysis. All papers selected for inclusion in the systematic review (that is – those that meet the inclusion criteria described in the protocol) need to be subjected to rigorous appraisal by two critical appraisers. The results of this appraisal can then be used to inform synthesis and interpretation of the results of the study. JBI Critical appraisal tools have been developed by the JBI and collaborators and approved by the JBI Scientific Committee following extensive peer review. Although designed for use in systematic reviews, JBI critical appraisal tools can also be used when creating Critically Appraised Topics (CAT), in journal clubs and as an educational tool.

| Review | er: Daniel de la Rosa Martinez. | | Date: | Martes 13 | de Abril 2021 |
|---------|--|--------|--------|------------|-------------------|
| Author | : Beatriz López-Barbeito. Year: 2020 | Record | i Numb | er: 142_33 | 275358_DDM |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | | | | |
| 2. | Were the study subjects and the setting described in detail? | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | |
| 5. | Were confounding factors identified? | | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was appropriate statistical analysis used? | | | | |
| Overall | appraisal; Include | nto 🗆 | | | |
| Comme | nts (Including reason for exclusion) | | | | |

El diagnostico no fue uniforme para todos y no queda claro el tiempo de seguimiento o si los sintomas son al momento de la revaloración

Analytical cross sectional studies Critical Appraisal Tool

Answers: Yes, No, Unclear or Not/Applicable

1. Were the criteria for inclusion in the sample clearly defined?

The authors should provide clear inclusion and exclusion criteria that they developed prior to recruitment of the study participants. The inclusion/exclusion criteria should be specified (e.g., risk, stage of disease progression) with sufficient detail and all the necessary information critical to the study.

2. Were the study subjects and the setting described in detail?

The study sample should be described in sufficient detail so that other researchers can determine if it is comparable to the population of interest to them. The authors should provide a clear description of the population from which the study participants were selected or recruited, including demographics, location, and time period.

3. Was the exposure measured in a valid and reliable way?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

Reliability refers to the processes included in an epidemiological study to check repeatability of measurements of the exposures. These usually include intra-observer reliability and inter-observer reliability.

4. Were objective, standard criteria used for measurement of the condition?

It is useful to determine if patients were included in the study based on either a specified diagnosis or definition. This is more likely to decrease the risk of bias. Characteristics are another useful approach to matching groups, and studies that did not use specified diagnostic methods or definitions should provide evidence on matching by key characteristics

5. Were confounding factors identified?

Confounding has occurred where the estimated intervention exposure effect is biased by the presence of some difference between the comparison groups (apart from the exposure investigated/of interest). Typical confounders include baseline characteristics, prognostic factors, or concomitant exposures (e.g., smoking). A confounder is a difference between the comparison groups and it influences the direction of the study results. A high quality study at the level of cohort design will identify the potential confounders and measure them (where possible). This is difficult for studies where behavioral, attitudinal or lifestyle factors may impact on the results.

6. Were strategies to deal with confounding factors stated?

Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or stratifying sampling of participants, effects of confounding factors can be adjusted for. When dealing with adjustment in data analysis, assess the statistics used in the study. Most will be some form of multivariate regression analysis to account for the confounding factors measured.

Were the outcomes measured in a valid and reliable way?

Read the methods section of the paper. If for e.g. lung cancer is assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If lung cancer is assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity. Having established the objectivity of the outcome measurement (e.g. lung cancer) instrument, it's important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? (e.g. radiographers). If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised?

8. Was appropriate statistical analysis used?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.

For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.

| Review | er Daniel Eduardo Sandoval Colin | _Date | 31/0 | 3/202 | 1 | |
|---------|--|----------|-------------|---------|-------------|-------------------|
| Author | Jonathan Wei Ting Wen LIU, Renata D'altoé DE LUCA, Heralde Oliveira MELLO NETO and Igor BARCELLOS | _Year_ | 2020 | Record | l Number_1 | 43_33331469_DES |
| | | | Yes | No | Unclear | Not applicable |
| 1, | Is the source of the opinion clearly identified? | | X | | | |
| 2. | Does the source of opinion have standing in th of expertise? | e field | × | | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | e | \boxtimes | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expre | | X | | | |
| 5. | Is there reference to the extant literature? | | X | | | |
| 6. | Is any incongruence with the literature/source logically defended? | 5 | | | | |
| Overall | appraisal: Include 🔲 Exclude 🗴 Seel | c furthe | rinfo 🗌 | | | |
| Comme | nts (Including reason for exclusion) | | | | | |
| No cu | imple los criterios de inclusión. Sin embargo, pu | ede se | r de utilid | ad para | la discusió | n. |
| _ | | | | | | |

| Review | er Daniel Eduardo Sandoval Colin Date | 31/0 | 3/2021 | <u></u> | |
|---------|--|--------------|-----------|--------------|-------------------|
| Author | Ana P. Bouças, Jakeline Rheinheimer and Jim Lagopoulos year | 2020 | Record | Number_14 | 14_33135582_DESC |
| | | Yes | No | Unclear | Not applicable |
| 1, | Is the source of the opinion clearly identified? | \mathbf{x} | | | |
| 2. | Does the source of opinion have standing in the field of expertise? | | | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | \boxtimes | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expressed? | X | | | |
| 5. | Is there reference to the extant literature? | X | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | | | X |
| Overall | appraisal: Include | erinfo 🗆 | ļ | | |
| Comme | nts (Including reason for exclusion) | | | | |
| No cu | mple los criterios de inclusión. Sin embargo, puede se | r de utilida | ad para l | a discusión. | 8 |
| | | | | | |

| Review | er Daniel Eduardo Sandoval Colin | _Date_ | | 31/03/20 | 21 | |
|--|--|-----------|-------------|----------|------------|-------------------|
| Author_ | Oliver O'Sulfivan | Year 20 | 20 | Record | Number_14 | 15_33144403_DES |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | X | | | |
| 2. | Does the source of opinion have standing in the of expertise? | field | | | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | 7 | X | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expres | sed? | \boxtimes | | | |
| 5. | Is there reference to the extant literature? | | | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | Ö | | | | |
| Overall a | appraisal: Include | further i | nfo 🗌 | | | |
| Commer | nts (Including reason for exclusion) | | | | | |
| Separate services | mple los criterios de inclusión. | | | | | |
| Series (Section Section Sectio | relevante para la discusión de este proy | - | - | | | |
| Concie | entiza sobre la necesidad de rehabilitación y eval | uación r | multidisi | plinaria | después de | la fase aguda. |

JBI Critical Appraisal Checklist for Case Series

| Reviewer_ | Daniel Eduardo Sandoval Colin | _Date | 31/03 | 31/03/2021 | | | |
|-------------------------|--|--------------|----------|---------------|----------------------|--|--|
| Author | Luigi Urciuoli and Elvira Guerriero | Year_ 202 | 0Re | cord Numb | er_146_33152991_DES0 | | |
| | | Yes | No | Unclear | Not applicable | | |
| • Were the series? | re clear criteria for inclusion in the case | | | | | | |
| | condition measured in a standard, reliable Il participants included in the case series? | | | | | | |
| | d methods used for identification of the for all participants included in the case | | | | | | |
| Did the co | ase series have consecutive inclusion of nts? | | | | | | |
| Did the coparticipal | ase series have complete inclusion of hts? | | | | | | |
| | e clear reporting of the demographics of the nts in the study? | | | | | | |
| • Was ther participa | e clear reporting of clinical information of the nts? | e 🗆 | | | | | |
| • Were the clearly re | outcomes or follow up results of cases ported? | | | | | | |
| | e clear reporting of the presenting nic(s) demographic information? | | | | | | |
| • Was stati | stical analysis appropriate? | | | | | | |
| - | praisal: Include | c further in | fo 🗆 | | | | |
| | a cuestionario porque no cumple con los criterios | de inclusión | No repor | tan persister | ncia de sintomas, | | |
| | | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Author | Denyse D. Lutchmanningh, Melissa P. Knasert, Danielle E. Artin-Ozerkis et al. Year | 2020 | Record | Number 14 | 17_33159907_DESC |
|---------|--|-------------|--------|-----------|-------------------|
| | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | \boxtimes | | | |
| 2. | Does the source of opinion have standing in the field of expertise? | X | | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | X | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expressed? | | | | |
| 5. | Is there reference to the extant literature? | X | | | |
| 6, | Is any incongruence with the literature/sources logically defended? | | | | ⊠ |
| Overall | appraisal: Include | er info | į | | |
| Comme | nts (Including reason for exclusion) | | | | |

Aborda principalmente las seculas de la función ventilatoria y cambios radiográficos.

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Review | er Daniel Eduardo Sandoval Colin | 31/0 | 31/03/2021 | | | | |
|-----------|--|----------|------------|--------|-----------|-------------------|--|
| Author | Mac Peng, Li Wang, Qing Xue et al. | _Year_ | 2020 | Record | Number_14 | 18_33152729_DES0 | |
| | | | Yes | No | Unclear | Not applicable | |
| 1. | Were the criteria for inclusion in the sample cl defined? | early | | | | | |
| 2. | Were the study subjects and the setting descri detail? | ibed in | | | | | |
| 3. | Was the exposure measured in a valid and reli way? | able | | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | | | | | |
| 5. | Were confounding factors identified? | | | | | | |
| 6. | Were strategies to deal with confounding factorstated? | ors | | | | | |
| 7. | Were the outcomes measured in a valid and re way? | eliable | | | | | |
| 8. | Was appropriate statistical analysis used? | | | | | | |
| Overall : | appraisal: Include 🔲 Exclude 🕱 See | k furthe | erinfo 🗌 | | | | |
| Comme | nts (Including reason for exclusion) | | | | | | |
| Noser | ealiza cuestionario porque no cumple con los criterio | s de inc | lusión. | | | | |
| No abor | rda síntomas persistentes. | | | | | | |

Encuesta en linea para estudiar la prevalencia de carga alostatica en trabajadores médicos vs trabajadores no médicos.

JBI Critical Appraisal Checklist for Case Series

| Author_Yale Tung-Chen, Milagros Marti de Gracia, Maria Luz Parra-Gordo et al y | ear_ 202 | 0 Re | cord Numb | er_149_33159704_DES |
|---|-------------|--------|-----------|---------------------|
| | Yes | No | Unclear | Not applicable |
| Were there clear criteria for inclusion in the case series? | | | | |
| • Was the condition measured in a standard, reliable way for all participants included in the case series? | | | | |
| Were valid methods used for identification of the condition for all participants included in the case series? | | | | |
| Did the case series have consecutive inclusion of participants? | | | | |
| • Did the case series have complete inclusion of participants? | | | | |
| Was there clear reporting of the demographics of the participants in the study? | | | | |
| Was there clear reporting of clinical information of the participants? | | | | |
| • Were the outcomes or follow up results of cases clearly reported? | | | | |
| Was there clear reporting of the presenting site(s)/clinic(s) demographic information? | | | | |
| • Was statistical analysis appropriate? | | | | |
| Overall appraisal: Include | further inf | 。 □ | | |
| Comments (Including reason for exclusion) | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Review | er Daniel Eduardo Sandoval Colin | Date | 1/04 | /2021 | | |
|---------|--|-------|--------|--------|----------|-------------------|
| Author, | Liam Townsend, Adam H. Dyer, Karen Jones et alYe | ar | 2020 | Record | Number_1 | 50_33166287_DES |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clear defined? | ly | X | | | |
| 2. | Were the study subjects and the setting described detail? | d in | X | | | |
| 3. | Was the exposure measured in a valid and reliable way? | е | X | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | X | | | |
| 5. | Were confounding factors identified? | | X | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | | X | |
| 7. | Were the outcomes measured in a valid and relial way? | ble | X | | | |
| 8. | Was appropriate statistical analysis used? | | X | | | |
| | appraisal: Include | rther | info 🔲 | | | |
| | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Reviewe | Daniel Eduardo Sandoval Colin Date | 1/04 | 4/2020 | | |
|-----------|--|-------------|--------|-----------|-------------------------|
| Author_ | Jose Vergara, Camilla Lirani-Silva, Martin B. Brodsky et al. Year 20 | 20 | Record | Number_15 | 51_33167752_DESC |
| | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | X | | | |
| | Does the source of opinion have standing in the field of expertise? | X | | | |
| | Are the interests of the relevant population the central focus of the opinion? | X | | | |
| | Is the stated position the result of an analytical process, and is there logic in the opinion expressed? | \boxtimes | | | |
| 5. | Is there reference to the extant literature? | X | | | |
| | Is any incongruence with the literature/sources logically defended? | | | | $\overline{\mathbf{x}}$ |
| Overall a | ppraisal: Include | nfo 🗆 |] | | |
| Commen | its (Including reason for exclusion) | | | | |
| No o | sumple los criterios de inclusión. | | | | |

Había sobre las posibles alteraciones neurológicas que pueden interferir en la deglución, con efecto no solo en el gusto y el olfato, sino también en la función sensoriomotora de la faringe y la laringe, que pueden comprometer la protección de las vías respiratorias y la seguridad de la deglución.

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Review | er Daniel Eduardo Sandoval Colin Da | te | 29/03 | /2021 | |
|--------|--|----------|--------|-----------|-------------------|
| Author | Swapna Mandal, Joseph Barnett, Simon E Brill et al. Year | 2020 | Record | Number_15 | 52_33172844_DESC |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | x | | | |
| 2. | Were the study subjects and the setting described in detail? | n 🗵 | | | |
| 3. | Was the exposure measured in a valid and reliable way? | × | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | × | | | |
| 5. | Were confounding factors identified? | X | | | |
| 6. | Were strategies to deal with confounding factors stated? | | X | | |
| 7. | Were the outcomes measured in a valid and reliable way? | e X | | | |
| 8. | Was appropriate statistical analysis used? | | X | | |
| | appraisal: Include | her info | | | |
| | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Reviewe | Paniel Eduardo Sandoval Colin | Date | 2 | 9/03/2 | 021 | |
|-----------|---|-----------|-------------|----------|-------------|-------------------|
| Author_ | Peter V. Dicpinigaltis and Brendan J. Canning | Year_ | 2020 | Record | Number 15 | 53_33188436_DES |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified | ? | \boxtimes | | | |
| | Does the source of opinion have standing in t of expertise? | he field | X | | | |
| | Are the interests of the relevant population t central focus of the opinion? | he | X | | | |
| | Is the stated position the result of an analytic process, and is there logic in the opinion expr | | \boxtimes | | | |
| 5. | Is there reference to the extant literature? | | X | | | |
| | Is any incongruence with the literature/source logically defended? | es | X | | | |
| Overall a | appraisal: Include | ek furthe | rinfo 🗆 | Ī | | |
| | nts (Including reason for exclusion) see datos para los propósitos de este trabajo, | puede s | er de utili | dad para | la discusió | n del manuscrito. |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Review | er Daniel Eduardo Sandoval Colin Date | 29/ | 03/202 | 1 | |
|--------|--|---------|--------|---------|-------------------|
| Author | Tadayuki Oshima, Kewin Tien Ho Sish, Takanori Yoshimoto et al. Year | 2020 | Record | Number_ | 154_33197076_DESC |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | X | | | |
| 2. | Were the study subjects and the setting described in detail? | X | | | |
| 3. | Was the exposure measured in a valid and reliable way? | X | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | X | | | |
| 5. | Were confounding factors identified? | X | | | |
| 6. | Were strategies to deal with confounding factors stated? | X | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | x | | |
| 8. | Was appropriate statistical analysis used? | x | | | |
| Commer | appraisal: Include | rinfo 🔲 | | | |
| Nosee | studia a sujetos con diagnóstico previo de COVID-19 | | | | |
| | | | | | |

| Review | er_ Daniel Eduardo Sandoval Colin | ate 30 | /03/20 | 21 | |
|--------|--|---------------|----------------|------------------|-----------------------------|
| Author | Manierosa Certa, Luciena Bragagnolo, Andres Tramarin et al. Ye | ar 2020 | Recor | d Number | 155_32827394_DESC |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | he 🗌 | | | |
| 2. | Were the exposures measured similarly to assign people | | | | |
| 3. | to both exposed and unexposed groups? | | | | |
| 4. | Was the exposure measured in a valid and reliable way? | | | | |
| 5. | Were confounding factors identified? | | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | | |
| 7. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | | |
| 8. | Were the outcomes measured in a valid and reliab way? | ole 🔲 | | | |
| 9. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explore | nd? 🗆 | | | |
| 11. | Were strategies to address incomplete follow up utilized? | | | | |
| 12. | Was appropriate statistical analysis used? | | | | |
| | appraisal: Include | rther info |] | | |
| | e realiza cuestionario porque no cumple con los crit | erios de incl | usión | | |
| 12.000 | gas intorneo postal agricotico de COVID-19. Se evelús positividad a 20, 32 y 49 dias | | 12 12 20 E. O. | e lgG-Ab en un e | ello pere estatios meyores. |

| Review | er Daniel Eduardo Sandoval Colin Dat | e 3 | 0/03/20 |)21 | |
|--------|--|-----------|---------|----------|-------------------|
| Author | Gloria Gambini, Maria Cristina Savastano, Alfonso Savastano et al. Year | 2021 | _ Recor | d Number | 156_33214412_DES0 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | X | | | |
| 2. | Were the exposures measured similarly to assign people | \square | | | |
| 3. | to both exposed and unexposed groups? | | | | |
| 4. | Was the exposure measured in a valid and reliable way? | X | | | |
| 5. | Were confounding factors identified? | X | | | |
| 6. | Were strategies to deal with confounding factors stated? | | X | | |
| 7. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | X | | | |
| 8. | Were the outcomes measured in a valid and reliable way? | X | | | |
| 9. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | X | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | X | | | |
| 11. | Were strategies to address incomplete follow up utilized? | | | | X |
| 12. | Was appropriate statistical analysis used? | | X | | |
| | appraisal: Include X Exclude | er info [|] | | |

| | er_Daniel Eduardo Sandoval ColinDate | | 30/03/20 | | |
|------|--|------|----------|----------|-------------------|
| thor | Fran A. Garz-Lord, Kathryn R. Segal BA and Michael L. Rinke Year | 2020 | Recor | d Number | 157_33213542_DES |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | | | | |
| 2. | Were the exposures measured similarly to assign people | | | | |
| 3. | to both exposed and unexposed groups? | | | | |
| 4. | Was the exposure measured in a valid and reliable way? | | | | |
| 5. | Were confounding factors identified? | | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | | |
| 7. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | | |
| 8. | Were the outcomes measured in a valid and reliable way? | | | | |
| 9. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | |
| 11. | Were strategies to address incomplete follow up utilized? | | | | |
| | Was appropriate statistical analysis used? | | П | | |

No se realiza cuestionario porque no cumple con los criterios de inclusion.

Las pruebas de PCR fueron inicialmente limitadas debido a la disponibilidad de hisopos y reactivos

| Review | er Daniel Eduardo Sandoval Colin Date | 30/ | 03/202 | | |
|--------|--|--------|--------|----------|-------------------|
| uthor | Bram van den Borst, Jeannette B Peters, Monique Brink et al. Year | 2020 | Recor | d Number | 158_33220049_DES |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | X | | | |
| 2. | Were the exposures measured similarly to assign people | X | | | |
| 3. | to both exposed and unexposed groups? | | | | |
| 4. | Was the exposure measured in a valid and reliable way? | X | | | |
| 5. | Were confounding factors identified? | X | | | |
| 6. | Were strategies to deal with confounding factors stated? | | | X | |
| 7. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | X | |
| 8. | Were the outcomes measured in a valid and reliable way? | X | | | |
| 9. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | X | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | × | | | |
| 11. | Were strategies to address incomplete follow up utilized? | | X | | |
| 12. | Was appropriate statistical analysis used? | X | | | |
| | appraisal: Include | info 🗆 |] | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Revie | ver Daniel Eduardo Sandoval Colin Date | 30/ | 03/202 | 1 | | |
|-------|--|--------|--------|----------|-------------------|-------|
| Autho | Marcel S.Woo, Jakob Malsy, Jana Pöttgen et al. _{Year} | 2020 | Record | Number_1 | 59_33376990 | _DESC |
| | | Yes | No | Unclear | Not applicable | |
| 1. | Were the criteria for inclusion in the sample clearly defined? | X | | | | |
| 2. | Were the study subjects and the setting described in detail? | X | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | X | | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | X | | | | |
| 5. | Were confounding factors identified? | X | | | | |
| 6. | Were strategies to deal with confounding factors stated? | x | | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | x | | | | |
| 8. | Was appropriate statistical analysis used? | X | | | | |
| | appraisal: Include Exclude Seek further | info 🗆 | | | | |
| | | | | | | _ |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | er Daniel Eduardo Sandoval Colin | _Date | 3 | 0/03/20 |)21 | |
|-----------|--|----------|-------------|-----------|----------------|-------------------|
| Author_ | M Mendelson, J Nel, L Blumberg et al. | _Year_ | 2020 | Record | Number_16 | 60_33403997_DESC |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | \square | | | |
| 2. | Does the source of opinion have standing in th of expertise? | e field | X | | | |
| 3. | Are the interests of the relevant population th central focus of the opinion? | e | \boxtimes | | | |
| 4. | Is the stated position the result of an analytica process, and is there logic in the opinion expre | | \square | | | |
| 5. | Is there reference to the extant literature? | | X | | | |
| 6. | Is any incongruence with the literature/source logically defended? | 5 | X | | | |
| Overall a | appraisal: Include | k furthe | erinfo 🗌 | | | |
| Commer | nts (Including reason for exclusion) | | | | | |
| No рове | e información para los propósitos de este traba | jo. No | cumple co | on los cr | iterios de inc | clusión. |
| _ | | | | | | |

| Author | Jarome R. Lechien, Fabrice Journe, Stephane Hans et al. Year | 2020 | Recor | d Number | 161_33330539_DES |
|--------|--|---------|-------|----------|-------------------|
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | | | | X |
| 2. | Were the exposures measured similarly to assign people | | | | X |
| 3. | to both exposed and unexposed groups? | | | | |
| 4. | Was the exposure measured in a valid and reliable way? | X | | | |
| 5. | Were confounding factors identified? | X | | | |
| 6. | Were strategies to deal with confounding factors stated? | X | | | |
| 7. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | | X |
| 8. | Were the outcomes measured in a valid and reliable way? | X | | | |
| 9. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | X | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | X |
| 11. | Were strategies to address incomplete follow up utilized? | | | | X |
| 12. | Was appropriate statistical analysis used? | X | | | |
| | appraisal: Include | rinfo 🗆 |] | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Reviewer | | Daniel de la Rosa Da | ate | 21-11- | 20 | | |
|----------|--------------------|--|-----------|--------|-----------|-------------------|--|
| Author | | R. Torres-Castroa et al Yes | 2020 | Record | l Number_ | 162_33262076 | |
| | | | Yes | No | Unclear | Not applicable | |
| 1. | Is the rev | iew question clearly and explicitly stated? | 1 | | | | |
| 2. | Were the question? | inclusion criteria appropriate for the review | | | | ∠ | |
| 3. | Was the s | search strategy appropriate? | | | | Z | |
| 4. | Were the | sources and resources used to search for dequate? | | | | Ø | |
| 5. | Were the | criteria for appraising studies appropriate? | | | | X | |
| 6. | | cal appraisal conducted by two or more independently? | | | | Ø | |
| 7. | Were the | re methods to minimize errors in data n? | | | | Ø | |
| 8. | Were the | methods used to combine studies appropria | te? | | | | |
| 9. | Was the I | ikelihood of publication bias assessed? | | | | | |
| 10. | | ommendations for policy and/or practice d by the reported data? | Z | | | | |
| 11. | Were the appropria | specific directives for new research ste? | Ø | | | | |
| Ove | rall appraisa | al: Include 🔲 Exclude 📈 Seek furt | ther info |] | | | |
| Con | ments (Incl | luding reason for exclusion) | | | | | |
| | Review | | | | | | |

JBI Critical Appraisal Checklist for Case Series

| Reviewer | Daniel de la Rosa | _Date | 02-0 | 2-21 | |
|---|--|---------------|--------|------------|-------------------|
| Author | Melanie Dani et al | Year 20 | 20_ Re | cord Numbe | 163_33243837 |
| | | Yes | No | Unclear | Not applicable |
| • Were there series? | clear criteria for inclusion in the case | | | | |
| | ndition measured in a standard, reliable participants included in the case series? | 2 | | | |
| | methods used for identification of the or all participants included in the case | Z | | | |
| Did the case participants | e series have consecutive inclusion of ? | | | 4 | |
| Did the case participants | e series have complete inclusion of ? | | ₫ | | |
| | clear reporting of the demographics of the in the study? | | | | |
| Was there of participants | lear reporting of clinical information of the | e 🖊 | | | |
| - Were the or clearly repo | utcomes or follow up results of cases rted? | 6 | | | |
| | clear reporting of the presenting c(s) demographic information? | 1 | | | |
| • Was statisti | cal analysis appropriate? | | | | |
| | ncluding reason for exclusion) | k further inf | . 🗆 | | |

JBI Critical Appraisal Checklist for Case Series

| Reviewer | Daniel de la Rosa | _Date | 02-0 | 2-21 | |
|-------------------------------|--|---------------|--------|-----------|-------------------|
| Author | Edward Needham et all | Year 20 | 20_ Re | cord Numb | er_164_33244712 |
| | | Yes | No | Unclear | Not applicable |
| • Were there series? | clear criteria for inclusion in the case | | | | |
| | ndition measured in a standard, reliable participants included in the case series? | 2 | | | |
| | methods used for identification of the or all participants included in the case | | | | |
| Did the case participants | e series have consecutive inclusion of ? | | | | |
| Did the case participants | e series have complete inclusion of ? | | | | |
| | lear reporting of the demographics of the in the study? | | D | | |
| Was there of participants | clear reporting of clinical information of the | e 🔲 | N | | |
| - Were the or clearly repo | utcomes or follow up results of cases rted? | J | | | |
| | clear reporting of the presenting c(s) demographic information? | | 1 | | |
| • Was statisti | cal analysis appropriate? | | | | 1 |
| | ncluding reason for exclusion) | k further inf | . 🗆 | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Rev | iewer | Daniel de la Rosa | ate | | 02-02- | 21 | |
|-----|--------------|---|------|--------|--------|---------|-------------------|
| Aut | hor | Elham Atabati, et al. Ye | ar | 2020 | Record | Number | 165_33274259 |
| | | | | Yes | No | Unclear | Not applicable |
| 1. | Is the rev | iew question clearly and explicitly stated? | | | | N | |
| 2. | Were the | inclusion criteria appropriate for the review | Ĉ | | | | |
| 3. | Was the | search strategy appropriate? | | | | | |
| 4. | Were the | sources and resources used to search for dequate? | | | | | Ц |
| 5. | Were the | criteria for appraising studies appropriate? | | | | | A |
| 6. | | cal appraisal conducted by two or more s independently? | | | | | N |
| 7. | Were the | ere methods to minimize errors in data n? | | | | | N |
| 8. | Were the | methods used to combine studies appropri | ate? | | | | P |
| 9. | Was the I | likelihood of publication bias assessed? | | | | | |
| 10. | | ommendations for policy and/or practice d by the reported data? | | X | | | |
| 11. | Were the | specific directives for new research ate? | | Q | | | |
| Ove | rall apprais | al: Include 🔲 Exclude 🖰 Seek für | ther | info 🗌 | | | |
| Con | nments (Inc | luding reason for exclusion) | | | | | |
| = | | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Rev | iewer | Daniel de la Rosa Date 21-11-20 | | | | | |
|--------|-----------------------|--|-----------|--------|-----------|-------------------|--|
| Author | | Scott Rooney, et al Yea | 2020 | Record | l Number_ | 21_32737507 | |
| | | | Yes | No | Unclear | Not applicable | |
| 1. | Is the rev | iew question clearly and explicitly stated? | 1 | | | | |
| 2. | Were the question? | inclusion criteria appropriate for the review | | | | | |
| 3. | Was the s | earch strategy appropriate? | | | | V | |
| 4. | Were the | sources and resources used to search for dequate? | | | | Ø | |
| 5. | Were the | criteria for appraising studies appropriate? | | | | d | |
| 6. | | al appraisal conducted by two or more independently? | | | | Ø | |
| 7. | Were the extraction | re methods to minimize errors in data n? | | | | Ø | |
| 8. | Were the | methods used to combine studies appropria | te? | | | Ø | |
| 9. | Was the I | ikelihood of publication bias assessed? | | | | Ø | |
| 10. | | ommendations for policy and/or practice d by the reported data? | Z | | | | |
| 11. | Were the appropria | specific directives for new research te? | Ø | | | | |
| Ove | rall appraisa | al: Include 🔲 Exclude 🖊 Seek furt | ther info | 1 | | | |
| | ments (Incl Review | uding reason for exclusion) | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

ARTICLE IN FRENCH - IT WAS NOT EVALUATED

| Review | Daniel de la Rosa | _Date | 14/1 | 1/20 | | |
|----------|---|-----------|-------|--------|---------|-------------------|
| Author_ | C. Andrejaka et al | Year 20 | 020 | Record | Number_ | 167_33280941 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | | | | |
| 2. | Does the source of opinion have standing in the of expertise? | field | | | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | | | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion express | sed? | | | | |
| 5. | Is there reference to the extant literature? | | | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | | | | |
| Overalla | appraisal: Include | further i | nfo 🔲 | | | |
| Commer | nts (Including reason for exclusion) | | | | | |
| | ARTICLE IN FRENCH - IT WA | S NO | EVAL | UATED | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Reviewer | Carlos Alberto Fermín Martínez Date | | 11/04 | /2021 | |
|------------|---|---------|--------|--------------|------------------|
| Author_ | Walsh-Messinger J, et al | 2020 | Record | Number 16 | 8_33269366_CAF |
| | | Yes | No | Unclear a | Not pplicable |
| | Vere the criteria for inclusion in the sample clearly defined? | 1 | | | |
| | Vere the study subjects and the setting described in letall? | 2 | | | |
| | Vas the exposure measured in a valid and reliable vay? | | | | |
| | Vere objective, standard criteria used for neasurement of the condition? | | | | |
| 5. V | Vere confounding factors identified? | | | | |
| | Vere strategies to deal with confounding factors tated? | | | | |
| | Vere the outcomes measured in a valid and reliable way? | | | | |
| 8. V | Vas appropriate statistical analysis used? | | | | |
| Overall ap | praisal: Include | rinto 🌌 | • | | |
| Comment | s (Including reason for exclusion) | | | | |

provean información solo de los pacientes que tuvieron PCR positiva.

| Review | er Carlos Alberto Fermin Martinez Date | | 11/ | 04/2021 | |
|--------|--|------|-------|-----------|-------------------|
| Author | Petersen MS, et al. Year | 2020 | Recor | d Number_ | 169_33252665_CAFM |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | 1 | | | |
| 2. | Were the exposures measured similarly to assign people | | | | |
| 3. | to both exposed and unexposed groups? | | | | |
| 4. | Was the exposure measured in a valid and reliable way? | Z | | | |
| 5. | Were confounding factors identified? | | | | |
| 6. | Were strategies to deal with confounding factors stated? | | 1 | | |
| 7. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | 1 | | | |
| 8. | Were the outcomes measured in a valid and reliable way? | Z | | | |
| 9. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 1 | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | 1 | | | |
| 11. | Were strategies to address incomplete follow up utilized? | | | | |
| 12. | Was appropriate statistical analysis used? | 1 | | | |

Comments (Including reason for exclusion)

En el estudio se incluyeron menores de edad y pacientes asintomáticos en la infección aguda, por lo que no cumple con los criterios de inclusión establecidos en nuestro protocolo. Se podría contactar a los autores para excluir a estos grupos de pacientes.

| Reviews | er Carlos Alberto Fermin Martinez Date | | 11/04 | 1/2021 | |
|---------|--|----------|--------|----------|-------------------|
| Author_ | Deisenhammer F, et al. Year | 2020 | Record | Number | 170_33315138_CAFM |
| | | Yes | No | Unclear | Not applicable |
| | Were the two groups similar and recruited from the same population? | | | | |
| | Were the exposures measured similarly to assign people | | | | |
| 3. | to both exposed and unexposed groups? | | | | |
| | Was the exposure measured in a valid and reliable way? | 1 | | | |
| 5. | Were confounding factors identified? | 1 | | | |
| | Were strategies to deal with confounding factors stated? | | | 1 | |
| | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | 1 | | | |
| | Were the outcomes measured in a valid and reliable way? | 1 | | | |
| | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 7 | | | |
| | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | / | |
| | Were strategies to address incomplete follow up utilizad? | | | 1 | |
| 12. | Was appropriate statistical analysis used? | 1 | | | |
| | appraisal: Include | erinfo [|] | | |

El artículo incluye menores de 18 años, no se hace el diagnóstico exclusivamente con PCR o prueba de antígenos y no reporta sintomas persistentes

| ermin Martinez | Date | | 11/04 | /2021 | |
|--|----------------|------------------------|----------------|----------------|-------------------|
| S, et al. | _Year_ | 2021 | Recor | d Number | 171_33521697_CAFM |
| | | Yes | No | Unclear | Not applicable |
| milar and recruited fr | rom the | | | | |
| easured similarly to a | ssign | 1 | | | |
| exposed groups? | | | | | |
| sured in a valid and re | iliable | 1 | | | |
| orsidentified? | | Z | | | |
| with confounding fac | ctors | | | | |
| ipants free of the out (or at the moment o | | / | | | |
| asured in a valid and | reliable | 7 | | | |
| reported and sufficie comes to occur? | ent to | Z | | | |
| e, and if not, were the v up described and ex | | 1 | | | |
| ess incomplete follow | w up | 1 | | | |
| ical analysis used? | | 1 | | | |
| ical | analysis used? | Exclude 🌠 Seek further | analysis used? | analysis used? | analysis used? |

El artículo no presenta síntomas persistentes, por lo que aunque la metodología sea robusta, no se justifica su inclusión en nuestro análisis.

| eview | erAlejandro Sicilia Andrade | Date | 30/04 | / 2021 | | |
|-------|--|------------|----------|--------|----------|-------------------|
| uthor | Aditi S. Shah, Alyson W. Wong, Cameron J Hague et al. | Year_ | 2020 | Recor | d Number | 172_33273023_AS |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from same population? | om the | M | | | |
| | Were the exposures measured similarly to as people | sign | \not | | | |
| 3. | to both exposed and unexposed groups? | | | | | |
| 4. | Was the exposure measured in a valid and re way? | liable | | | | |
| 5. | Were confounding factors identified? | | | | | |
| 6. | Were strategies to deal with confounding fac stated? | tors | | D | | |
| 7. | Were the groups/participants free of the oute at the start of the study (or at the moment of exposure)? | | | Ø | | |
| 8. | Were the outcomes measured in a valid and way? | reliable | \angle | | | |
| 9. | Was the follow up time reported and sufficient be long enough for outcomes to occur? | nt to | P | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and ex | | P | | | |
| 11. | Were strategies to address incomplete follow utilized? | <i>и</i> р | | Ø | | |
| 12. | Was appropriate statistical analysis used? | | | | Ø | |
| | appraisal: Include Exclude Security | ek furthe | r info 🗌 | | | |

| Reviewe | Alejandro Sicilia Andrade | Date | 30/04 | / 2021 | | |
|------------|---|--------|----------|--------|-----------|-------------------|
| Author_ | Thomas Sonnweber, Sabina Sahanic, Alex Pizzini et al. | Year_ | 2020 | Recor | d Number_ | 173_33303539_ASA |
| | | | Yes | No | Unclear | Not applicable |
| | Were the two groups similar and recruited from same population? | the | | | | |
| | Were the exposures measured similarly to assigneople | n | | | | |
| 3. t | o both exposed and unexposed groups? | | | | | |
| | Was the exposure measured in a valid and relial way? | ble | V | | | |
| 5. V | Were confounding factors identified? | | K | | | |
| | Were strategies to deal with confounding factor stated? | rs | d | | | |
| ē | Were the groups/participants free of the outcor at the start of the study (or at the moment of exposure)? | ne | A | | | |
| | Were the outcomes measured in a valid and reli way? | iable | 6 | | | |
| | Was the follow up time reported and sufficient be long enough for outcomes to occur? | to | | | | |
| | Was follow up complete, and if not, were the easons to loss to follow up described and explo | ored? | Ø | | | |
| | Were strategies to address incomplete follow u utilized? | р | 1 | | | |
| 12. V | Was appropriate statistical analysis used? | | P | | | |
| Overall ap | opraisal: Include | furthe | r info 🔲 | | | |
| This | is a study of excellent quality: | | | | | |

| uthor | C. Huart, C. Philipott, I. Konstantinidis, A. Alfundag et al. | _Year_ | 2020 | Reco | rd Number_ | 175_32812014_AS |
|---------|--|-----------|---------|------|------------|-------------------|
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from same population? | om the | | | K | |
| | Were the exposures measured similarly to as people | sign | | | Z | |
| 3. | to both exposed and unexposed groups? | | | | 1 | |
| 4. | Was the exposure measured in a valid and re way? | liable | | | F | |
| 5. | Were confounding factors identified? | | | b | | |
| 6. | Were strategies to deal with confounding fac stated? | tors | | P | | |
| 7. | Were the groups/participants free of the out at the start of the study (or at the moment of exposure)? | | | | d | |
| 8. | Were the outcomes measured in a valid and way? | reliable | A | | | |
| 9. | Was the follow up time reported and sufficie be long enough for outcomes to occur? | nt to | | | P | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and ex | | | | Ó | |
| 11. | Were strategies to address incomplete follow utilized? | / up | | | \not | |
| 12. | Was appropriate statistical analysis used? | | | | | |
| verall: | appraisal: Include 🔲 Exclude 🗦 Se | ek furthe | rinfo 🔲 | | | |
| omme | nts (Including reason for exclusion) | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Review | PF_Alejandro Sicilia Andrade | Date_30 | /04/2021 | | | |
|--------|--|------------|----------|--------|---------|-------------------|
| Author | Mark Vink, Alexandra Vink-Niese | Year_202 | 0 | Record | Number_ | 176_33322316_ASA |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | | | | |
| 2. | Does the source of opinion have standing in the of expertise? | field | Ħ | | | |
| 3. | Are the interests of the relevant population the central focus of the opinion? | | 7 | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expres | sed? | \neq | | | |
| 5. | Is there reference to the extant literature? | | 4 | | | |
| 6. | Is any incongruence with the literature/sources logically defended? | | f | | | |
| | appraisal; Include 🔲 Exclude 📮 Seek | further in | fo 🗆 | | | |
| | | | | | | |
| 140-00 | manyon tomorumoo natratas areas assasso. | | | | | |
| | nts (Including reason for exclusion) incluyen revisiones narrativas en el estudo. | | | | | _ |

| uthor | Mayssam Nehme, Olivia Brailfard et al. | ar 20 | nan Red | ord Number | 177_3328467 |
|---------|---|------------|---------|------------|-------------------|
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from t same population? | he 🗖 | | | |
| 2. | Were the exposures measured similarly to assign people | 1 | | | |
| 3. | to both exposed and unexposed groups? | / | | | |
| 4. | Was the exposure measured in a valid and reliable way? | | | | |
| 5. | Were confounding factors identified? | | 9 | 7 🗆 | |
| 6. | Were strategies to deal with confounding factors stated? | | 7 | 1 🗆 | |
| 7. | Were the groups/participants free of the outcom at the start of the study (or at the moment of exposure)? | # | | | |
| 8. | Were the outcomes measured in a valid and relia way? | ble 🖊 | | | |
| 9. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | Þ | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explor | ed? | | | |
| 11. | Were strategies to address incomplete follow up utilized? | | Y | 1 0 | |
| 12. | Was appropriate statistical analysis used? | | | 16 | |
| verall: | appraisal: Include 🔲 Exclude 📈 Seek fu | rther info | | | |
| mme | nts (Including reason for exclusion) | | | | |

| Review | er Alejandro Sicilia Andrade | Date | 30/04 | 1/2021 | | |
|----------|---|----------|----------|--------|-----------|-------------------|
| Author | Bin Lieng, Lingli Xie, Fan Yang, Joyman Makamure, et al. | Year_ | 2020 | Recor | d Number_ | 178_33318560_ASA |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited fro same population? | m the | A | | | |
| 2. | Were the exposures measured similarly to ass people | ign | Z | | | |
| 3. | to both exposed and unexposed groups? | | | | | |
| 4. | Was the exposure measured in a valid and reli way? | able | | | | |
| 5. | Were confounding factors identified? | | # | | | |
| 6. | Were strategies to deal with confounding fact stated? | ors | | Z | | |
| 7. | Were the groups/participants free of the outcoment of the start of the study (or at the moment of exposure)? | ome | Ø | | | |
| 8. | Were the outcomes measured in a valid and re way? | eliable | | | | |
| 9. | Was the follow up time reported and sufficien be long enough for outcomes to occur? | t to | \not | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and exp | lored? | F | | | |
| 11. | Were strategies to address incomplete follow utilized? | up | | | | |
| 12. | Was appropriate statistical analysis used? | | Ø | | | |
| | General Andrews North North North North National Control North National North National North National | k furthe | r info 🔲 | | | |
| | nts (Including reason for exclusion) | | | | | |
| Erafficu | io no menciona los sintomas del seguimiento. | | | | | |

JBI Critical Appraisal Checklist for Qualitative Research

| Reviewer Daniel de la Rosa. | Date 03-02-21 |
|-----------------------------|---------------|
| | |

| Aut | hor Tom Kingstone et al Year: 2020 Re | ecord Number: 179_33051223 | | | | | |
|-----|---|----------------------------|----------|---------|-------------------|--|--|
| | | Yes | No | Unclear | Not applicable | | |
| 1. | Is there congruity between the stated philosophical perspective and the research methodology? | | | | | | |
| 2. | Is there congruity between the research methodology and the research question or objectives? | | | | | | |
| 3. | Is there congruity between the research methodology and the methods used to collect data? | | | | | | |
| 4. | Is there congruity between the research methodology and the representation and analysis of data? | | | | | | |
| 5, | Is there congruity between the research methodology and the interpretation of results? | | | | | | |
| 6. | Is there a statement locating the researcher culturally or theoretically? | | | | | | |
| 7. | Is the influence of the researcher on the research, and vice- versa, addressed? | | | | | | |
| 8. | Are participants, and their voices, adequately represented? | | | | | | |
| 9. | Is the research ethical according to current criteria or, for recent studies, and is there evidence of ethical approval by an appropriate body? | | | | | | |
| 10. | Do the conclusions drawn in the research report flow from the analysis, or interpretation, of the data? | | | | | | |
| Ove | rall appraisal: Include | r info |] | | | | |
| Con | nments (Including reason for exclusion) | | | | | | |
| | Qualitative Research articles are not included as | inclusio | n criter | ia | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Reviewe | Daniel de la Rosa | Date | 04 | 4-02-21 | | |
|------------|--|--------|--------|---------|---------|-------------------|
| Author_ | Roy Meys, et al | ear | 2020 | Record | Number_ | 180_33317214 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample cle defined? | arly | 1 | | | |
| 2. | Were the study subjects and the setting describ detail? | ed in | | | | |
| 3. | Was the exposure measured in a valid and relia way? | ble | Z | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | | Z | | | |
| 5. | Were confounding factors identified? | | | 1 | | |
| 6. | Were strategies to deal with confounding facto stated? | rs | | 1 | | |
| 7. | Were the outcomes measured in a valid and re way? | liable | Z | | | |
| 8. | Was appropriate statistical analysis used? | | N | | | |
| Overall ap | ppraisal: Include Exclude Seek f | urther | info 🗌 | | | |
| Commen | ts (Including reason for exclusion) | | | | | |
| - | | | | | | |

El único síntoma persistente que se reporta es disnea en 64% de los pacientes, sin embargo, solo un pequeño porcentaje de los pacientes (23%, n=49) tuvieron COVID-19 confirmado por PCR. Se intenta mostrar la información de síntomas persistentes desagregada para los pacientes con PCR positiva, pero al parecer hay un error en la presentación de estos resultados. Se podría contactar a los autores para obtener solo la información de los pacientes PCR positivos, sin embargo, la baja calidad del estudio, aunado a el bajo porcentaje de pacientes con prueba de PCR, considero que no se justifica contactar a los autores y es mejor rechazar el artículo.

JBI Critical Appraisal Checklist for Case Series

| Reviewer | Daniel de la Rosa Martinez | _Date | (| 03-02-21 | |
|---------------------------|---|----------------|------------------------|----------|-------------------|
| Author | David García-Azorín, et al | Year <u>20</u> | er <u>24_3299</u> 8840 | | |
| | | Yes | No | Unclear | Not applicable |
| • Were the series? | ere clear criteria for inclusion in the case | | | | |
| | condition measured in a standard, reliable Ill participants included in the case series? | | | V | |
| | id methods used for identification of the for all participants included in the case | A | | | |
| Did the oparticipa | ase series have consecutive inclusion of nts? | | | | |
| Did the control participa | ase series have complete inclusion of nts? | | | 1 | |
| | e clear reporting of the demographics of the nts in the study? | | | | |
| Was ther participa | e clear reporting of clinical information of the nts? | · 🖊 | | | |
| - Were the | outcomes or follow up results of cases ported? | d | | | |
| | e clear reporting of the presenting inic(s) demographic information? | 1 | | | |
| • Was stat | istical analysis appropriate? | | | | 1 |
| | praisal: Include | k further inf | . 🗆 | | |

Reviewer Enrique Cañedo Guerra Date 4/04/2021

| Author | Ortelli, | P.O | , et al. | Year | 2020 | Record | Number | 182 | 33359928 | ECG |
|--------|----------|-----|----------|------|------|--------|--------|-----|----------|-----|
|--------|----------|-----|----------|------|------|--------|--------|-----|----------|-----|

| | | Yes | No | Unclear | Not applicable |
|---------|--|------------|---------|-----------|-------------------|
| 1. | Were the two groups similar and recruited from the same population? | | | | d |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | N |
| 3. | Was the exposure measured in a valid and reliable way? | | 1 | | |
| 4. | Were confounding factors identified? | | Z | | |
| 5. | Were strategies to deal with confounding factors stated? | | 1 | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | N | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | Z | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | d | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | |
| 10. | . Were strategies to address incomplete follow up utilized? | | | | P |
| 11. | . Was appropriate statistical analysis used? | Z | | | |
| Overall | appraisal; Include Exclude Seek furthe | r info | | | |
| Comme | ents (including reason for exclusion) | | | | |
| Estudio | no especifica si se les hizo prueba de PCR. Fueron hospitaliz | ados, pero | no se e | specifica | |

© JBI, 2020. All rights reserved. JBI grants use of these tools for research purposes only. All other enquiries should be sent to jbisynthesis@adelaide.edu.au.

Reviewer Enrique Cañedo Guerra Date 4/04/2021

| Author | Arnold, | D. T. | , et al. | Year | 2020 | Record | Number | 183 | 33273026 | ECG |
|--------|---------|-------|----------|------|------|--------|--------|-----|----------|-----|
| | | | | | | | | | | |

| | | | Yes | No | Unclear | Not applicable |
|----|-------|--|--------|----|---------|-------------------|
| | 1. | Were the two groups similar and recruited from the same population? | | | | N |
| | 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | X |
| | 3. | Was the exposure measured in a valid and reliable way? | 7 | | | |
| | 4. | Were confounding factors identified? | Ø | | | |
| | 5. | Were strategies to deal with confounding factors stated? | Z | | | |
| | 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | Z | |
| | 7. | Were the outcomes measured in a valid and reliable way? | P | | | |
| | 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | P | | | |
| | 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | 7 | | | |
| | 10. | Were strategies to address incomplete follow up utilized? | | | | P |
| | 11. | Was appropriate statistical analysis used? | Z | | | |
| Ov | erall | appraisal; Include 🔲 Exclude 🖊 Seek further | r info | | | |
| Co | mme | nts (including reason for exclusion) | | | | |
| | | | | | | |

Algunos valores de proporciones de sintomas no se pueden medir de la base de datos.



CHECKLIST FOR CASE CONTROL STUDIES

Critical Appraisal tools for use in JBI Systematic Reviews

INTRODUCTION

JBI is an international research organisation based in the Faculty of Health and Medical Sciences at the University of Adelaide, South Australia. JBI develops and delivers unique evidence-based information, software, education and training designed to improve healthcare practice and health outcomes. With over 70 Collaborating Entities, servicing over 90 countries, JBI is a recognised global leader in evidence-based healthcare.

JBI Systematic Reviews

The core of evidence synthesis is the systematic review of literature of a particular intervention, condition or issue. The systematic review is essentially an analysis of the available literature (that is, evidence) and a judgment of the effectiveness or otherwise of a practice, involving a series of complex steps. JBI takes a particular view on what counts as evidence and the methods utilised to synthesise those different types of evidence. In line with this broader view of evidence, JBI has developed theories, methodologies and rigorous processes for the critical appraisal and synthesis of these diverse forms of evidence in order to aid in clinical decision-making in healthcare. There now exists JBI guidance for conducting reviews of effectiveness research, qualitative research, prevalence/incidence, etiology/risk, economic evaluations, text/opinion, diagnostic test accuracy, mixed-methods, umbrella reviews and scoping reviews. Further information regarding JBI systematic reviews can be found in the JBI Evidence Synthesis Manual.

JBI Critical Appraisal Tools

All systematic reviews incorporate a process of critique or appraisal of the research evidence. The purpose of this appraisal is to assess the methodological quality of a study and to determine the extent to which a study has addressed the possibility of bias in its design, conduct and analysis. All papers selected for inclusion in the systematic review (that is – those that meet the inclusion criteria described in the protocol) need to be subjected to rigorous appraisal by two critical appraisers. The results of this appraisal can then be used to inform synthesis and interpretation of the results of the study. JBI Critical appraisal tools have been developed by the JBI and collaborators and approved by the JBI Scientific Committee following extensive peer review. Although designed for use in systematic reviews, JBI critical appraisal tools can also be used when creating Critically Appraised Topics (CAT), in journal clubs and as an educational tool.

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE CONTROL STUDIES

Reviewer Enrique Cañedo Guerra Date 4/04/2021

Author Galván-Tejada, C. E., et al. Year 2020 Record Number 184 33327641 ECG

| | | Yes | No | Unclear | Not applicable |
|---------|---|--------------|------------------|-----------------|-------------------|
| 1. | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | N | | | |
| 2. | Were cases and controls matched appropriately? | N | | | |
| 3. | Were the same criteria used for identification of cases and controls? | 1 | | | |
| 4. | Was exposure measured in a standard, valid and reliable way? | | | 7 | |
| 5, | Was exposure measured in the same way for cases and controls? | 7 | | | |
| 6. | Were confounding factors identified? | | | | |
| 7. | Were strategies to deal with confounding factors stated? | N | | | |
| 8. | Were outcomes assessed in a standard, valid and reliable way for cases and controls? | > | | | |
| 9, | Was the exposure period of interest long enough to be meaningful? | D | | | |
| 10. | Was appropriate statistical analysis used? | D | | | |
| Overall | appraisal: Include 🗌 Exclude 🗹 Seek | further info | | | |
| Comme | nts (Including reason for exclusion) | | | | |
| Dicen q | ue incluyeron a sujetos con diagnóstico confirmado | por laborato | rio de acuerdo a | los lineamiento | s de la OMS. |
| Sin emb | pargo, esto implicaría que podrían estar sujetos sin | PCR dado q | ue la definición | operacional tom | a en cuenta |
| prueba | de antigenos. | | | | |

EXPLANATION OF CASE CONTROL STUDIES CRITICAL APPRAISAL

How to cite: Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). IBI Manual for Evidence Synthesis. IBI, 2020. Available from https://synthesismanual.jbi.global

Case Control Studies Critical Appraisal Tool

Answers: Yes, No, Unclear or Not/Applicable

1. Were the groups comparable other than presence of disease in cases or absence of disease in controls?

The control group should be representative of the source population that produced the cases. This is usually done by individual matching; wherein controls are selected for each case on the basis of similarity with respect to certain characteristics other than the exposure of interest. Frequency or group matching is an alternative method. Selection bias may result if the groups are not comparable.

2. Were cases and controls matched appropriately?

As in item 1, the study should include clear definitions of the source population. Sources from which cases and controls were recruited should be carefully looked at. For example, cancer registries may be used to recruit participants in a study examining risk factors for lung cancer, which typify population-based case control studies. Study participants may be selected from the target population, the source population, or from a pool of eligible participants (such as in hospital-based case control studies).

3. Were the same criteria used for identification of cases and controls?

It is useful to determine if patients were included in the study based on either a specified diagnosis or definition. This is more likely to decrease the risk of bias. Characteristics are another useful approach to matching groups, and studies that did not use specified diagnostic methods or definitions should provide evidence on matching by key characteristics. A case should be defined clearly. It is also important that controls must fulfil all the eligibility criteria defined for the cases except for those relating to diagnosis of the disease.

4. Was exposure measured in a standard, valid and reliable way?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

Case control studies may investigate many different 'exposures' that may or may not be associated with the condition. In these cases, reviewers should use the main exposure of interest for their review to answer this question when using this tool at the study level.

Reliability refers to the processes included in an epidemiological study to check repeatability of measurements of the exposures. These usually include intra-observer reliability and inter-observer reliability.

5. Was exposure measured in the same way for cases and controls?

As in item 4, the study should clearly describe the method of measurement of exposure. The exposure measures should be clearly defined and described in detail. Assessment of exposure or risk factors should have been carried out according to same procedures or protocols for both cases and controls.

6. Were confounding factors identified?

Confounding has occurred where the estimated intervention exposure effect is biased by the presence of some difference between the comparison groups (apart from the exposure investigated/of interest). Typical confounders include baseline characteristics, prognostic factors, or concomitant exposures (e.g. smoking). A confounder is a difference between the comparison groups and it influences the direction of the study results. A high quality study at the level of case control design will identify the potential confounders and measure them (where possible). This is difficult for studies where behavioral, attitudinal or lifestyle factors may impact on the results.

7. Were strategies to deal with confounding factors stated?

Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or stratifying sampling of participants, effects of confounding factors can be adjusted for. When dealing with adjustment in data analysis, assess the statistics used in the study. Most will be some form of multivariate regression analysis to account for the confounding factors measured. Look out for a description of statistical methods as regression methods such as logistic regression are usually employed to deal with confounding factors/ variables of interest.

8. Were outcomes assessed in a standard, valid and reliable way for cases and controls?

Read the methods section of the paper. If for e.g. lung cancer is assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If lung cancer is assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

Having established the objectivity of the outcome measurement (e.g. lung cancer) instrument, it's important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? (e.g. radiographers). If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised?

9. Was the exposure period of interest long enough to be meaningful?

It is particularly important in a case control study that the exposure time was sufficient enough to show an association between the exposure and the outcome. It may be that the exposure period may be too short or too long to influence the outcome.

10. Was appropriate statistical analysis used?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.

For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.

Reviewer Enrique Cañedo Guerra Date 4/04/2021

Author Ikegami, S, et al. Year 2020 Record Number 185 32840002 ECG

| | | | Yes | No | Unclear | Not applicable |
|----|---------|--|----------|----|---------|-------------------|
| | 1. | Were the two groups similar and recruited from the same population? | | | | P |
| | 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | 7 |
| | 3. | Was the exposure measured in a valid and reliable way? | × | | | |
| | 4. | Were confounding factors identified? | ø | | | |
| | 5. | Were strategies to deal with confounding factors stated? | d | | | |
| | 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | A | | | |
| | 7. | Were the outcomes measured in a valid and reliable way? | Z | | | |
| | 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 7 | | | |
| | 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | # | | | |
| | 10. | Were strategies to address incomplete follow up utilized? | | | | Z |
| | 11. | Was appropriate statistical analysis used? | | | | |
| ov | erall : | appraisal; Include 🔲 Exclude 🖊 Seek furthe | r info 🔲 | | | |
| Co | mme | nts (including reason for exclusion) | | | | |
| | | | | | | |

© JBI, 2020. All rights reserved. JBI grants use of these tools for research purposes only. All other enquiries should be sent to jbisynthesis@adelaide.edu.au.

No trata de sintomas persistentes, si no de persistencia de PCR positiva.

Reviewer Enrique Cañedo Guerra Date 4/04/2021

Author Ikegami, S, et al. Year 2020 Record Number 186 33310664 ECG

| | | Yes | No | Unclear | Not applicable |
|-------|--|----------|----|---------|-------------------|
| 1 | . Were the two groups similar and recruited from the same population? | | | | Z |
| 2 | . Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | Z |
| 3 | . Was the exposure measured in a valid and reliable way? | Z | | | |
| 4 | . Were confounding factors identified? | _ | | | |
| 5 | . Were strategies to deal with confounding factors stated? | Z | | | |
| 6 | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | | |
| 7 | . Were the outcomes measured in a valid and reliable way? | 7 | | | |
| 8 | . Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 7 | | | |
| 9 | . Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | |
| 1 | 0. Were strategies to address incomplete follow up utilized? | | | | A |
| 1 | Was appropriate statistical analysis used? | ф | | | |
| Overa | Il appraisal: Include 🔲 Exclude 🗹 Seek furthe | r info |] | | |
| Comm | nents (including reason for exclusion) | | | | |

El artículo trata de persistencia de anticuerpos específicos contra SARS-CoV-2, no de sintomas.

© JBI, 2020. All rights reserved. JBI grants use of these tools for research purposes only. All other enquiries should be sent to jbisynthesis@adelaide.edu.au.

Reviewer Enrique Cañedo Guerra Date 4/04/2021

Author Jacobs, LG, et al. Year 2020 Record Number 187 33306721 ECG

| | | Yes | No | Unclear | Not applicable |
|---------|--|-----------|----------|-------------|-------------------|
| 1. | Were the two groups similar and recruited from the same population? | | | | 山 |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | Z |
| 3. | Was the exposure measured in a valid and reliable way? | Z | | | |
| 4. | Were confounding factors identified? | 7 | | | |
| 5. | Were strategies to deal with confounding factors stated? | D | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | Ø | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | N | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | y | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | Z | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | | | |
| 11. | Was appropriate statistical analysis used? | 1 | | | |
| Overall | appraisal: Include 🖊 Exclude 🗆 Seek furthe | r info | I | | |
| Comme | nts (including reason for exclusion) | | | | |
| Autorre | porte de sintomas por los pacientes, pero de todas formas o | reo que e | s inform | ación útil, | |

© JBI, 2020. All rights reserved. JBI grants use of these tools for research purposes only. All other enquiries should be sent to jbisynthesis@adelaide.edu.au.

Reviewer Enrique Cañedo Guerra Date 4/04/2021

Author Stavem, K, et al. Year 2020 Record Number 188 33273028 ECG

| | | Yes | No | Unclear | Not applicable |
|--------|--|--------|----|---------|-------------------|
| 1. | Were the two groups similar and recruited from the same population? | | | | Ø |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | Z |
| 3. | Was the exposure measured in a valid and reliable way? | Z | | | |
| 4. | Were confounding factors identified? | | | | |
| 5. | Were strategies to deal with confounding factors stated? | Z | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | N | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | × | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | N | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | Z | | | |
| 10 | Were strategies to address incomplete follow up utilized? | Z | | | |
| 1 | . Was appropriate statistical analysis used? | 中 | | | |
| Overal | l appraisal; Include 🔲 Exclude 🗹 Seek furthe | r info |] | | |
| Comm | ents (including reason for exclusion) | | | | |

C

No queda claro como se hizo la recolección de datos de los sintomas. Algunas suposiciones se hicieron para determinar que los pacientes eran elegibles en el estudio.

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

Reviewer Enrique Cañedo Guerra Date 14/04/2021

| Author | El Sayed, S, et al. Year 2020 Record Number 189 33332 | 756 ECG | i | | |
|---------|--|-------------|---------|------------|---------------------|
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | | B | | |
| 2. | Were the study subjects and the setting described in detail? | | D | | |
| 3. | Was the exposure measured in a valid and reliable way? | N | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | A | | | |
| 5. | Were confounding factors identified? | A | | | |
| 6, | Were strategies to deal with confounding factors stated? | 4 | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | Þ | | | |
| 8. | Was appropriate statistical analysis used? | P | | | |
| Overall | appraisal: Include | info 🖒 |) | | |
| Comme | ents (Including reason for exclusion) | | | | |
| Se com | enta información de anhedonia y fatiga medida con dos e | scalas dif | erentes | en pacient | es recuperados con |
| | 19 que hayan tenido dos pruebas negativas. Se podría haber | | | | |
| | eo por conveniencia. Valdría la pena preguntarle a los autore | es si en su | estudio | selecciona | ron a pacientes con |
| prueba | de PCR positivo en el diagnóstico. | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR QUALITATIVE RESEARCH

Reviewer Enrique Cañedo Guerra Date 14/04/2021

Author Ladds, E, et al. Year 2020 Record Number 190 33342437 ECG

| | | Yes | No | Unclear | Not applicable |
|-----|---|-----------|----|---------|-------------------|
| 1. | Is there congruity between the stated philosophical perspective and the research methodology? | Ŋ | | | |
| 2. | Is there congruity between the research methodology and the research question or objectives? | Q | | | |
| 3. | Is there congruity between the research methodology and the methods used to collect data? | Ø | | | |
| 4. | Is there congruity between the research methodology and the representation and analysis of data? | P | | | |
| 5. | Is there congruity between the research methodology and the interpretation of results? | \not | | | |
| 6. | Is there a statement locating the researcher culturally or theoretically? | 7 | | | |
| 7. | Is the influence of the researcher on the research, and vice- versa, addressed? | Z | | | |
| 8. | Are participants, and their voices, adequately represented? | \square | | | |
| 9. | Is the research ethical according to current criteria or, for recent studies, and is there evidence of ethical approval by an appropriate body? | Z | | | |
| 10. | Do the conclusions drawn in the research report flow from the analysis, or interpretation, of the data? | Þ | | | |
| Ove | rall appraisal: Include \square Exclude $ abla$ Seek furthe | er info 🗆 |] | | |

Comments (Including reason for exclusion)

Es un estudio cualitativo donde no todos los pacientes fueron diagnósticados con prueba de PCR aparentemente. Al parecer algunos sujetos solo fueron incluidos por presencia de síntomas en un periodo de tiempo.

| Review | er Enrique Cañedo Guerra Date | | | | |
|---------|--|-----------------|----------------|---------|-------------------|
| Author | Chun Gao, et. al. Year 2020 Record Number 192 330 | 68796 EC Yes | <u>G</u> No | Unclear | Not applicable |
| | Were the two groups similar and recruited from the same population? | X | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | X | | | |
| 3. | Was the exposure measured in a valid and reliable way? | X | | | |
| 4. | Were confounding factors identified? | × | | | |
| 5. | Were strategies to deal with confounding factors stated? | × | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | X | | |
| 7. | Were the outcomes measured in a valid and reliable way? | × | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | × | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | × | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | | | X |
| 11. | Was appropriate statistical analysis used? | X | | | |
| Overall | appraisal: Include | r info | | | |
| Comme | nts (including reason for exclusion) | | | | |

The clinical status of patients is unclear throughout the study. It is implied that their symptoms were recollected from hospital admission. The primary objective of the study is to explore factors associated with prolonged viral shedding, not long COVID.

Reviewer Enrique Cañedo Guerra Date 04/04/2021

| | | Yes | No | Unclear | Not applicable |
|-----|--|----------|----|---------|-------------------|
| 1. | Were the two groups similar and recruited from the same population? | | | | × |
| 2. | Were the exposures measured similarly to assign people | | | | V |
| 3. | to both exposed and unexposed groups? | | | | |
| 4, | Was the exposure measured in a valid and reliable way? | X | | | |
| 5. | Were confounding factors identified? | | X | | |
| 6. | Were strategies to deal with confounding factors stated? | | × | | |
| 7. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | M | | |
| 8. | Were the outcomes measured in a valid and reliable way? | | × | | |
| 9. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | X | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | × | | | |
| 11. | Were strategies to address incomplete follow up utilized? | | | | × |
| 12. | Was appropriate statistical analysis used? | × | | | |
| | appraisal: Include Exclude | r info 🔲 | | | |

Reviewer Monica Itzel Martínez Gutiérrez Date 01/04/2021

| Author | Chen, Y., Zuiani, A., Fischinger, S., Year 2020 Recor | | d Number194 33171099 | | | |
|--------|--|-----|----------------------|---------|-------------------|--|
| | Mullur, J., Atyeo, C. et.al. | Yes | No | Unclear | Not applicable | |
| 1. | Were the two groups similar and recruited from the same population? | | | | 1 | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | 1 | |
| 3. | Was the exposure measured in a valid and reliable way? | Z | | | | |
| 4. | Were confounding factors identified? | | 1 | | | |
| 5. | Were strategies to deal with confounding factors stated? | | 1 | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | 1 | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 1 | | | | |
| 9. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | 1 | | | | |
| 10 | . Were strategies to address incomplete follow up utilized? | | | | 1 | |
| 11 | Was appropriate statistical analysis used? | 1 | | П | П | |

| Overall appraisal: | Include | | Exclude | Seek further info |
|-------------------------|-------------|---------|---------|-------------------|
| Comments (Including rea | ison for ex | clusion |) | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE CONTROL STUDIES

| | P. M., Varese, N., Stojanovic, S., McMahon, J. et al. | Yes | No | Unclear | Not |
|-----|---|-------|-------------|---------|------------|
| | | | | 3111103 | applicable |
| 1. | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | 1 | | | |
| 2. | Were cases and controls matched appropriately? | | | | |
| 3. | Were the same criteria used for identification of cases and controls? | V | | | |
| 4. | Was exposure measured in a standard, valid and reliable way? | M | | | |
| 5. | Was exposure measured in the same way for cases and controls? | Z | | | |
| 6. | Were confounding factors identified? | | | | |
| 7. | Were strategies to deal with confounding factors stated? | | d | | |
| В. | Were outcomes assessed in a standard, valid and reliable way for cases and controls? | 1 | | | |
| 9. | Was the exposure period of interest long enough to be meaningful? | Z | | | |
| 10. | Was appropriate statistical analysis used? | | | | |
| | ppraisal: Include Exclude Exclude Its (Including reason for exclusion) | Seekf | urther info |] | |

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

Reviewer Enrique Cañedo Guerra Date 03/04/2021

Author Richard C. Gerkin, Kathrin Ohla, et al. Year 2020 Record Number 196 33367502 ECG

| | | Yes | No | Unclear | Not applicable |
|---------|--|--------|----|---------|-------------------|
| 1. | Were the criteria for inclusion in the sample clearly defined? | 文 | | | |
| 2. | Were the study subjects and the setting described in detail? | X | | | |
| 3. | Was the exposure measured in a valid and reliable way? | X | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | X | | | |
| 5. | Were confounding factors identified? | | | X | |
| 6. | Were strategies to deal with confounding factors stated? | | | × | |
| 7. | Were the outcomes measured in a valid and reliable way? | X | | | |
| 8. | Was appropriate statistical analysis used? | Y | | | |
| Overall | appraisal: Include 💢 Exclude 🗆 Seek further | info 🔲 | | | |

Comments (Including reason for exclusion)

Sólo se comenta en una sección sobre la recuperación de la función olfatoria en los primeros 40 días de seguimiento después del episodio agudo. 50.7% de los 3147 pacientes reportaron pérdida del olfato persistente, pero no se tiene información de ningún síntoma adicional.

Reviewer Monica Itzel Martínez Gutiérrez Date 01/04/2021

| | Fian, J., Zhang, M., Jin, M., Zhang, F., Year 2020 Reco hu, Q., et al. | Yes | No | Unclear | Not applicable |
|-----|--|-----|----|---------|-------------------|
| 1. | Were the two groups similar and recruited from the same population? | d | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | d | | | |
| 3. | Was the exposure measured in a valid and reliable way? | d | | | |
| 4. | Were confounding factors identified? | Z | | | |
| 5. | Were strategies to deal with confounding factors stated? | 1 | | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | d | | | |
| 7. | Were the outcomes measured in a valid and reliable way? | Ø | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 1 | | | |
| 9. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | 1 | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | | | 1 |
| 11 | Was appropriate statistical analysis used? | M | | П | П |

| Overall appraisal: | Include [| Exclude | . 🖊 | Seek further info |
|-----------------------|-------------------|----------------|----------|---|
| Comments (Including | reason for exclu | sion) | | |
| Es un estudio centrad | o en el resultado | del uso de t | ocilizum | ab como tratamiento en pacientes con cuadro |
| severo de COVID, don | de se reporta m | gioría clínica | y dimin | ución de la mortalidad. |

Reviewer Enrique Cañedo Guerra Date 4/04/2021

| Author Zhang, X | et al. Year | 2020 Record | Number | 198 | 33388574 | ECG |
|-----------------|-------------|-------------|--------|-----|----------|-----|
|-----------------|-------------|-------------|--------|-----|----------|-----|

| | | Yes | No | Unclear | Not applicable |
|---------|--|--------|----|---------|-------------------|
| 1. | Were the two groups similar and recruited from the same population? | | | D | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | X |
| 3. | Was the exposure measured in a valid and reliable way? | A | | | |
| 4. | Were confounding factors identified? | | V | | |
| 5. | Were strategies to deal with confounding factors stated? | | Z | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | P | | |
| 7. | Were the outcomes measured in a valid and reliable way? | N | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | A | | | |
| 9. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | N | |
| 10. | Were strategies to address incomplete follow up utilized? | | N | | |
| 11. | Was appropriate statistical analysis used? | N | | | |
| Overall | appraisal: Include | r info | | | |
| Comme | nts (including reason for exclusion) | | | | |

© JBI, 2020. All rights reserved. JBI grants use of these tools for research purposes only. All other enquiries should be sent to jbisynthesis@adelaide.edu.au.

No se mencionan datos de sintomas ni características de los pacientes.

Reviewer Mónica Itzel Martinez Gutiérrez Date 02/04/2021

| uthor | Xiaoyong Zhang, Suwen Lu, Hui Li, Year 2020 Record | d Numb | er 199 | 33351168 | MIMG |
|-------|---|--------|--------|----------|-------------------|
| | Yi Wang, Zhen Lu, et al. | Yes | No | Undear | Not applicable |
| i. | Were the two groups similar and recruited from the same population? | | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | 1 |
| 3. | Was the exposure measured in a valid and reliable way? | 1 | | | |
| 4. | Were confounding factors identified? | | d | | |
| 5. | Were strategies to deal with confounding factors stated? | | 1 | | |
| 6, | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure) ? | | 1 | | |
| 7. | Were the outcomes measured in a valid and reliable way? | 4 | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 1 | | | |
| 9. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | 1 | | |
| 11. | Was appropriate statistical analysis used? | 1 | П | П | |

| Overall appraisal: | Include | | Exclude | 1 | Seek further info |
|--------------------------|----------------|--------|-------------|-------|---|
| Comments (Including | reason for exc | lusion | Y | | |
| El seguimiento de pac | ientes convale | ciente | es solo con | forma | una sección en el artículo, no se mencionan las |
| características clínicas | o demográfic | as de | estos pacie | ntes | |

Reviewer Enrique Cañedo Guerra Date 4/16/2021

Author Blair, PW, et al. Year 2021 Record Number 200 33614816 ECG

| | | | Yes | No | Unclear | Not applicable |
|---|-----|--|----------|----|---------|-------------------|
| | 1. | Were the two groups similar and recruited from the same population? | | | | Ø |
| | 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | Z |
| | 3. | Was the exposure measured in a valid and reliable way? | Z | | | |
| | 4. | Were confounding factors identified? | | Z | | |
| | 5. | Were strategies to deal with confounding factors stated? | | 1 | | |
| | 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | | | |
| | 7. | Were the outcomes measured in a valid and reliable way? | 7 | | | |
| | 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | 7 | | | |
| | 9. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | Z | | | |
| | 10. | Were strategies to address incomplete follow up utilized? | | | | |
| | 11. | Was appropriate statistical analysis used? | Z | | | |
| | | appraisal: Include 🖊 Exclude 🗌 Seek further | r info 🔲 | | | |
| C | mme | nts (including reason for exclusion) | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

Reviewer Mónica Itzel Martínez Gutiérrez Date 02/04/2021

Author Dadhwal, R., Sharma, M., & Surani, S., Year 2021 Record Number 201 33564509 MIMG

| | | Yes | No | Unclear | Not applicable |
|----|---|------------|------|---------|-------------------|
| 1. | Were patient's demographic characteristics clearly described? | | 1 | | |
| 2. | Was the patient's history clearly described and presented as a timeline? | 1 | | | |
| 3. | Was the current clinical condition of the patient on presentation clearly described? | 1 | | | |
| 4. | Were diagnostic tests or assessment methods and the results clearly described? | 1 | | | |
| 5. | Was the intervention(s) or treatment procedure(s) clearly described? | 1 | | | |
| 6. | Was the post-intervention clinical condition clearly described? | | 1 | | |
| 7. | Were adverse events (harms) or unanticipated events identified and described? | | 1 | | |
| 8. | Does the case report provide takeaway lessons? | 1 | | | |
| | rall appraisal: Include Exclude Seek f | further in | fo 🗌 | | |
| - | | | | | |
| | 22 | | | | |

© JBI, 2020. All rights reserved. JBI grants use of these tools for research purposes only. All other enquiries should be sent to jbisynthesis@adelaide.edu.au.

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE CONTROL STUDIES

Reviewer: Mónica Itzel Martínez Gutiérrez Date 29/03/21

Author Kiva A. Fisher Samantha M. Olson Mark W. Tenforde Wesley H. Self Michael Wu et al.

Year 2021 Record Number 202 33405338 MIMG

| | | | Yes | No | Unclear | applicable |
|-----|------|---|------|--------------|---------|------------|
| | 1 | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | 1 | | | |
| | 2. | Were cases and controls matched appropriately? | Z | | | |
| | 3. | Were the same criteria used for identification of cases and controls? | 1 | | | |
| | 4. | Was exposure measured in a standard, valid and reliable way? | | | | |
| | 5. | Was exposure measured in the same way for cases and controls? | 1 | | | |
| | 6. | Were confounding factors identified? | | | | |
| | 7. | Were strategies to deal with confounding factors stated? | | | | |
| | 8. | Were outcomes assessed in a standard, valid and reliable way for cases and controls? | 1 | | | |
| | 9. | Was the exposure period of interest long enough to be meaningful? | | | | |
| | 10. | Was appropriate statistical analysis used? | | | | |
| | | ppraisal: Include 🔲 Exclude 🗀 | Seek | further info | | |
| Cou | mmon | ts (Including reason for evaluation) | | | | |

Comments (Including reason for exclusion)

Las entrevistas realizadas para el reporte de la salud física y mental de los participantes, fueron realizadas con preguntas modificadas del CDC Healthy Days Measures y éste no ha sido validado para abordar la calidad de vida relacionada con la salud durante la fase de convalecencia de la enfermedad aguda y los días en el cuestionario fueron ajustados a 14 días previos al diagnóstico en vez del original, de 30 días.

© JBI, 2020. All rights reserved. JBI grants use of these Studies - 1

Critical Appraisal Checklist for Case Control

| ermirli, S., Altundag A., et. al. Year 2 two groups similar and recruited from the oulation? exposures measured similarly to assign exposed and unexposed groups? exposure measured in a valid and reliable | Ves | _ Recor | d Number Unclear | Not applicable |
|--|--|--|--|--|
| exposures measured similarly to assign exposed and unexposed groups? | | No | Unclear | |
| exposures measured similarly to assign exposed and unexposed groups? | | | | |
| xposed and unexposed groups? | | | | |
| 30.53 | × | | | |
| exposure measured in a valid and reliable | X | | | |
| | | | | |
| founding factors identified? | × | | | |
| ategies to deal with confounding factors | × | | | |
| groups/participants free of the outcome art of the study (or at the moment of)? | × | | | |
| outcomes measured in a valid and reliable | × | | | |
| follow up time reported and sufficient to nough for outcomes to occur? | × | | | |
| w up complete, and if not, were the o loss to follow up described and explored? | × | | | |
| ategies to address incomplete follow up | × | | | |
| ropriate statistical analysis used? | X | | | |
| F | ollow up time reported and sufficient to nough for outcomes to occur? w up complete, and if not, were the oloss to follow up described and explored? Itegies to address incomplete follow up | ollow up time reported and sufficient to nough for outcomes to occur? w up complete, and if not, were the loss to follow up described and explored? | ollow up time reported and sufficient to nough for outcomes to occur? w up complete, and if not, were the loss to follow up described and explored? Integies to address incomplete follow up | ollow up time reported and sufficient to nough for outcomes to occur? w up complete, and if not, were the loss to follow up described and explored? Integies to address incomplete follow up |

Comments (Including reason for exclusion)

| Review | er Fermández Chirino Luisa | Date | 15/04/ | 2021 | | |
|---------|---|--------|-------------|-------|----------|------------------|
| Author, | Kavaz, E., Tahir, E., et. al. | Year20 |)21 | Recor | d Number | 204_33386439_LFC |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from same population? | the | × | | | |
| | Were the exposures measured similarly to assig people | n | \boxtimes | | | |
| 3. | to both exposed and unexposed groups? | | | | | |
| 4. | Was the exposure measured in a valid and reliable way? | ble | X | | | |
| 5. | Were confounding factors identified? | | | | × | |
| 6. | Were strategies to deal with confounding factor stated? | rs | | | | |
| 7. | Were the groups/participants free of the outcor at the start of the study (or at the moment of exposure)? | ne. | × | | | |
| 8. | Were the outcomes measured in a valid and rel way? | iable | | | | |
| 9. | Was the follow up time reported and sufficient be long enough for outcomes to occur? | to | × | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explo | ored? | | X | | |
| 11. | Were strategies to address incomplete follow u utilized? | р | × | | | |
| 12. | Was appropriate statistical analysis used? | | X | | | |

Comments (Including reason for exclusion)

JBI CRITICAL APPRAISAL CHECKLIST FOR QUALITATIVE RESEARCH

Reviewer Mónica Itzel Martínez Gutiérrez Date 30/03/2021

| Autho | Emma Ladds, Alex Rushforth, Sietse Weringa, Sharon Taylor, Clare Rayner, Laiba Husain and Trisha | Record Nu | mber | 205 3347 | 9069 MIMG |
|-------|---|-----------|------|----------|-------------------|
| | Greenhalgh | Yes | No | Unclear | Not applicable |
| | Is there congruity between the stated philosophica perspective and the research methodology? | | | | |
| | Is there congruity between the research methodolog and the research question or objectives? | v 🗾 | | | |
| | Is there congruity between the research methodolog and the methods used to collect data? | y 🖊 | | | |
| | Is there congruity between the research methodolog and the representation and analysis of data? | v 🗹 | | | |
| 5. | Is there congruity between the research methodolog and the interpretation of results? | y 🗾 | | | |
| | Is there a statement locating the researcher culturall or theoretically? | у 🗆 | 1 | | |
| | Is the influence of the researcher on the research, and vice-versa, addressed? | d 🗆 | 1 | | |
| | Are participants, and their voices, adequately represented? | v П | 1 | | |
| | Is the research ethical according to current criteria or for recent studies, and is there evidence of ethica approval by an appropriate body? | | | | |
| | Do the conclusions drawn in the research report flow from the analysis, or interpretation, of the data? | / | | | |

| Overall appraisal: | Include | | Exclude | | Seek further info |
|------------------------|---------------|---------|--------------|---------|---|
| Comments (Including | reason for ex | clusion |) | | |
| Es un estudio qualitat | vo que no cu | mple o | on los crite | rios de | inclusión, no se hace seguimiento de los síntomas |
| posteriores a la enfer | medad agud | a sino | que más b | ien rej | porta las experiencias del personal de salud (que |

posteriores a la enfermedad aguda sino que más bien reporta las experiencias del personal de salud (que fueron a su vez pacientes) con el denominado "long COVID", centrándose en temas como facilidad de acceso a los servicios, atención al paciente, responsabilidad clínica y la propuesta de un modelo para mejorar la atención a los pacientes con long COVID

| er Fermández Chirino Luisa | Date | 15/04/ | 2021 | | |
|--|---|---|---|---|--|
| Langham, D., Loe, J., et. al. | Year20 | 021 | Recor | d Number | 206_33419864_LFC |
| | | Yes | No | Unclear | Not applicable |
| Were the two groups similar and recruited from same population? | n the | X | | | |
| people | ţn | × | | | |
| to both exposed and unexposed groups? | | | | | |
| Was the exposure measured in a valid and relia way? | ble | X | | | |
| Were confounding factors identified? | | | | × | |
| Were strategies to deal with confounding factor stated? | rs | | | × | |
| Were the groups/participants free of the outcoment of the start of the study (or at the moment of exposure)? | me | × | | | |
| Were the outcomes measured in a valid and rel way? | iable | | | | |
| Was the follow up time reported and sufficient be long enough for outcomes to occur? | to | × | | | |
| Was follow up complete, and if not, were the reasons to loss to follow up described and explo | ored? | | X | | |
| Were strategies to address incomplete follow u utilized? | Р | × | | | |
| Was appropriate statistical analysis used? | | X | | | |
| | Were the two groups similar and recruited from same population? Were the exposures measured similarly to assign people to both exposed and unexposed groups? Was the exposure measured in a valid and reliaway? Were confounding factors identified? Were strategies to deal with confounding factorstated? Were the groups/participants free of the outcoat the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliaway? Was the follow up time reported and sufficient be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and expletive strategies to address incomplete follow up utilized? | Were the two groups similar and recruited from the same population? Were the exposures measured similarly to assign people to both exposed and unexposed groups? Was the exposure measured in a valid and reliable way? Were confounding factors identified? Were strategies to deal with confounding factors stated? Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliable way? Was the follow up time reported and sufficient to be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and explored? Were strategies to address incomplete follow up utilized? | Were the two groups similar and recruited from the same population? Were the exposures measured similarly to assign people to both exposed and unexposed groups? Was the exposure measured in a valid and reliable way? Were confounding factors identified? Were strategies to deal with confounding factors stated? Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliable way? Was the follow up time reported and sufficient to be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and explored? Were strategies to address incomplete follow up utilized? | Were the two groups similar and recruited from the same population? Were the exposures measured similarly to assign people to both exposed and unexposed groups? Was the exposure measured in a valid and reliable way? Were confounding factors identified? Were strategies to deal with confounding factors stated? Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliable way? Was the follow up time reported and sufficient to be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and explored? Were strategies to address incomplete follow up utilized? | Were the two groups similar and recruited from the same population? Were the exposures measured similarly to assign people to both exposed and unexposed groups? Was the exposure measured in a valid and reliable way? Were confounding factors identified? Were strategies to deal with confounding factors stated? Were the groups/participants free of the outcome at the start of the study for at the moment of exposure)? Were the outcomes measured in a valid and reliable way? Were the outcomes measured in a valid and reliable way? Was the follow up time reported and sufficient to be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and explored? Were strategies to address incomplete follow up utilized? |

Comments (Including reason for exclusion)

Useful for discussion

| Review | er Fermández Chirino Luisa | Date | 15/04/ | 2021 | | |
|--------|--|--------|--------|-------|----------|-------------------|
| Author | Niklassen, A. S., Draf, J., et. al. | Year20 | 21 | Recor | d Number | 207_33404079_LF0 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from same population? | n the | X | | | |
| | Were the exposures measured similarly to assig people | ţn | × | | | |
| 3, | to both exposed and unexposed groups? | | | | | |
| 4. | Was the exposure measured in a valid and relia way? | ble | X | | | |
| 5. | Were confounding factors identified? | | × | | | |
| 6. | Were strategies to deal with confounding factor stated? | rs | × | | | |
| 7. | Were the groups/participants free of the outcoment of the start of the study (or at the moment of exposure)? | me | × | | | |
| 8. | Were the outcomes measured in a valid and rel way? | iable | | | | |
| 9. | Was the follow up time reported and sufficient be long enough for outcomes to occur? | to | × | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explo | ored? | | X | | |
| 11. | Were strategies to address incomplete follow u utilized? | р | X | | | |
| 12. | Was appropriate statistical analysis used? | | × | | | |

Comments (Including reason for exclusion)

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE CONTROL STUDIES

| Review | er Fernández Chirino Luisa | Date 15/04 | | | | |
|---------|---|---------------|----------|--------------|-------------------|--|
| Author | Ramman, B., Cassar, M.P., et. al | Year 2021 | Record N | lumber 208_3 | _33490928_LFC | |
| | | Yes | No | Unclear | Not applicable | |
| 1. | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | × | | | | |
| 2. | Were cases and controls matched appropriately? | × | | | | |
| 3. | Were the same criteria used for identification of cases and controls? | × | | | | |
| 4. | Was exposure measured in a standard, valid and reliable way? | × | | | | |
| 5. | Was exposure measured in the same way for cases and controls? | × | | | | |
| 6. | Were confounding factors identified? | | | | | |
| 7. | Were strategies to deal with confounding factors stated? | × | | | | |
| 8. | Were outcomes assessed in a standard, valid and reliable way for cases and controls? | × | | | | |
| 9. | Was the exposure period of interest long enough to be meaningful? | × | | | | |
| 10. | Was appropriate statistical analysis used? | × | | | | |
| Overall | appraisal: Include 🛛 Exclude 🔲 Seel | (further info | | | | |
| Comme | nts (Including reason for exclusion) | | | | | |
| | | | | | | |
| _ | | | | | - | |

EXPLANATION OF CASE CONTROL STUDIES CRITICAL APPRAISAL

How to cite: Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). IBI Manual for Evidence Synthesis. IBI, 2020. Available from https://synthesismanual.jbi.global

Case Control Studies Critical Appraisal Tool

Answers: Yes, No, Unclear or Not/Applicable

1. Were the groups comparable other than presence of disease in cases or absence of disease in controls?

The control group should be representative of the source population that produced the cases. This is usually done by individual matching; wherein controls are selected for each case on the basis of similarity with respect to certain characteristics other than the exposure of interest. Frequency or group matching is an alternative method. Selection bias may result if the groups are not comparable.

2. Were cases and controls matched appropriately?

As in item 1, the study should include clear definitions of the source population. Sources from which cases and controls were recruited should be carefully looked at. For example, cancer registries may be used to recruit participants in a study examining risk factors for lung cancer, which typify population-based case control studies. Study participants may be selected from the target population, the source population, or from a pool of eligible participants (such as in hospital-based case control studies).

3. Were the same criteria used for identification of cases and controls?

It is useful to determine if patients were included in the study based on either a specified diagnosis or definition. This is more likely to decrease the risk of bias. Characteristics are another useful approach to matching groups, and studies that did not use specified diagnostic methods or definitions should provide evidence on matching by key characteristics. A case should be defined clearly. It is also important that controls must fulfil all the eligibility criteria defined for the cases except for those relating to diagnosis of the disease.

4. Was exposure measured in a standard, valid and reliable way?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

Case control studies may investigate many different 'exposures' that may or may not be associated with the condition. In these cases, reviewers should use the main exposure of interest for their review to answer this question when using this tool at the study level.

Reliability refers to the processes included in an epidemiological study to check repeatability of measurements of the exposures. These usually include intra-observer reliability and inter-observer reliability.

5. Was exposure measured in the same way for cases and controls?

As in item 4, the study should clearly describe the method of measurement of exposure. The exposure measures should be clearly defined and described in detail. Assessment of exposure or risk factors should have been carried out according to same procedures or protocols for both cases and controls.

6. Were confounding factors identified?

Confounding has occurred where the estimated intervention exposure effect is biased by the presence of some difference between the comparison groups (apart from the exposure investigated/of interest). Typical confounders include baseline characteristics, prognostic factors, or concomitant exposures (e.g. smoking). A confounder is a difference between the comparison groups and it influences the direction of the study results. A high quality study at the level of case control design will identify the potential confounders and measure them (where possible). This is difficult for studies where behavioral, attitudinal or lifestyle factors may impact on the results.

7. Were strategies to deal with confounding factors stated?

Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or stratifying sampling of participants, effects of confounding factors can be adjusted for. When dealing with adjustment in data analysis, assess the statistics used in the study. Most will be some form of multivariate regression analysis to account for the confounding factors measured. Look out for a description of statistical methods as regression methods such as logistic regression are usually employed to deal with confounding factors/ variables of interest.

8. Were outcomes assessed in a standard, valid and reliable way for cases and controls?

Read the methods section of the paper. If for e.g. lung cancer is assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If lung cancer is assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

Having established the objectivity of the outcome measurement (e.g. lung cancer) instrument, it's important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? (e.g. radiographers). If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised?

9. Was the exposure period of interest long enough to be meaningful?

It is particularly important in a case control study that the exposure time was sufficient enough to show an association between the exposure and the outcome. It may be that the exposure period may be too short or too long to influence the outcome.

10. Was appropriate statistical analysis used?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.

For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE CONTROL STUDIES

| Review | er Fernández Chirino Luisa | Date 15/04 | /2021 | | |
|---------|---|--------------|----------|--------------|-------------------|
| Author | Ratchford, S., M., Stickford, J. L., et. al | Year 2021 | Record N | lumber 209_3 | 3306450_LFC |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | X | | | |
| 2. | Were cases and controls matched appropriately? | | | | |
| 3. | Were the same criteria used for identification of cases and controls? | × | | | |
| 4. | Was exposure measured in a standard, valid and reliable way? | × | | | |
| 5. | Was exposure measured in the same way for cases and controls? | × | | | |
| 6. | Were confounding factors identified? | × | | | |
| 7. | Were strategies to deal with confounding factors stated? | × | | | |
| 8. | Were outcomes assessed in a standard, valid and reliable way for cases and controls? | × | | | |
| 9. | Was the exposure period of interest long enough to be meaningful? | | | | |
| 10. | Was appropriate statistical analysis used? | × | | | |
| Overall | appraisal: Include 🔲 Exclude 🔀 Seek | further info | ı | | |
| Comme | nts (including reason for exclusion) | | | | |
| Not re | elevant to Long COVID. | | | | |
| - | | | | | |

EXPLANATION OF CASE CONTROL STUDIES CRITICAL APPRAISAL

How to cite: Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). IBI Manual for Evidence Synthesis. IBI, 2020. Available from https://synthesismanual.jbi.global

Case Control Studies Critical Appraisal Tool

Answers: Yes, No, Unclear or Not/Applicable

1. Were the groups comparable other than presence of disease in cases or absence of disease in controls?

The control group should be representative of the source population that produced the cases. This is usually done by individual matching; wherein controls are selected for each case on the basis of similarity with respect to certain characteristics other than the exposure of interest. Frequency or group matching is an alternative method. Selection bias may result if the groups are not comparable.

2. Were cases and controls matched appropriately?

As in item 1, the study should include clear definitions of the source population. Sources from which cases and controls were recruited should be carefully looked at. For example, cancer registries may be used to recruit participants in a study examining risk factors for lung cancer, which typify population-based case control studies. Study participants may be selected from the target population, the source population, or from a pool of eligible participants (such as in hospital-based case control studies).

3. Were the same criteria used for identification of cases and controls?

It is useful to determine if patients were included in the study based on either a specified diagnosis or definition. This is more likely to decrease the risk of bias. Characteristics are another useful approach to matching groups, and studies that did not use specified diagnostic methods or definitions should provide evidence on matching by key characteristics. A case should be defined clearly. It is also important that controls must fulfil all the eligibility criteria defined for the cases except for those relating to diagnosis of the disease.

4. Was exposure measured in a standard, valid and reliable way?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

Case control studies may investigate many different 'exposures' that may or may not be associated with the condition. In these cases, reviewers should use the main exposure of interest for their review to answer this question when using this tool at the study level.

Reliability refers to the processes included in an epidemiological study to check repeatability of measurements of the exposures. These usually include intra-observer reliability and inter-observer reliability.

5. Was exposure measured in the same way for cases and controls?

As in item 4, the study should clearly describe the method of measurement of exposure. The exposure measures should be clearly defined and described in detail. Assessment of exposure or risk factors should have been carried out according to same procedures or protocols for both cases and controls.

6. Were confounding factors identified?

Confounding has occurred where the estimated intervention exposure effect is biased by the presence of some difference between the comparison groups (apart from the exposure investigated/of interest). Typical confounders include baseline characteristics, prognostic factors, or concomitant exposures (e.g. smoking). A confounder is a difference between the comparison groups and it influences the direction of the study results. A high quality study at the level of case control design will identify the potential confounders and measure them (where possible). This is difficult for studies where behavioral, attitudinal or lifestyle factors may impact on the results.

7. Were strategies to deal with confounding factors stated?

Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or stratifying sampling of participants, effects of confounding factors can be adjusted for. When dealing with adjustment in data analysis, assess the statistics used in the study. Most will be some form of multivariate regression analysis to account for the confounding factors measured. Look out for a description of statistical methods as regression methods such as logistic regression are usually employed to deal with confounding factors/ variables of interest.

8. Were outcomes assessed in a standard, valid and reliable way for cases and controls?

Read the methods section of the paper. If for e.g. lung cancer is assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If lung cancer is assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

Having established the objectivity of the outcome measurement (e.g. lung cancer) instrument, it's important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? (e.g. radiographers). If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised?

9. Was the exposure period of interest long enough to be meaningful?

It is particularly important in a case control study that the exposure time was sufficient enough to show an association between the exposure and the outcome. It may be that the exposure period may be too short or too long to influence the outcome.

10. Was appropriate statistical analysis used?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.

For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.

Reviewer Mónica Itzel Martínez Gutiérrez Date 31/03/2021

| hor_ | Rosales-Castillo A, García de Los Year 2021 Reco Ríos C, Mediavilla García | ord Num | ber <u>210</u> | 33521308 | MIMG |
|------|--|---------|----------------|----------|-------------------|
| | NIOS C, MECIAVIIIA GAICIA | Yes | No | Unclear | Not applicable |
| i. | Were the two groups similar and recruited from the same population? | | | | |
| 2. | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | | | | |
| 3. | Was the exposure measured in a valid and reliable way? | | | | |
| 4. | Were confounding factors identified? | | Z | | |
| 5. | Were strategies to deal with confounding factors stated? | | Z | | |
| 6. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | | Z | | |
| 7. | Were the outcomes measured in a valid and reliable way? | | | | |
| 8. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | | | | |
| 9. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | | | | |
| 10. | Were strategies to address incomplete follow up utilized? | | | Z | |
| 11 | Was appropriate statistical analysis used? | П | П | | П |

| Overall appraisal: | Include | | Exclude | Seek further info | |
|---------------------|---------------|-----------|---------|-------------------|--|
| Comments (Including | reason for ex | clusion | 1) | | |
| comments (meading) | reason for ex | verusioi. | *** | | |
| | | | | | |
| | | _ | | | |
| | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE CONTROL STUDIES

| Review | er Fernández Chirino Luisa | Date 15/04 | /2021 | | |
|-----------|---|----------------|----------|--------------|-------------------|
| Author, | Sheng, W.H., Lui, W.D., et. al | Year 2021 | Record N | lumber_211_3 | 3139151_LFC |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | × | | | |
| 2. | Were cases and controls matched appropriately? | × | | | |
| 3. | Were the same criteria used for identification of cases and controls? | × | | | |
| 4. | Was exposure measured in a standard, valid and reliable way? | × | | | |
| 5. | Was exposure measured in the same way for cases and controls? | × | | | |
| 6. | Were confounding factors identified? | | | | |
| 7. | Were strategies to deal with confounding factors stated? | × | | | |
| 8. | Were outcomes assessed in a standard, valid and reliable way for cases and controls? | × | | | |
| 9. | Was the exposure period of interest long enough to be meaningful? | × | | | |
| 10. | Was appropriate statistical analysis used? | × | | | |
| Overall : | appraisal: Include 🗌 Exclude 🔀 Seel | c further info | | | |
| Comme | nts (Including reason for exclusion) | | | | |
| Does | not speak about Long COVID. | | | | |
| - | | | | | |

EXPLANATION OF CASE CONTROL STUDIES CRITICAL APPRAISAL

How to cite: Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). IBI Manual for Evidence Synthesis. IBI, 2020. Available from https://synthesismanual.jbi.global

Case Control Studies Critical Appraisal Tool

Answers: Yes, No, Unclear or Not/Applicable

1. Were the groups comparable other than presence of disease in cases or absence of disease in controls?

The control group should be representative of the source population that produced the cases. This is usually done by individual matching; wherein controls are selected for each case on the basis of similarity with respect to certain characteristics other than the exposure of interest. Frequency or group matching is an alternative method. Selection bias may result if the groups are not comparable.

2. Were cases and controls matched appropriately?

As in item 1, the study should include clear definitions of the source population. Sources from which cases and controls were recruited should be carefully looked at. For example, cancer registries may be used to recruit participants in a study examining risk factors for lung cancer, which typify population-based case control studies. Study participants may be selected from the target population, the source population, or from a pool of eligible participants (such as in hospital-based case control studies).

3. Were the same criteria used for identification of cases and controls?

It is useful to determine if patients were included in the study based on either a specified diagnosis or definition. This is more likely to decrease the risk of bias. Characteristics are another useful approach to matching groups, and studies that did not use specified diagnostic methods or definitions should provide evidence on matching by key characteristics. A case should be defined clearly. It is also important that controls must fulfil all the eligibility criteria defined for the cases except for those relating to diagnosis of the disease.

4. Was exposure measured in a standard, valid and reliable way?

The study should clearly describe the method of measurement of exposure. Assessing validity requires that a 'gold standard' is available to which the measure can be compared. The validity of exposure measurement usually relates to whether a current measure is appropriate or whether a measure of past exposure is needed.

Case control studies may investigate many different 'exposures' that may or may not be associated with the condition. In these cases, reviewers should use the main exposure of interest for their review to answer this question when using this tool at the study level.

Reliability refers to the processes included in an epidemiological study to check repeatability of measurements of the exposures. These usually include intra-observer reliability and inter-observer reliability.

5. Was exposure measured in the same way for cases and controls?

As in item 4, the study should clearly describe the method of measurement of exposure. The exposure measures should be clearly defined and described in detail. Assessment of exposure or risk factors should have been carried out according to same procedures or protocols for both cases and controls.

6. Were confounding factors identified?

Confounding has occurred where the estimated intervention exposure effect is biased by the presence of some difference between the comparison groups (apart from the exposure investigated/of interest). Typical confounders include baseline characteristics, prognostic factors, or concomitant exposures (e.g. smoking). A confounder is a difference between the comparison groups and it influences the direction of the study results. A high quality study at the level of case control design will identify the potential confounders and measure them (where possible). This is difficult for studies where behavioral, attitudinal or lifestyle factors may impact on the results.

7. Were strategies to deal with confounding factors stated?

Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or stratifying sampling of participants, effects of confounding factors can be adjusted for. When dealing with adjustment in data analysis, assess the statistics used in the study. Most will be some form of multivariate regression analysis to account for the confounding factors measured. Look out for a description of statistical methods as regression methods such as logistic regression are usually employed to deal with confounding factors/ variables of interest.

8. Were outcomes assessed in a standard, valid and reliable way for cases and controls?

Read the methods section of the paper. If for e.g. lung cancer is assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If lung cancer is assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

Having established the objectivity of the outcome measurement (e.g. lung cancer) instrument, it's important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? (e.g. radiographers). If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised?

9. Was the exposure period of interest long enough to be meaningful?

It is particularly important in a case control study that the exposure time was sufficient enough to show an association between the exposure and the outcome. It may be that the exposure period may be too short or too long to influence the outcome.

10. Was appropriate statistical analysis used?

As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.

For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.

JBI CRITICAL APPRAISAL CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES

| Review | er Marco Antonio Delaye Martínez Date | 20/04 | /21 | | |
|--------|--|--------------|--------|---------|-------------------|
| Author | Townsend L., Dowds J., O'Brien K., et al. Year 20 | 020 | Record | Number_ | 212_3341302 |
| | | Yes | No | Unclear | Not applicable |
| 1. | Were the criteria for inclusion in the sample clearly defined? | \checkmark | | | |
| 2. | Were the study subjects and the setting described in detail? | 1 | | | |
| 3. | Was the exposure measured in a valid and reliable way? | 1 | | | |
| 4. | Were objective, standard criteria used for measurement of the condition? | 1 | | | |
| 5, | Were confounding factors identified? | 1 | | | |
| 6. | Were strategies to deal with confounding factors stated? | V | | | |
| | Were the outcomes measured in a valid and reliable way? | ✓ | | | |
| 8. | Was appropriate statistical analysis used? | 4 | | | |
| | appraisal: Include Exclude Seek further into the final seek further into the seek furth | nfo 🗌 | | | |
| No c | omments. | | | | |

| Review | _{er} Fermández Chirino Luisa | Date | 15/04/ | 2021 | | |
|--------|--|--------|-------------|-------|----------|------------------|
| Author | Myall, K.J., Mukherjee, B., et. al. | Year20 |)21 | Recor | d Number | 213_33433263_LF0 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from same population? | n the | X | | | |
| 2. | Were the exposures measured similarly to assigneople | gn | × | | | |
| 3, | to both exposed and unexposed groups? | | | | | |
| 4. | Was the exposure measured in a valid and relia way? | ible | × | | | |
| 5. | Were confounding factors identified? | | M | | | |
| 6. | Were strategies to deal with confounding factorstated? | ors | × | | | |
| 7. | Were the groups/participants free of the outco at the start of the study (or at the moment of exposure)? | me | X | | | |
| 8. | Were the outcomes measured in a valid and re way? | liable | | | | |
| 9. | Was the follow up time reported and sufficient be long enough for outcomes to occur? | to | × | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and expl | ored? | \boxtimes | | | |
| 11. | Were strategies to address incomplete follow utilized? | 1Þ | × | | | |
| 12. | Was appropriate statistical analysis used? | | X | | | |

Comments (Including reason for exclusion)

JBI CRITICAL APPRAISAL CHECKLIST FOR TEXT AND OPINION PAPERS

| Author | Wijeratne G., Crewther S. | Year_2020 | _ | Record | Number_2 | 14_33543150 |
|---------|---|----------------|----|--------|----------|-------------------|
| | | Y | es | No | Unclear | Not applicable |
| 1. | Is the source of the opinion clearly identified? | | 1 | | | |
| 2. | Does the source of opinion have standing in the of expertise? | ne field | 1 | | | |
| 3, | Are the interests of the relevant population the central focus of the opinion? | • | 1 | | | |
| 4. | Is the stated position the result of an analytical process, and is there logic in the opinion expression. | | / | | | |
| 5, | Is there reference to the extant literature? | • | 1 | | | |
| 6. | Is any incongruence with the literature/source logically defended? | es D | | | ₹ | |
| Overall | appraisal; Include \square Exclude $oldsymbol{M}$ See | k further info | | | | |
| Comme | nts (Including reason for exclusion) | | | | | |

| er Marco Antonio Delaye Martínez | Date | | | | |
|--|--|--|--|---|--|
| Moreno-Perez et al | Year_ | 2021 | Recor | d Number | 215_33450302 |
| | | Yes | No | Unclear | Not applicable |
| Were the two groups similar and recruited from same population? | n the | 1 | | | |
| 그림 그 이번 사람들은 아이는 아이를 하면 하는데 이렇게 하면 하는데 아이를 하는데 | | V | | | |
| Was the exposure measured in a valid and relia way? | able | | | | |
| Were confounding factors identified? | | | | | |
| Were strategies to deal with confounding factorstated? | FS | J | | | |
| Were the groups/participants free of the outco at the start of the study (or at the moment of exposure)? | me | ✓ | | | |
| Were the outcomes measured in a valid and re way? | liable | | | | |
| Was the follow up time reported and sufficient be long enough for outcomes to occur? | to | V | | | |
| Was follow up complete, and if not, were the reasons to loss to follow up described and expl | ored? | 1 | | | |
| Were strategies to address incomplete follow utilized? | ıp | • | | | |
| Was appropriate statistical analysis used? | | ~ | | | |
| appraisal: Include | furthe | rinfo 🗆 |] | | |
| | Were the two groups similar and recruited from same population? Were the exposures measured similarly to assign people to both exposed and unexposed groups. Was the exposure measured in a valid and reliable way? Were confounding factors identified? Were strategies to deal with confounding factor stated? Were the groups/participants free of the outcoat the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliable way? Was the follow up time reported and sufficient be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and explain was appropriate statistical analysis used? Was appropriate statistical analysis used? | Were the two groups similar and recruited from the same population? Were the exposures measured similarly to assign people to both exposed and unexposed groups? Was the exposure measured in a valid and reliable way? Were confounding factors identified? Were strategies to deal with confounding factors stated? Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliable way? Was the follow up time reported and sufficient to be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and explored? Were strategies to address incomplete follow up utilized? Was appropriate statistical analysis used? Seek furthe | Were the exposures measured similarly to assign people to both exposed and unexposed groups? Was the exposure measured in a valid and reliable way? Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? Was the follow up time reported and sufficient to be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and explored? Were strategies to address incomplete follow up utilized? Was appropriate statistical analysis used? Exclude Seek further info | Moreno-Perez et al Year Yes No Were the two groups similar and recruited from the same population? Were the exposures measured similarly to assign people to both exposed and unexposed groups? Was the exposure measured in a valid and reliable way? Were confounding factors identified? Were strategies to deal with confounding factors stated? Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliable way? Was the follow up time reported and sufficient to be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and explored? Were strategies to address incomplete follow up utilized? Was appropriate statistical analysis used? | Moreno-Perez et al Year Year Yes No Unclear Were the two groups similar and recruited from the same population? Were the exposures measured similarly to assign people to both exposed and unexposed groups? Was the exposure measured in a valid and reliable way? Were confounding factors identified? Were strategies to deal with confounding factors stated? Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? Were the outcomes measured in a valid and reliable way? Was the follow up time reported and sufficient to be long enough for outcomes to occur? Was follow up complete, and if not, were the reasons to loss to follow up described and explored? Were strategies to address incomplete follow up utilized? Was appropriate statistical analysis used? |

| | TATOMINE DESCRIPTION OF THE CONTRACTOR OF THE CO | 15/04 | | 337 X | 040 00440700 154 |
|-------|--|-------------|------|----------------------|------------------|
| uthor | Weerahandi, H., Hochman, K., et. al. Year2 | Ves | Reco | rd Number Unclear | Not applicable |
| 1. | Were the two groups similar and recruited from the same population? | × | | | |
| | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | \boxtimes | | | |
| | Was the exposure measured in a valid and reliable way? | × | | | |
| 5. | Were confounding factors identified? | × | | | |
| 6. | Were strategies to deal with confounding factors stated? | × | | | |
| 7. | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | × | | | |
| 8. | Were the outcomes measured in a valid and reliable way? | | | | |
| 9. | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | × | | | |
| 10. | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | \boxtimes | | | |
| 11. | Were strategies to address incomplete follow up utilized? | × | | | |
| 12. | Was appropriate statistical analysis used? | X | | | |

Comments (Including reason for exclusion)

JBI CRITICAL APPRAISAL CHECKLIST FOR CASE REPORTS

| Re | viewer Marco Antonio Delaye Martínez | Date_ | 20/04/ | 21 | | |
|----|--|--------|----------|---------|---------|-------------------|
| Au | thor_lqbal P., Laswi B., Jamshaid M., et al\ | /ear | 2020 | Record | Number_ | 217_33446625 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | Were patient's demographic characteristics clearly described? | | | | | |
| 2. | Was the patient's history clearly described and press as a timeline? | ented | 1 | | | |
| 3. | Was the current clinical condition of the patient on presentation clearly described? | | | | | |
| 4. | Were diagnostic tests or assessment methods and the results clearly described? | ne | ď | | | |
| 5. | Was the intervention(s) or treatment procedure(s) or described? | learly | ď | | | |
| 6. | Was the post-intervention clinical condition clearly described? | | ₹ | | | |
| 7. | Were adverse events (harms) or unanticipated even identified and described? | ts | ₹ | | | |
| 8. | Does the case report provide takeaway lessons? | | | | | |
| Ov | erall appraisal: Include 🔲 Exclude 🗹 Seek f | urther | info 🗌 | | | |
| Co | mments (Including reason for exclusion) | | | | | |
| N | o se reporta suficiente evidencia para atribuir e | stas o | caracter | ísticas | a PACS. | |
| | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR

CASE CONTROL STUDIES

| Review | rer | Marco Antonio Delaye Martínez | Date_ | 20/04/2 | 1 | |
|--------|------------------|---|-----------|-------------|--------------|-------------------|
| Author | Ortelk et al. | P., Ferrazzoli D., Sebastianelli L., | Year 2020 | _ Record No | umber 218_33 | 359928 |
| | | | Yes | No | Unclear | Not applicable |
| 1. | present | ne groups comparable other than the ce of disease in cases or the absence of in controls? | ≰ | | | |
| 2. | | ases and controls matched riately? | | | | |
| 3. | | ne same criteria used for identification s and controls? | ✓ | | | |
| 4. | | posure measured in a standard, valid iable way? | ¥ | | | |
| 5. | | posure measured in the same way for nd controls? | ₹ | | | |
| 6. | Were c | onfounding factors identified? | ¥ | | | |
| 7. | | trategies to deal with confounding stated? | | | | |
| 8. | | utcomes assessed in a standard, valid iable way for cases and controls? | ¥ | | | |
| 9. | | e exposure period of interest long to be meaningful? | | | | |

| 10. Was approp | riate statistical an | alysis used? | | | | |
|---------------------|----------------------|----------------|--------------|--------------|----------|--|
| Overall appraisal: | Include | Exclude | Seek furthe | r info | | |
| Comments (Including | reason for exclusion |) | | | | |
| No aporta inform | acion útil para | los fines de l | a presente r | evisión sist | emática. | |
| | | | | | | |

JBI CRITICAL APPRAISAL CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESES

| Rev | riewer Fernández Chirino Luisa Date | 15/04/ | 2020 | | | | |
|-----|--|----------------------|------|-------------------------------|-------------------|--|--|
| Aut | hor Tjan, L. H., Nagano, T., et. al. Year 2 | _{Year} 2020 | | Record Number 219_33575497_LF | | | |
| | | Yes | No | Unclear | Not applicable | | |
| 1. | Is the review question clearly and explicitly stated? | × | | | | | |
| 2. | Were the inclusion criteria appropriate for the review question? | | | | | | |
| 3. | Was the search strategy appropriate? | × | | | | | |
| 4. | Were the sources and resources used to search for studies adequate? | × | | | | | |
| 5. | Were the criteria for appraising studies appropriate? | X | | | | | |
| 6. | Was critical appraisal conducted by two or more reviewers independently? | × | | | | | |
| 7. | Were there methods to minimize errors in data extraction? | × | | | | | |
| 8. | Were the methods used to combine studies appropriate | | | | | | |
| 9. | Was the likelihood of publication bias assessed? | X | | | | | |
| 10. | Were recommendations for policy and/or practice supported by the reported data? | | | \boxtimes | | | |
| 11. | Were the specific directives for new research appropriate? | | | | | | |
| Öve | rall appraisal: Include 🔲 Exclude 🔀 Seek furthe | r info | | | | | |
| Con | nments (Including reason for exclusion) | | | | | | |
| To | general. | | | | | | |

| Review | er Marco Antonio Delaye Martínez | Date | 20/ | 04/21 | | |
|---------|--|------------|----------|-------|------------|-------------------|
| Author | Brant-Zawadski M., Fridman D., | Year_2 | 020 | Recor | d Number | 220_33604403 |
| | Robinson P., et al. | | Yes | No | Unclear | Not applicable |
| 1. | Were the two groups similar and recruited fr same population? | rom the | ≰ | | | |
| 2. | Were the exposures measured similarly to as people to both exposed and unexposed grou | 1100000 | 1 | | | |
| 3. | Was the exposure measured in a valid and re way? | eliable | 4 | | | |
| 4. | Were confounding factors identified? | | V | | | |
| 5. | Were strategies to deal with confounding factorized? | tors | ✓ | | | |
| 6. | Were the groups/participants free of the out at the start of the study (or at the moment of exposure)? | | ✓ | | | |
| 7. | Were the outcomes measured in a valid and way? | reliable | V | | | |
| 8. | Was the follow up time reported and sufficie be long enough for outcomes to occur? | ent to | V | | | |
| 9, | Was follow up complete, and if not, were the reasons to loss to follow up described and ex | | V | | | |
| 10 | . Were strategies to address incomplete follow utilized? | v up | ✓ | | | |
| 11 | . Was appropriate statistical analysis used? | | V | | | |
| Overall | appraisal: Include Exclude Se | ek further | info 🗆 |] | | |
| Comme | ents (Including reason for exclusion) | | | | | |
| Flar | tículo no aporta información útil para l | os fines | de la n | resem | te revisió | n sistemática |